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Abstract: 
 
During last decades studies on embryonic stem cell (ESC) differentiation have led to a better 
understanding of tissue homeostasis, including hematopoietic cell development. It is also 
generally accepted that ESC-derived progenitors or somatic cells hold great potential as novel cell 
sources for cell or tissue replacement therapy. This thesis focuses on establishing ESC culture and 
ESC differentiation into hematopoietic cells. Hematopoietic cells were derived from ESC 
following established protocols by OP9 stroma cell co-culture and embryoid body (EB) 
formation.  
 
To enhance hematopoietic cell generation from ESC, we assessed the impact of Bmi1 (B 
lymphoma Mo-MLV insertion region 1 homolog). Bmi1 is a Polycomb group (PcG) protein and a 
key epigenetic regulator during development. It plays an essential role in maintaining adult stem 
cell self-renewal as revealed by loss of function and over-expression studies. However, the role of 
Bmi1 on pluripotent stem cells has not been explored so far. Here we found that Bmi1 is not 
expressed in pluripotent ESC. To examine the impact of Bmi1 on self-renewal and differentiation 
of pluripotent stem cells, we introduced Bmi1 into ESC by lentivirus vector. Bmi1-transduced 
ESC (Bmi1-ESC) could be maintained in an undifferentiated state during culture similar to 
control ESC. Upon differentiation, Bmi1-ESC showed similar pattern of mesoderm 
hemangioblasts formation, yielding Flk1+ cells at frequencies similar as controls. However, 
primitive hematopoietic cell generation from mesoderm was highly enhanced, as determined by 
colony forming assay. Global transcriptional profiling by DNA microarrays identified a panel of 
genes that were distinctly regulated by Bmi1 during differentiation. Several homeotic genes were 
repressed, but GATA-2 expression was induced. When we studied EB-derived Bmi1-ESC in 
serum-free medium with hematopoietic cytokines, Bmi1 led to more than 100-fold expansion of 
hematopoietic stem/progenitor cells within 2-3 weeks of culture versus control ESC. 
Additionally, Ink4a/Arf locus appeared being silenced in Bmi1-ESC derived hematopoietic 
progenitor cells, which relates to their high proliferation capacity. Taken together, these data 
demonstrate distinct activities of Bmi1 on ESC and ESC-derived hematopoietic progenitor cells. 
The activity of Bmi1 described here suggests how aberrant Bmi1 expression might contribute to 
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leukemia formation in adult hematopoietic cells. Finally, Bmi1 might be a candidate gene for 
facilitating adult stem cell derivation from ESC. 
 
The better understanding of the transcriptional circuities that maintain ESC identity has allowed 
novel approaches of generating pluripotent stem cells from somatic cells. For a variety of reasons, 
hematopoietic stem/progenitor cells (HSC/HPC) represent an advantage cell source for 
reprogramming. For example, they are easily accessible and can be readily isolated. They can be 
rapidly expanded to a large cell number with hematopoietic cytokines. Therefore, the second part 
of this thesis focuses on reprogramming of ex vivo expanded Flt3+ HSC into pluripotent ESC-like 
cells. Flt3+ HSC were reprogrammed into pluripotent state by different approaches, including 
ESC fusion and pluripotent factor transduction. Initially, we found that reprogrammed Flt3 ESC 
hybrids obtained by cell fusion of Flt3+ HSC with ESC, contained donor cell memory, both in 
epigenetic information and in differentiation behavior. To examine whether somatic memory is 
also retained in Flt3 iPSC, we compared gene expression profiles of reprogrammed Flt3 ESC 
hybrids, Flt3 iPSC, ESC and Flt3+ HSC by DNA microarray. We found that expression profiles 
of pluripotent stem cells from different origins clustered together. This indicates that pluripotent 
stem cells from different origins maintain their specific epigenetic and gene expression profiles. 
Further analysis of Flt3+ HSC-derived pluripotent stem cells is ongoing in our lab. These studies 
will be helpful for understanding the molecular mechanisms underlying reprogramming, also will 
shed light on the understanding of the ground state of pluripotency. 
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Zusammenfassung: 
 
In den letzten Jahres hat die Erforschung der Differenzierung von embryonalen Stammzellen 
(embryonic stem cells, ESC) zu neuen Erkenntnissen zur Gewebshomeostase, einschließlich der 
Bildung von hämatopoetischen Zellen geführt. Es wird erwartet, dass von ESC abgeleitete 
somatische Zellen eine ausgezeichnete Quelle zur Zellisolation für die regenerative Medizin 
darstellen. Der erste Teil dieser Arbeit beschäftigt sich mit der Etablierung eines 
Differenzierungssystems von ESC in hämatopoetische Stammzellen (hematopoietic stem cells, 
HSC). Die Differenzierung in hämatopoetische Zellen wurde durch Kokultur von ESC mit OP9 
Stromazellen oder durch Bildung von embryonalen Körperchen (embryoid bodies, EB) erzielt. 
 
Um die Bildung von hämatopoetischen Zellen aus ESC zu verstärken, wurde die Bedeutung von 
Bmi1 (B lymphoma Mo-MLV insertion region 1 homolog) erforscht. Bmi1 ist ein Polycomb 
Group (PcG) Protein und besitzt eine Schlüsselfunktion bei der epigenetischen Regulation der 
Genexpression. So wurde durch  Funktionsverlustmutation und Überexpressionsstudien gezeigt, 
dass Bmi1 essentiell für die Erhaltung von adulten Stammzellen ist. Die Rolle von Bmi1 in 
pluripotenten Stammzellen wurde bisher jedoch nicht erforscht. Um den Einfluss von Bmi1 auf 
die Selbsterneuerung und Differenzierung von pluripotenten Stammzellen zu bestimmen, wurde 
Bmi1 durch Lentiviren in ESC eingebracht. Diese Bmi1 transduzierten ESC (Bmi1-ESC) 
verhielten sich im undifferenzierten Zustand ähnlich wie ESC Kontrollzellen. Nach 
Differenzierung mittels EB Formation zeigten Bmi1-ESC ähnliche mesodermale Muster wie die 
Kontrollen. Allerdings war die primitive hämatopoetische Zellgeneration vom Mesoderm durch 
Bmi1 verstärkt, was durch einen Assay zur Ermittlung der koloniebildenden Einheiten bestätigt 
wurde. Auch wurden mittels globaler DNA Microarray Analysen Gene identifiziert, die während 
der Differenzierung unterschiedlich durch Bmi1 reguliert wurden. Zahlreiche homeotische Gene 
wurden reprimiert, jedoch wurde GATA-2 induziert. Durch die Kultivierung der aus EB-
abstammenden Bmi1-ESC in serumfreiem Medium mit Zytokinen, zeigten Zellen mit Bmi1 
innerhalb von zwei Wochen eine mehr als 100-fach höhere Expansionsfähigkeit von 
hämatopoetischen Stamm-/Vorläuferzellen im Vergleich zu Kontrollzellen. Möglicherweise ist 
dieses hohe proliferative Potential auf die Abschaltung des Ink4a/Arf Locus durch Bmi1 
zurückzuführen. Zusammengefasst zeigen diese Daten einen Einfluss von Bmi1 auf pluripotente 
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ESC und auf hämatopoetische Vorläuferzellen, die von ESC abgeleitet sind. Das hier 
beschriebene Verhalten von Bmi1 deutet darauf hin, dass die anormale Expression von Bmi1 zur 
Entwicklung von Leukämie beitragen kann. Auch bietet die Expression  von Bmi1 eine 
Möglichkeit, die Herstellung von adulten Stammzellen aus ESC zu verstärken.  
 
Das zunehmende Wissen über die molekularen Mechanismen der ESC Selbsterneuerung erlaubt 
die Entwicklung von neuen Ansätzen für die Generierung von pluripotenten Stammzellen aus 
somatischen Zellen. Aus verschiedenen Gründen sind hämatopoetische Stamm-/Vorläuferzellen 
für die Reprogrammierung und Induktion von Pluripotenz in besonderem Masse geeignet. Zum 
Beispiel können hämatopoetische Stamm-/Vorläuferzellen relativ einfach isoliert und in großen 
Zellzahlen kultiviert werden. Unser Labor hat verschiedene Protokolle für die ex vivo 
Expandierung von HSC etabliert. Der zweite Teil der Arbeit beschreibt zwei verschiedene 
Strategien zur Reprogrammierung der ex vivo expandierten Flt3+ HSC Zellen; zum einen die 
Fusion mit ESC (Flt3 ESC Hybridzellen) und zum anderen die Induktion mittels Expression von 
Pluripotenzfaktoren (Flt3 induced pluripotent stem cells, Flt3 iPSC). Es wurde gefunden, dass 
Flt3 ESC Hybridzellen und Flt3 iPSC sich hinsichtlich ihres Pluripotenzverhaltens sehr ähnlich 
sind.  Flt3 ESC Hybridzellen zeigten aber ein somatisches „Gedächtnis“, d. h. ein Verhalten, das 
mit dem epigenetischen Profil und Expressionsrepertoire der Ausgangszellpopulation assoziiert 
ist.  Diese Studien werden derzeitig in unserem Labor fortgesetzt. Diese Ergebnisse tragen zum 
Verständnis der molekularen Mechanismen der Reprogrammierung bei und durch welche 
Faktoren der Grundzustand von Pluripotenz definiert ist. 
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Symbol Description 
  
[3H] tritium 
Ab antibody 
APC antigen presenting cell 
AP alkaline phosphatase 
BL-CFU blast colony-forming unit 
Bmi1 B lymphoma Mo-MLV insertion region 1 homolog 
BSA bovine serum ovalbumin  
BM bone marrow 
BFU-E burst forming unit erythroid 
CFU-E colony-forming unit erythroid 
CFU-GM colony-forming unit granulocyte macrophage 
ChIP chromatin immunoprecipitation 
c-Myc v-myc myelocytomatosis viral oncogene homolog  
CSC chondroitin sulphate C 
Dex dexmethasone 
DNA desoxyribonucleid acid 
dNTP desoxyribonucleatide triphosphate 
E. coli  Escherichia coli  
EB embryo bodies 
EDTA ethylenediaminetetraacetic acid 
ESC embryonic stem cells 
Ezh2 enhancer of zeste homolog 2 
FACS fluorescence activated cell sorter (flow cytometry)  
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
Flt3 FMS-like tyrosine kinase 3 
Flt3L FMS-like tyrosine kinase 3 ligand 
GAPDH glycerolaldehydphosphate dehydrogenase  
GFP green fluorescent protein 
GM-CSF granulocyte macrophage-colony stimulating factor 
gPS germline pluripotent stem cells 
HBS HEPES buffered saline 
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HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HSC hematopoietic stem cell 
hyperIL6 IL-6/IL-6 receptor fusion protein  
IGF1 insulin-like growth factor 1  
iPSC induced pluripotent stem cell 
kb kilo bases  
Klf4 Krüppel-like factor 4 
MCS multiple cloning site 
MEF mouse embryonic fibroblast 
mRNA messenger ribonucleic acid 
MW  molecular weight [kDa] 
Nanog Nanog homeobox 
Oct4 Octamer-binding protein 4 
PB polybrene 
PBS phosphate buffered saline 
PcG Polycomb group protein 
PCR polymerase chain reaction 
PE phycoerythrin  
PI propidium iodide 
PSC pluripotent stem cell 
RNA ribonucleic acid 
RT reverse transcription reaction; reverse transcriptase  
SCF stem cell factor, Kit ligand  
SDS sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
Sox2 SRY (sex determining region Y)-box 2  
trxG Trithorax-group 
Ub ubiquitination 
wt wildtype  
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1. Introduction 
 
1.1 Pluripotent Stem Cells 
 
Stem cells, the term has been used describing a wide range of cell types during the development 
of multi-cellular organisms. Compared to committed cell lineages, stem cells are characterized by 
capacities of renewing themselves and generating other cell lineages. Embryonic stem cells (ESC) 
represent the type of best-understood pluripotent stem cells. During development, the counter cell 
population of ESC exits transiently in the inner cell mass (ICM) of embryonic blastocyst-stage. In 
1981, pluripotent ESC lines were firstly established from mice pre-implantation embryos. Under 
appropriate conditions, ESC can be expanded and maintained in self-renewal state without 
limitation. In particular, they can participate fully in fetal development when reintroduced into 
embryo (Evans and Kaufman, 1981; Martin, 1981). In current biological research, the 
establishment of mouse ESC was considered as one of major breakthroughs in developmental 
biology, as it enabled the study of gene function in vivo via ESC trans-genetics to generate gene 
knockout mice (Buecker et al., 2010). More importantly, ESC differentiation is an important 
model system for elucidating cell fate determination during development. With established 
protocols for differentiation, ESC can generate a wide range of cell lineages, including muscle 
cells, neural cells and hematopoietic cells (Glaser et al., 2008). During last decades, significant 
attention and extensive efforts have focused on elucidating the underlying molecular mechanisms 
that control ESC self-renewal and differentiation. Much progress has been made in understanding 
the core transcriptional circuits, which regulate ESC identity (Boiani and Scholer, 2005a). 
 
The characteristics of mouse ESC stimulated interests of isolating analogous cells of human 
origin. In 1998, nearly two decades after establishing mouse ESC line, Thomson and colleagues 
firstly generated human ESC line from in vitro fertilization-produced blastocysts. Human ESC 
displayed similar unlimited self-renewal and differentiation properties as mouse ESC (Smith, 
2001). The establishment of human ESC makes both scientists and the public believe that 
pluripotent ESC will serve as an in-exhaustible cell source for regenerative medicine. Up to date, 
numerous ESC lines have been established. Scientists working on ESC agreed on standards for 
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characterizing ESC. For example, they can be maintained in long-term culture without losing 
self-renewal ability; the cells can be frozen and re-thawed; they express pluripotency marker 
genes; importantly, they are able to contribute to all three germ layer cells and form teratoma in 
vivo. 
 
 When cultured in vitro, ESC are normally grown on mitotically inactivated MEF (mouse 
embryonic fibroblast) feeders, which provides a sustainable microenvironment for ESC 
proliferation. For mouse ESC, LIF (leukemia inhibitory factor) signaling is required for 
maintaining their undifferentiated states; therefore, LIF cytokine is required for culturing mouse 
ESC. The downstream gene Stat3 is phosphorylated by LIF activated LIF-gp130 heterodimer 
receptor (Figure 1.1) (Smith, 2001). Besides LIF, fetal calf serum (FCS) and MEF feeder provide 
other essential factors for ESC self-renewal. By screening cytokines secreted from feeder cells, 
Qi and colleagues found that BMP4 (bone morphogenetic protein 4) signaling is another essential 
extra-cellular signaling pathway for mouse ESC self-renewal (Qi et al., 2004). Importantly, they 
found that integration effects of BMP4 and LIF signaling can sustain ESC self-renewal in a 
feeder independent manner. Hence, LIF and BMP4 signaling pathways seem playing central roles 
in maintaining mouse ESC identity.  
 
Instead of LIF signaling, human ESC requires FGF (fibroblast growth factor), which stimulates 
different molecular signaling pathway to maintain their undifferentiated status during in vitro 
culture. In 2007, two studies demonstrated pluripotent mouse pluripotent stem cell line can be 
derived from mouse epiblast instead of ICM and are termed as EpiSC. Interestingly, EpiSC 
shares similar features to human ESC (Brons et al., 2007; Tesar et al., 2007); for instance, EpiSCs 
also require bFGF signaling pathway for maintaining self-renewal. Thus, origin of human ESC is 
assumed as an epiblast-like state and the differences between mouse and human ESC may result 
from the difference of temporal developmental status. 
 
Over the past few years, much advance has been made in understanding the molecular 
mechanisms behind ESC self-renewal. Besides signaling pathways responding to external growth 
factors, a number of intrinsic regulators have been identified and demonstrated being essential for 
ESC identity. These regulators include Oct4, Nanog, Sox2, Klf4 and Zfx. Oct4, a member of POU 
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transcriptional family is a master regulator for ESC identify. During embryonic development, 
Oct4 is expressed in ICM, where ESC are isolated from. Later, the expression of Oct4 becomes 
restricted to epiblast and is eventually silenced in differentiated somatic cells (Boiani and Scholer, 
2005a). With the development of new technology, such as CHIP-seq (chromatin immune-
precipitation coupled with massively parallel short-tag-based sequencing), it allows to elucidate 
the interaction between different transcription factors, factors and chromosomes and a 
transcriptional circuit formed by the pluripotent regulators has been deciphered. It is known that 
pluripotent transcriptional circuits combining external signaling regulate the self-renewal and 
proliferation of ESC (Figure 1.1) (Chen et al., 2008).   
 
ESC are characterized by an open and loose chromatin, showing high rates of histone protein 
exchange. Upon differentiation, specific regions are increasingly organized into more rigid 
heterochromatin (Meshorer et al., 2006; Efroni et al., 2008). The open chromatin correlates with a 
globally permissive-transcription state and endows ESC in a ready to differentiation state during 
culture. Epigenetic modifiers, such as Polycomb proteins (PcG) are crucial for pluripotency 
establishment and maintenance. PcG proteins are mainly responsible for catalyzing tri-
methytalation lysine 27 of histone 3 (H3K27me3). In ESC, more than 2500 PcG target genes 
have been identified and most of them are associated with ESC differentiation and development 
(Boyer et al., 2006; Mikkelsen et al., 2007). Importantly, the regulatory regions of these PcG 
targeted genes were also co-occupied by the pluripotent transcriptional complexes formed by 
Oct4, Nanog and Sox2 (Lee et al., 2006). In the last few years, a specific landscape of ESC 
chromosomes has been proposed as “bivalent domain”. They are regulatory regions of chromatin 
consisting of H3K27me3 (lysine 27 trimethylation of histone3) and H3K4me3 (lysine 4 
trimethylation of histone3) (Bernstein et al., 2006). The relative levels of H3K27me3 and 
H3K4me3 effectively controls differentiation genes being repressed or activated. Recent studies 
have been suggested that the pluripotency related transcriptional network in ESC can be dominant 
to maintain ESC self-renewal without PcG components (Silva and Smith, 2008). However with 
loss of such epigenetic regulators, it is still unclear how this affects the stability of ESC genomics. 
Further studies on how epigenetic regulators cooperating pluripotency factors to organize ESC 
chromatin will lead to a better understanding of ESC epigenetic status.  
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Increasing knowledge on ESC self-renewal and the molecular mechanisms behind pluripotency 
allowed generating pluripotent stem cell from differentiated somatic cells. The process of 
reverting somatic cell nucleus to an undifferentiated state or acquiring pluripotency is termed as 
reprogramming. Initially, by introducing a somatic cell nucleus into an enucleated oocyte (SCNT), 
the epigenetic profile of the somatic cell nucleus is reorganized and converted into a pluripotent 
state and cloned embryos are generated. When subjected to culture, such cloned embryo can give 
rise to ESC lines (Hochedlinger and Jaenisch, 2003). Accordingly, nuclear transfer technology 
indicates that oocyte contains factors, which can reorganize the epigenetic profile landscape of 
somatic cell nucleus and drive them into a pluripotent state. With reprogrammed somatic cells by 
SCNT, cloned animal have been generated but the efficiency of this technique has remained 
extremely low (Yang et al., 2007). Similarly, the genomic information in somatic cells can also 
be reprogrammed into undifferentiated state though fusion with ESC. By separating ESC into 
cytoplasm and karyoplast fraction, karyoplast was demonstrated containing factors of being able 
to reprogram somatic cells, and fusion mediated reprogramming process need DNA replication 
and cell division (Do and Scholer, 2004).  
 
In 2006, a landmark work by Yamanaka group indicated that MEF could be induced to 
pluripotent state by introducing several transcriptional factors (Oct4, Klf4, Sox2 and c-Myc). They 
termed this type of pluripotent cells as induced pluripotent stem cells (iPSC) (Takahashi and 
Yamanaka, 2006). iPSC were verified to exhibit properties of ESC in many respects, including 
cell proliferation, gene expression profiles and differentiation into three-germ layer cells. More 
importantly, they can produce viable mice through tetraploid complementation (Zhao et al., 
2009). Over last few years, iPSC technology has been developed in a fast-pace and iPSC can be 
generated from a wide range of tissue cells from different species, such as pig, rat and human. 
Currently, iPSC generation has become a popular means to reprogram somatic cells. Cells 
plasticity, pluripotency and reprogramming have been the hot topics of contemporary biological 
research. The development of these fields will not only contribute to a better understanding of 
developmental biology, but also hold the great promise in regenerative medicine. 
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Figure 1.1: Integration of external signaling pathway and the transcriptional regulatory network in 
undifferentiated ESC (Chen et al., 2008). 
  
LIF and BMP4 are external factors being necessary to repress the onset of lineage commitment program in ESC. 
The intrinsic network formed by Oct4, Nanog, Sox2 cooperating other factors maintaining ESC in an 
undifferentiated state. 
 
1.2  Adult Stem Cells 
 
1.2.1 HSC, the Best Studied Adult Stem Cell 
 
Hematopoietic stem cells (HSC) represent one of the best-characterized adult stem cells and 
have often served as a paradigm for other types of stem cells. HSC are persisting through whole 
life to generate mature blood cells by self-renewal and differentiation without limitation. 
However, in adults, HSC only represent a rare cell population, which sparsely locate in the bone 
marrow. The existence of HSC was first proved by Till and McCulloch in 1961 (Till and Mc, 
1961; McCulloch and Till, 1962). Since then, phenotypes and functional properties of HSC 
have been extensively studied and well documented. Experimental systems for analyzing HSC 
have been well established. For example, to assess the differentiation potential of HSC, 
transplanting single HSC into a lethally irradiated mouse can reconstitute the entire blood 
system and rescue the animal (Zon, 2008). A couple of markers, which are specifically 
expressed by HSC, have been identified, such as c-Kit, stem cell antigen 1 (Sca1) and CD150. 
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Compared to other adult stem cells, the phenotype of HSC has been well defined. Thus, HSC 
can be isolated by using a cocktail of monoclonal antibodies which are specific for HSC 
antigens (Zon, 2008).  
 
Quiescence, self-renewal and differentiation of HSC are known being regulated by the 
integrated action  of intrinsic regulators and extrinsic microenvironments (Zon, 2008). A list of 
transcriptional factors including Hoxb4, Stat3/5, Gata2 and Myc, has been identified and they 
are demonstrated playing crucial roles in maintaining undifferentiated status of HSC (Figure 1.2) 
(Akala and Clarke, 2006; Zon, 2008). By loss of function studies, the self-renewal capacity of 
HSC decreased in these transcriptional factors mutant mice. Conversely over-expression 
resulted in an increased self-renewal ability of HSC (Akala and Clarke, 2006). In recent years, 
significant attention has focused on the interaction between HSC and their supporting 
microenvironments, also known as niche. The niche mainly exists within the bone marrow and 
organizes the supporting cells and hematopoietic growth factors to support the activities of 
hematopoiesis, such as HSC quiescence, self-renewal and differentiation. Much information has 
been obtained in understanding the HSC niche by innovative techniques, such as time-laps in 
vivo imaging microscopy and ex vivo mimicking the niche microenvironments. However, the 
dynamic altering surroundings of HSC are much more complicated than as expected. It is still 
hard to study HSC niche in detail. For example, with different mouse systems, conflicting 
results had been reported on the role of N-cadherin in regulating the interaction of HSC with 
bone marrow niche (Li and Zon, 2010).  
 
Behaviors of HSC, such as quiescence, self-renewal and differentiation are much depending on 
their natural microenvironments. Obviously, these natural microenvironments of HSC are not 
determined by single molecule or simply one cell type. It is probable that self-renewal of HSC 
is differently regulated with other types of stem cells. A better understanding of the interaction 
of HSC and the niche will bring about identifying the new properties of HSC, developing new 
strategies to expand and characterize them ex vivo. 
 
 Despite the progress towards understanding transcription circuits of pluripotent stem cells, the 
molecular mechanisms which equilibrate HSC differentiation and self-renewal are still poorly 
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understood (Deneault et al., 2009).  Mostly because HSC are sparsely residing in bone marrow 
and only represent 0.01% of cells in bone marrow. And their self-renewal is highly dependent 
on the supporting microenvironments. The complicated interaction with supporting niche 
makes the difficulty of establishing similar ex vivo culture systems to ESC. Even though labs 
worldwide have tried many years for establishing protocols of ex vivo expanding HSC and 
hundreds of protocols have been reported, the successful expansion HSC without loss their self-
renewal capacity has not been achieved. All these represent challenges for further investigation 
and application of HSC. 
 
Figure 1.2: Molecular circuits governing HSC self-renewal.  These regulators include factors that are 
intrinsic factors of HSC and external factors from the niche (Akala and Clarke, 2006).  
 
1.2.2  Stem Cells: Pluripotent ESC and Multipotent HSC 
 
Both ESC and HSC are characterized with unlimited self-renewal capacities; however, the 
molecular mechanisms and cellular futures behind their self-renewal are strikingly different. To 
understand the basis of stem cell self-renewal, several studies have tried to elucidate whether 
different types of stem cells are regulated with common regulators. To answer this question, gene 
expression profile studies of different types of stem cells were compared (Ramalho-Santos et al., 
2002; Hieronymus et al., 2008). Transcriptional profiles were found to overlap and some 
common essential regulators are found for different types of stem cells. For example, Zfx, a zinc 
finger transcriptional factor was found being required for self-renewal of both ESC and HSC 
(Galan-Caridad et al., 2007). However, it is still hard to define “stemness” among different stem 
cell types. It is possible that self-renewal is regulated in a distinct manner in different types of 
stem cells because there are different molecular signaling pathways involved. Studies on gene 
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expression profiles also indicated that “stemness” in different types of stem cells is governed and 
cooperated by distinct genetic programs, which also determine the unique behaviors of different 
stem cells.  
 
Characteristics of ESC and HSC are quite different in many respects (Figure 1.3). For example, 
ESC represents typical pluripotent stem cells and they transiently exist during development. ESC 
can be established as cell line easily, maintained and expanded in defined culture conditions in 
vitro. Therefore, culturing ESC allows obtaining a large number of cells, which can be used for 
genetic and biochemical assay to decipher underlying molecular mechanisms of their unlimited 
self-renewal. Compared to ESC, the self-renewal of HSC very much depends on their in vivo 
natural niche. They are multipotent and sustain all lineages of hematopoietic cells throughout 
whole life. Attempts of maintaining or expanding HSC in vitro have so far been unsuccessful, 
even though many protocols have been established. That means in vitro culture for a short period 
will alter their properties and phenotypes. Standards for characterization ESC have been well 
established. Several master regulators have been determined dominant in maintaining ESC 
identities. A combination of pluripotent factors: Oct4, Nanog, Sox2 and c-Myc, is sufficient to 
reprogram somatic cells into ESC-like cells, known as iPSC (Takahashi and Yamanaka, 2006). 
However, reprogramming lineage committed hematopoietic cells back into HSC has not been 
successful (Deneault et al., 2009). The differences between ESC and HSC were listed in Table 1.  
 
 
 
Figure 1.3: Cultured pluripotent ESC and multipotent Flt3+ HSC. 
A: Cultured undifferentiated pluripotent ESC: Merge of phase-contrast and eGFP of ESC cultured on MEF (R1 ESC, 
transduced with construct of Oct4 promoter followed by eGFP protein)  
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B: Flt3+ HSC: Phase contrast imagines of mouse bone marrow Flt3+ HSC growing on OP9 stromal cells. Dark, 
round cells showed cobblestone forming cells of Flt3+ HSC, which grew underneath of OP9 cells. Scale bare 
represents 100 µm. 
 
Table 1.1: Pluripotent ESC & multipotent HSC 
 
 Embryonic stem cells Hematopoietic stem cells 
Location/Derivation Inner cell mass of epiblast Bone marrow or peripheral blood systems 
Differentiation 
potential Pluripotent Multipotent 
Capacity of self-
renewal 
In vivo: Transient  
In vitro: Unlimited self-renewal 
In vivo: throughout whole life 
In vitro:  modest  
Conditions for self-
renewal In vitro defined specific conditions 
Depends on the niches in 
vivo 
External signaling LIF-Stat3, BMP4-Id2 etc Wnt, Hedgehog etc 
Intrinsic 
transcriptional 
network 
Oct4, Nanog, Sox2 etc Hoxb4, Bmi1, Stat5 etc 
Division Symmetrical self-renewal division Asymmetrical and symmetrical division 
 
 
 
1.3 ESC Hematopoiesis 
 
1.3.1 Blood Cell Generation, Lessons From ESC Differentiation 
 
The term of hematopoiesis, meaning making blood cells, originates from ancient Greek (hemato 
is known as blood and “poiesis”, means “to make”) (Jezierski et al., 2007). How hematopoietic 
cells emerge during development, where and when of the starting point of hematopoiesis during 
development have long been an intriguing question. Current understanding of hematopoiesis is 
mainly based on studying mouse development. During mouse embryogenesis, hematopoiesis 
begin with the first primitive erythroid cells in the yolk sac (YS) region on day 7.5 (Moore and 
Metcalf, 1970). Besides red lineage cells, primitive hematopoietic cells also include a minor 
population of megakaryocytes and macrophages (Palis et al., 1999; Klimchenko et al., 2009). 
Following the primitive hematopoiesis is the definitive hematopoiesis, occurring on the floor of 
the dorsal aorta in the aorta-gonad-mesonephros (AGM) region at 10.5 dpc (Medvinsky and 
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Dzierzak, 1996). Hematopoietic cells from YS and AGM region are localized in fetal liver and 
finally migrated in adult bone marrow (Kumaravelu et al., 2002).  
 
Upon differentiation, ESC can generate a variety of cell types, including hematopoietic cells. 
Keller and colleagues pioneered taking mouse ESC as a model to investigate hematopoiesis 
(Kennedy et al., 1997). As ESC differentiation recapitulates the development of earlier 
hematopoietic precursors, successive events of hematopoietic cell generation have been described. 
For example, pre-mesodermal gene Brychuray is expressed on day 2 of differentiation. At day 5, 
more than 50% of cells in the differentiation cultures will express the hematopoietic vascular 
receptor tyrosine kinase Flk1 (known as VEGF receptor-2). These Flk1+ cells can response 
VEGF and gives rise to blast colonies in semi-solid medium (Kennedy et al., 1997). Upon 
transfer to liquid culture with appropriate cytokines, these blast colonies generate both 
hematopoietic and adherent cells. Cells within the adherent population display characteristics of 
endothelial lineage, which express endothelial markers like CD31 (Choi et al., 1998). Further, 
Keller and colleagues demonstrated the multipotent Flk1+ progenitor cells give rise to 
mesodermal lineages cells, including cardiomyocyte, endothelial and vascular smooth muscle 
lineages (Kattman et al., 2006). Based on these findings, they proposed that during embryonic 
development hematopoietic cells arise from mesodermal multipotent precursor “hemangioblast”. 
Later experiments showed that hemangioblast is generally associated with the emergence of 
blood cells (Jezierski et al., 2007). 
 
Model of hematopoietic cell generation from hemangioblast was based on colony forming assay 
of single cells. It is still unclear whether hematopoietic cells are from mesodermal cells; 
mesoderm-derived endothelial cells or multipotent hemangioblasts. Recently, by taking an ESC 
in vitro differentiation as a model, several studies provided direct evidence that blood cells can be 
generated from mesoderm hemangioblast through an intermediate stage: haemogenic 
endothelium (Eilken et al., 2009; Lancrin et al., 2009). However, it still cannot be excluded that 
hematopoietic cells originate from hemangioblast or other origins. The faithful recapitulation of 
embryonic development in ESC/EB differentiation and the accessible of different stages of 
developmental cells will provide valuable clues to elucidate hematopoietic cells formation during 
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development. Based on the observation of ESC hematopoiesis, hematopoietic cell generation 
during embryonic development can be explained by two models (Figure 1.4).  
 
 
 
Figure 1.4: Models of hematopoietic cell arising by differentiating ESC. 
Modified from Jezierski, et al (Jezierski et al., 2007). 
 
A: Hematopoietic cells are directly generated from hemangioblast cells 
B: Hematopoietic cells are generated through an intermediate stage of haemogenic endothelium. 
 
The observation of hematopoietic cells generating from haemogenic endothelium during ESC 
differentiation raised the question of whether it is the same situation as in vivo development. Very 
recent studies, by taking zebrafish and mouse embryos as a model and with living imaging 
technology, allowing access and visualize living cells in the dynamic and physiological context, 
proved that HSC can be directly generated from aortic haemogenic endothelial cells in living 
embryo (Bertrand et al. 2010; Boisset et al. 2010). Thus, hematopoietic cell formation during 
embryo development has been becoming clearer. However, the molecular mechanism behind 
hematopoietic cell fate decision from haemogenic endothelium still remains largely unknown. 
ESC differentiation system will remain as an invaluable tool to further explore the biological 
process of hematopoietic cell development. 
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1.3.2 Deriving Hematopoietic Cells from ESC 
 
To derive hematopoietic stem/progenitor cells from ESC, two culture systems are generally used: 
(I) EB (embryoid body) formation. It allows ESC differentiation in a relatively spontaneous 
manner. By removing the conditions for maintaining ESC self-renewal, ESC aggregate into 3-
dimensional structure known as EB.  EB contains all three germ layer-derived cells; (II) Co-
culturing with stromal cells. Plating ESC on stromal feeder cells, like OP9 cells, which can 
provide supporting hematopoiesis microenvironment and direct differentiation into mesoderm 
layer derived cells. Regardless of the different culture systems, both approaches allow ESC 
differentiation into blood cell lineages. The kinetics of hematopoietic events and kinetics of gene 
expression are comparable between these two approaches (Zhang et al., 2005). For example, in 
both cases, the expression of Flk1/KDR, a specific marker for mesoderm blast colony forming 
cells (BL-CFC), onsets on day 3 of differentiation and shows highest expression around day 5 of 
differentiation. Hemangioblasts, known as common progenitors of hematopoietic and endothelial 
cells transiently exit during ESC differentiations and have been obtained by EB formation and co-
culture with stromal cells.  Definitive functional hematopoietic cell lineages, such as erythroid 
cells, B cells and dendritic cells have been obtained with different cytokines. A more detailed 
overview of deriving specific lineages of hematopoietic cells from ESC can be found in several 
review papers (Olsen et al., 2006; Kaufman, 2009) .  
 
 
Figure 1.5: Systems of pluripotent stem cells in vitro hematopoiesis (Kaufman, 2009). 
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Pluripotent stem cells, such as ESC and iPSC, can be subjected to differentiation by EB formation or co-culture with 
stromal cell to derive mesodermal hemangioblast cells. Hematopoietic lineage cells can be obtained by further 
differentiation with different hematopoietic cytokines or growth factors. 
 
1.3.3  Intrinsic Regulators for ESC Hematopoiesis 
  
Despite of extensive studies on ESC hematopoiesis, hematopoietic cell derivation from ESC is 
still difficult. Directly generating HSC from pluripotent stem cells is still impossible. Referring to 
hematopoietic stem/progenitor cell genes to genetically modify the differentiating process has 
been proved as a feasible approach to generate transplantable HSC from ESC. The self-renewal 
of HSC and the generation of lineage-committed blood cells are tightly controlled by a list of 
transcription factors (Cantor and Orkin, 2001; Zenke and Hieronymus, 2006). Most of the 
transcriptional factors, which are essential for the self-renewal of HSC, such as Scl, Runx1, Gata2 
and Mll have been described being crucial for the proper development of earlier hematopoietic 
cells. More importantly, their aberrant expression has been implicated in a variety of leukemia.  
 
ESC in vitro differentiation systems provide an invaluable platform for studying roles of 
transcription factors in early stages of embryonic hematopoiesis. Different stages of differentiated 
ESC can be controlled and specific lineage cells can be sorted. Introducing ectopic genes has 
been well established. By gain or loss of studies, the role of key hematopoietic cell related gene 
function has been well described (Table 2). Further studies of these regulators in hematopoiesis 
will lead to a better understanding of their impact on abnormal hematopoiesis. Most of these 
transcriptional factors show the capacities of facilitating hematopoietic cell development; 
therefore, they will be the candidates for facilitating the generation of engineered HSC from ESC 
or iPSC.  
 
Hoxb4 and Engineered HSC from ESC 
 
Hoxb4 is a member of homeobox transcription factors. Ectopically expressed Hoxb4 can enhance 
adult HSC ex vivo self-renewal and expansion (Antonchuk et al., 2002). The effects of Hoxb4 on 
adult HSC incited extensive studies of its role on hematopoietic stem/progenitor cell 
differentiation from ESC (Kyba et al., 2002; Morgan et al., 2004; Pilat et al., 2005). In mouse 
ESC, hematopoietic stem/progenitor cells with long-term repopulation capacities are obtained by 
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ectopic Hoxb4 expression (Kyba et al., 2002). By transplantation, engineered ESC-HSC based on 
Hoxb4 can give rise to functional leukocyte cells, like T and dendritic cells in vivo (Chan et al., 
2008). However, experimental results about the impact of Hoxb4 on hematopoietic cell 
differentiation from human ESC are still inconsistent and Hoxb4 might act in a dose dependent 
manner (Wang et al., 2005a; Unger et al., 2008). The differences might be that human ESC 
hematopoiesis and adult stem cell self-renewal are intrinsically different from mouse ESC.  So 
far, downstream target genes of Hoxb4 on hematopoiesis remain largely unknown (Lee et al., 
2010). By comparing the gene expression profile of Hoxb4 over-expressed adult HSC and ESC-
derived hematopoietic cells, Hoxb4 was found coordinate with extracellular signaling in 
promoting self-renewal of HSC (Schiedlmeier et al., 2007). One concern on modifying ESC 
through virus is the mutation, which is caused by exogenous DNA insertion, and it might 
potentially increase the possibility of tumorgenesis in transplantation. A recent study shed light 
on novel approach of achieving the effects of Hoxb4 in spite of virus; Lu and colleagues used 
recombinant Hoxb4 protein which displayed enhancing hematopoietic cell development from 
human ESC (Lu et al., 2007). Regulating Hoxb4 expression by non-virus system is a considerable 
progress for generating HSC from ESC, expanding ESC-derived hematopoietic cells and finally 
being used in clinical therapy. 
 
Scl, Mesoderm Patterning and the Formation of Hematopoietic Precursor Cells 
 
Stem cell leukemia (Scl), also known as T-cell acute lymphocytic leukemia 1 (Tal1), is one of 
helix-loop-helix family transcriptional factors and plays a crucial role in the establishment of 
hematopoietic and endothelial cell lineages during embryo development in mice (Souroullas et 
al., 2009). The role of Scl on hematopoietic cell development has been extensively studied. Scl is 
not absolutely required for adult HSC self-renewal but is essential for HSC differentiation into 
erythroid and megakaryocytic lineages (Okuda et al., 1996; Hall et al., 2003; Souroullas et al., 
2009). By taking ESC in vitro differentiation as a model, the expression pattern of Scl was found 
coinciding with mesodermal marker Flk1; and hematopoietic, endothelial cell development are 
from sequentially generated Flk1+ and Scl+ cells (Chung et al., 2002). Over-expression Scl has 
shown its essential role in mesoderm germ layer patterning. For example, continuous Scl 
expression during ESC differentiation results in markedly increased hematopoiesis (Ismailoglu et 
al., 2008). Thus, Scl is not only essential for hematopoietic cell generation, but also involved in 
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mesoderm germ layer patterning. A recent study by taking ESC differentiation as a model system 
indicated that Scl is indispensable for the establishment of haemogenic endothelium (Lancrin et 
al., 2009), which is supposed as direct precursors of definitive HSC. The pluripotency gene Oct4 
is important for patterning of different germ layers and depressed Oct4 expression leads to a 
defect in mesoderm germ layer and primitive hematopoiesis. However, enforced expression Scl 
can rescue this deficiency of differentiation caused by lacking Oct4 (Kong et al., 2009). Taken 
together, by in vivo and ESC in vitro differentiation studies, Scl has been proved as one of the key 
regulators in hematopoietic cell formation. However, downstream targets of Scl remain largely 
unknown and future studies are necessary to elucidate the molecular mechanisms underlying the 
impact of Scl on hematopoiesis.  
 
Runx1/AML1, a Key Gene for HSC Emergence  
 
Runx1 (runt-related transcription factor 1), originally known as Aml1 (acute myeloid leukemia 1), 
was initially identified in human leukemia. Runx1 is essential for establishment of the definitive 
hematopoietic system formation in embryogenesis and maintaining of adult hematopoiesis 
(Okuda et al., 1996). Recent evidence from living embryos and ESC differentiation demonstrates 
that the establishment of definitive HSC is through a transient haemogenic endothelium stage. 
Derivates from Runx1-/- Flk1+ cells were mostly expressing the endothelial cell marker CD31, 
rather than early hematopoietic marker CD41, an early hematopoietic cell marker (Lancrin et al., 
2009). Thus, Runx1 is critically required for HSC formation from haemogenic endothelium cells. 
Additionally, with enforced Runx1 expression during ESC differentiation, endothelial cells genes 
were found being repressed, while hematopoietic cell gene were activated; Runx1 might be 
promoting hematopoietic cell generation at the expanse of endothelial cell fates during 
development (Sakai et al., 2009). ESC are characterized with specialized epigenetic status. A 
large number of genes associated with development are altered in expression during 
differentiation. The differentiating process is also coincident with dynamic modification of 
chromosome structures (Hemberger et al., 2009). Pu.1 has been known as one of major 
downstream targets of Runx1 during adult hematopoiesis (Huang et al., 2008). Pu.1 can activate 
the expression of csf1 (colony-stimulated factor 1 receptor), triggering the circuits of 
myelopoiesis. During cascades of hematopoietic cell generation in differentiating ESC, 
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remodeling of Pu.1 chromatin region is only available at hemangioblasts stage. Runx1 transiently 
binds to Pu.1 cis-elements and mediates its expression. Chromatin reorganization of Csf1r 
requires the prior expression of Pu.1 together with Runx1 binding (Hoogenkamp et al., 2009). 
This consecutive gene expression during development indicates that the process of ESC 
differentiation accompanies with the dynamic epigenetic changes and the requirements of specific 
transcriptional factors at different stages of developments (Hoogenkamp et al., 2009). Thus, this 
ESC in vitro differentiation system can provide an ideal model for studying the dynamic 
epigenetic modification in cells fate decision during developments.  
 
PcG Protein Bmi1, Specifically Expressed in Postnatal Adult HSC 
 
PcG proteins were initially described in Drosphila where they control embryonic development by 
repressing homeotic gene expression (Muyrers-Chen et al., 2004; Ringrose and Paro, 2004; 
Sauvageau and Sauvageau, 2010). PcG proteins are conserved from Drosphila to human and 
most of them are involved in maintenance of cellular memory by modifying chromosome 
structure and silencing gene expression. PcG proteins occur in large protein complexes to exert 
transcriptional repressor activity, referred to as Polycomb repressor complexes (PRC) (Ringrose 
and Paro, 2004; Sauvageau and Sauvageau, 2010). In mammals, two PRC complexes, PRC1 and 
PRC2, have been described. PRC2, which contains Eed, Suz12 and Ezh2 proteins, is recruited to 
chromatin and trimethylates lysine residue 27 of histone 3 (H3K27me3). PRC1 contains Bmi1, 
Ring1A/B, Cbx, Mel18 and Mph, and is recruited to specific sites formed by PRC2, referred to as 
maintaining complex (Ringrose and Paro, 2004). 
 
PRC and H3K27me3 co-occupy cis-regulatory elements of a large number of development 
associated genes (Boyer et al., 2006; Bracken et al., 2006). Genome-wide mapping of histone 
modification in ES cells (ESC) identified regions, which are modified with both H3K27me3 and 
histone 3 lysine 4 trimethylation (H3K4me3) (Azuara et al., 2006; Bernstein et al., 2006; Boyer et 
al., 2006). H3K4me3 is catalyzed through trithorax group proteins and associated with active 
transcription units (Ringrose and Paro, 2004). The simultaneous occurrence of H3K4me3 and 
H3K27me3, referred to as “bivalent domain”, effectively controls gene transcription and poise 
genes in a ready for transcription status (Azuara et al., 2006; Bernstein et al., 2006). 
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Down-regulation of the PRC2 component Eed and Suz12 caused silenced differentiation-
associated genes to become derepressed in ESC (Boyer et al., 2006). Furthermore, ESC could not 
be established from Ezh2 deficient mice (O'Carroll et al., 2001). For PRC1 it has been shown that 
RingA/B is directly involved in the transcriptional network associated with ESC pluripotency 
(Endoh et al., 2008). All these studies indicate that PcG proteins are highly critical for embryonic 
development, the establishment and maintenance of ESC pluripotency. Recent studies 
demonstrated that PRC2 components, such as Ezh2 and Suz12, also orchestrate gene expression 
in adult stem cells (Majewski et al., 2008; Cui et al., 2009; Ezhkova et al., 2009). 
 
Unlike other PcG components that are ubiquitously expressed during development, Bmi1, a key 
component of PRC1, is selectively expressed in diverse postnatal adult stem cells, including 
neural stem cells (NSC) and hematopoietic stem cell (HSC) (Lessard and Sauvageau, 2003; Park 
et al., 2003; Molofsky et al., 2005; Liu et al., 2006; Oguro et al., 2010). Bmi1 activity in 
maintaining the pool of adult stem cells is mainly due to repression of the Inka4a/Arf locus, 
which encodes inhibitors of the cell cycle kinase p16Ink4a and p19Arf (Jacobs et al., 1999; 
Lessard and Sauvageau, 2003; Molofsky et al., 2005; Akala et al., 2008). Accordingly, in Bmi1 
deficient (Bmi1-/-) mice the number of adult HSC is markedly decreased. Additionally, in 
competitive transplantation experiments the repopulation capacity of Bmi1-/- HSC was 
significantly decreased, thus mirroring their deficiency in self-renewal (Lessard and Sauvageau, 
2003; Park et al., 2003). In fact with HSC differentiation, Bmi1 expression declines gradually 
(Hosen et al., 2007). In contrast, Bmi1 over-expression enhances HSC self-renewal both in 
human and mouse system (Iwama et al., 2004; Rizo et al., 2008). Despite increasing evidence of 
Bmi1 activity in maintaining the pool of adult stem cells, its role in pluripotent stem cells has so 
far not been studied. 
 
In this study, we examined the activity of Bmi1 on ESC and on hematopoietic stem/progenitor 
cells derived from ESC. We present evidence for a novel activity of Bmi1 in enhancing 
hematopoietic cell development from ESC. 
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Figure 1.5: Bmi1 is an essential factor in regulating postnatal HSC (Jang and Sharkis, 2007).  
Bmi1 is expressed in adult mouse and human HSC. The number of HSC in fetal liver of Bmi1-/- mice is normal; 
while number of HSC in postnatal is markedly reduced in the Bmi1-/- animals (Park et al., 2003). 
 
GATA Factors in ESC Hematopoiesis 
 
GATA factors belong to zinc finger transcription factors family and represent well-studied 
regulators in hematopoietic system. Among them, Gata1, Gata2 are highly involved in both adult 
and embryonic hematopoiesis (Cantor and Orkin, 2001), while Gata3 is mainly involved in T 
lineage cell development during hematopoiesis. By taking ESC in vitro differentiation as a 
model, significant new insights in the roles of GATA factors during embryonic hematopoiesis 
have been revealed. In human, acute megakaryoblastic leukemia occurrence is mostly 
characterized with GATA1 mutation. Correspondingly, during ESC differentiation the 
commitment of erythromegakaryocytic is blocked by lose of Gata1 function (Stachura et al., 
2006). By OP9 co-culture system, erythroid progenitor cells from Gata1-/- ESC could be 
expanded in the presence of EPO and these EPO expanded cells displayed multi-potent 
differentiation capacities in myeloid lineage (Kitajima et al., 2006b). All these indicated the 
instructive role of Gata1 for erythroid lineage commitment. In comparison to Gata1, Gata2 is 
expressed in a wider range of hematopoietic lineage cells, including HSC, HPC and erythroid 
lineage cells. During ESC hematopoiesis, the expression of Gata2 starts around on day 4 of 
differentiation (Figure 4.1). By comparing the gene expression profiles between Flk1+ Scl+, a 
subset of hemangioblast, and their differentiated progenies, Gata2 was found highly enriched in 
hemangioblast cell population and enforced Gata2 expression led to expanding primary erythroid 
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colonies (Briegel et al., 1993). Recently, Gata2 was found to be a direct target gene of BMP4 
signaling, which is highly involved in mesoderm cells differentiation (Lugus et al., 2007). 
Enforced Gata2 expression could up-regulate BMP4, Flk1 and Scl and subsequently conferred a 
proliferative signal to primitive erythroid progenitor. In contrast, over-expression of Gata2 can 
inhibit myeloid lineage cell differentiation (Kitajima et al., 2006a). Also, Gata2 was found 
cooperating with Smad5 to activate EKLF expression, a erythroid spesific transcriptional factor, 
prior to erythroid commitment during hematopoiesis (Lohmann and Bieker, 2008). Collectively, 
by utilizing ESC in vitro differentiation as a model, Gata2 has been proved to play important and 
contextual role in the generation mesoderm, hemangioblast and primitive erythroid lineage cells. 
Gata1 and Gata2 are regulated by multiple transcriptional factors through own feedback. 
However, how GATA factors cooperating with other transcriptional factors to establish 
transcription program during early embryonic hematopoietic cell emergence and development 
remains largely unknown. By integrating bioinformatics and other experimental approaches, the 
ESC in vitro differentiation system will contribute to a better understanding of GATA factors 
fundamental principle role underlying in controlling hematopoiesis.  
 
Other Factors Involved in ESC Hematopoiesis 
 
Besides regulators mentioned above, several other genes or mutated molecular forms were also 
studied during the ESC hematopoiesis. For example, Bcr-Abl, which is a mutant oncogene and 
molecular hallmark of chronic myelogenous leukemia, can activate Stat3 signaling and 
persistence of ESC in an undifferentiated phenotype without LIF during culture (Coppo et al., 
2003). During differentiation, Bcr-Abl can stimulate multipotent hematopoietic progenitors 
expansion (Era and Witte, 2000). Collectively, according to the effects of hematopoietic 
regulators on ESC hematopoiesis, most of them displayed active effects on hematopoietic cell 
development during ESC differentiation. This is consisting with the notion that embryonic 
pathways may get reactivated during adult ontogenesis. Also, recent studies demonstrated that the 
occurrence of several types hematopoietic malignancies display various degree of aberrant 
expression of the key transcriptional factors. In this respect, ESC differentiation system will 
provide an invaluable platform to analyze the association between key regulators and the 
occurrence of hematopoietic diseases.  
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Table 1.2: Summary of genetic modification strategies that may promote or influence specific hematopoietic 
stem/progenitor cell differentiation from ESC in vitro 
 
Genes Culture system ESC line Strategies Activities Reference 
Hoxb4 ESC/EB ESC/OP9 
Mouse 
Human 
 
Virus over 
expression 
Derived HSC with 
capacities of repopulating 
and rescuing lethally 
irradiated mice; Derivation 
of functional immune cells 
(Kyba et al., 2002; Pilat 
et al., 2005; Chan et al., 
2008; Unger et al., 
2008). 
 
Cdx4 ESC/OP9 Mouse ESC 
Inducible 
expression 
Hematopoietic cell potential 
from ESC. 
Activation of Hox genes. 
Conferring high proliferation 
to ESC-HPC. 
(Wang et al., 2005b; 
Lengerke et al., 2008; 
McKinney-Freeman et 
al., 2008) 
 
Scl ESC/EB ESC/OP9 
Common 
Marmose
t 
Mouse 
ESC 
Lentivirus, 
induced 
expression 
Mesoderm pattern & 
required for establishment 
of haemogenic endothelium 
population 
(Ismailoglu et al., 2008; 
Kong et al., 2009; 
Lancrin et al., 2009) 
Stat5 EBC/OP9 Mouse ESC 
Lentivirus 
Retrovirus 
Enhanced hematopoietic 
cell generation 
(Kyba et al., 2002; 
Schuringa et al., 2004)  
Mixl1 ESC/EB Mouse ESC 
Lentivirus 
overexpressi
on 
Accelerating mesoderm 
patterning and the potential 
of hematopoietic cells 
(Willey et al., 2006) 
 
Bmi1 EB formation 
Mouse 
ESC Lentivirus 
The proliferation and self-
renewal of ESC-HPC were 
promoted 
Ding et al, Stem Cells 
and Dev, in press; and 
this thesis 
Gata1 ESC/OP9 Mouse ESC 
Gata1 -/- 
ESC line 
Required for erythroid cells 
and Gata1 -/- ESC-HPC 
showed multipotency for 
myeloid cells 
Kitajima et al. 2006; 
Zheng et al. 2006 
Gata2 ESC/OP9 Mouse ESC 
Induced 
expression 
Involvement in mesoderm 
formation and required for 
primitive hematopoiesis 
(Kitajima et al., 2006a; 
Lugus et al., 2007) 
Runx1 EB/OP9 Mouse ESC 
Induced 
expression 
Promotes hematopoietic cell 
transition from endothelial 
cells and 
(Lancrin et al., 2009; 
Sroczynska et al., 
2009)  
Sox7 ESC/EB Mouse ESC Knockdown  
Balance the proliferation 
and differentiation at the 
onset of hematopoiesis 
(Gandillet et al., 2009) 
Hhex OP9 Mouse ESC 
Hhex-/- ESC 
line 
Delayed hemangioblast 
development; reduced 
maturation of hematpoietic 
precursors  
(Paz et al., 2010) 
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1.3.4 Extrinsic Signaling Pathways in ESC Hematopoiesis 
 
The formation of blood cells during embryo development requires interacting activities of 
extrinsic signaling pathways and specific cellular transcriptional regulators. Besides the effects of 
hematopoietic cytokines to promote survival and self-renewal of HSC, such as Flt3L, SCF and 
TPO, cellular signaling pathways, including BMP, Wnt and Notch have been demonstrated to 
play key roles in hematopoietic cell generation and development (Cerdan and Bhatia, 2010). The 
complicated situation of in vivo embryo development makes it hard to access the right stage of 
embryo and limits further elucidating roles of extracellular signaling in hematopoietic 
development during embryogenesis. ESC differentiation resembles the early stages of embryo 
development and provides an invaluable system for studying key signaling pathways in primitive 
hematopoiesis. In recent years, by studying ESC in vitro differentiation systems, roles of several 
key extracellular regulators on hematopoiesis have been defined. Especially the development of 
serum-free medium culture system allowed elucidating the role of specific signaling pathway in 
hematopoietic cells arising during ESC differentiation (Pearson et al., 2008).  
 
 
TGFβ/BMPs-smad Signaling Pathway 
 
TGF-β family signaling is a conserved signaling pathway and it is known as a master regulator of 
cell fate in a wide range of developmental processes (Blank et al., 2008). BMP4, a member of 
TGF-β super-family, is not only involved in maintaining ESC self-renewal but also essential for 
early stages of development, especially on mesoderm germ layer formation. BMP4 signaling has 
been shown to promote hematopoietic cell differentiation from ESC by enhancing mesoderm 
germ layer generation (Johansson and Wiles, 1995; Chadwick et al., 2003; Park et al., 2004). 
Recently, BMP4 signaling was found to be able to up-regulate Gata2 expression and thus 
promoted the primitive hematopoiesis (Lugus et al., 2007). In parallel, mesoderm induction was 
found increased by short-term treatment with BMP4 in human ESC (Zhang et al., 2008).  
 
Wnt/beta-catenin Signaling  
 
Wnt signaling has been known of playing a very important role in hematopoiesis, mainly 
promoting self-renewal of adult HSC and regulating lineage commitment during differentiation. 
During mouse ESC differentiation, Wnt signaling was found to promote embryonic 
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hematopoiesis (Lako et al., 2001; Corrigan et al., 2009). Consisting with findings in the mouse 
system, in human ESC the role of Wnt pathway was demostrated to support the generation of 
bipotent haemogenic cell development (Woll et al., 2008). Wnt signaling in hematopoiesis of 
ESC displayed developmental stage-specific and antagnistic activities (Naito et al., 2006). Also, 
as shown recently in mouse ESC hematopoiesis, Wnt pathway was proven to have a cross-talking 
function with known embryonic hematopoiesis regulators, such as BMP4 and Cdx/Hoxb4 
(Lengerke et al., 2008).  
 
Retinonic Acid 
 
Retinonic acid (RA) functions in patterning the early developing embryo being involving in HSC 
self-renewal and differentiation (Evans, 2005). Recent evidence indicated that RA also 
participates in yolk sac blood island formation. By studying hematopoietic cells arising during 
human ESC in vitro differentiation, Yu and colleagues found that exogenously RA efficiently 
induced paraxial mesoderm cell formation; the generation of hematopoietic progenitor from 
mesodermal cells was also enhanced by RA (Yu et al., 2010). 
 
Notch Signaling 
 
Notch signaling is activated through interaction between Notch receptors and their ligands, 
mainly of the Delta/Jagged family. This signaling pathway regulates a broad range activities of 
stem cells, including NSC, myogenesis and HSC (Bray, 2006). In adult HSC, activation of 
Notch1 has been reported to promote HSC self-renewal/expansion both in mice and humans 
(Stier et al., 2002). Most importantly, Notch signaling is highly activated in thymus organ and 
was found essential for lymphoid lineages development, especially T cells. While in Notch 
deficient mouse embryos, HSC failed to develop from endothelial cells (Kumano et al., 2003). 
Zuniga-Pflucker and colleagues developed a system for deriving T cells from ESC by engineered 
OP9 stromal cell, which was constitutively expressing Notch ligand Delta1. By this system, 
lymphoid cells, expressing T cells marker: CD25 and CD4 are successfully generated from 
mouse ESC (de Pooter et al., 2006).  
 
Many studies have demonstrated that multiple signaling pathways combine together to regulate 
biological process during development. By utilizing serum-free culture system during ESC 
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differentiation, recent studies have defined roles of signaling pathways cooperated in a 
developmental stage specific manner (Nostro et al., 2008). By defing specific external cell 
signaling pathway with different growth factors,  Pearson and colleagues showed that BMP4, 
actvin A, bFGF and VEGF are efficiently to drive hematopoietic cells differentiation from ESC 
(Pearson et al., 2008).  
 
So far, most culture systems for studying hematopoietic cell differentiation from ESC have been 
performed on two dimensional tissue culture plastics. Considering the dynamic process of 
embryogenesis, it is applealing to study the differentiation in dymatic process on a three-
dimension enviroments. For example, a recent study indicated that biomechanical stimuli 
enhanced ESC hematopoiesis (Adamo et al., 2009). Scaffolds structures have an influence on 
hematopoietic cell development from ESC (Taqvi and Roy, 2006). Thus, it seems that physical 
and mechanical properties have a significant influence on hematopoietic cell differentiation. To 
better mimic in vivo situation of development, differentiation ESC in 3-dimension scaffolds will 
be a very good option for studying ESC hematopoiesis. By screening the biomaterials bank based 
on different types of stem cells, scaffolds from biomaterials supporting both ESC and HSC would 
set up the basis for studying hematopoiesis in three-dimension environments (Neuss et al., 2008). 
With the development of tissue engineering technology, future work can screen biomaterials 
supporting stem cells self-renewal and establishing three-dimension co-culture system. 
Mimicking in vivo microenvironments for hematopoietic cell formation will lead to a new 
understanding of hematopoietic cell development. 
 
1.3.5 Perspectives of Deriving Hematopoietic Cells from Pluripotent Stem Cells 
 
ESC/iPSC culture and differentiation systems have provided a remarkable platform to understand 
hematopoiesis. Generating transplantable hematopoietic cells will be one of main ultimate goals 
of pluripotent stem cell based cell replacement therapy (Kaufman, 2009). Transplantation 
HSC/HPC has been widely used to treat a variety of acquired/genetic diseases caused by 
hematopoietic disorders. Currently, in clinical therapy, sources of HSC are mainly from adult 
tissues, such as BM, umbilical cord blood cells or mobilized peripheral blood cells. However, 
expanding HSC without compromising their constitution capacity still remains a challenge. 
Limited source of adult HSC has hampered the application of HSC in clinical. Therefore, it is 
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urgent to find a more readily available and renewable cell source for transplantation. In this 
regard, human ESC and iPSC can be believed as an unlimited cell source of somatic cells, 
including hematopoietic cells.  
 
After many years of study, hematopoietic cell differentiation from ESC has been well established 
(Olsen et al., 2006). However, before application of HSC from human pluripotent stem cells for 
clinical purpose, several issues need to be taken into consideration and solved (Kaufman, 2009). 
Firstly, by phenotype analysis, most hematopoietic cell lineages have been derived from 
pluripotent stem cells. However whether these in vitro generated hematopoietic cells are being 
able to appropriately function after integrating into in vivo microenvironments needs further 
testing. Secondly, compared to other cell lineages, such as neural cells, hematopoietic cell 
derivation from ESC is quite difficult and elusive. It still remains as a challenge for producing the 
clinical scale number of cells. Thirdly, a process of deriving patient specific hematopoietic cells 
takes a long time. It includes establishing pluripotent cell lines from somatic cells, maintaining 
self-renewal and differentiation into hematopoietic cells. The cells would have been through a 
long-term of culture and intensive selection process. All these might result in gene mutation, 
chromosome lose or translocation and course safety problems. So far, most transplantation 
experiments for testing the function of ESC-derived hematopoietic cells have been performed in 
immune-deficient mice. How to bypass the recipient immune response still remains a challenge. 
iPSC from antologous cell sources makes host immune responses not an expected issue. The 
generated ESC-HPC are mostly artificial cells from in vitro culture systems. Either gene 
expression profiles or phenotypes display much differences with counterpart populations in vivo 
(McKinney-Freeman et al., 2009). Thus, there still remain a number of challenges to be overcome 
before applying human pluripotent stem cell-derived hematopoietic cells to “bed side”. 
 
1.4 Plasticity and Reprogramming of Hematopoietic Cells  
 
The commitment and differentiation process of HSC accompany the successive lose of self-
renewal and developmental potential, and result in the final restriction into a terminally 
differentiated mature cell types (Zenke and Hieronymus, 2006). A number of studies showed that 
non-hematopoietic lineage cells, such as smooth muscle cells and neural cells could also be 
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derived from HSC. However, data about whether HSC can be capable to commit to other tissue 
cells is still conflicting (Wagers and Weissman, 2004). HSC self-renewal and differentiation are 
determined by the combining effects of key transcription factors and external cues. Increasing 
evidence demonstrated that committed cell fate can be converted from one to another by gain or 
loss-of specialized transcriptional factors. For example, ectopic expression of Gata1, erythroid 
lineage cells can be produced from freshly isolated myeloid progenitor cells (Heyworth et al., 
2002). Correspondingly erythroid progenitor derived from Gata1-/- ESC showed macrophage 
differentiation potential. B and T progenitor/committed cells could be converted into 
granulocytes and macrophages by enforcing expression C/EBPa, which is a transcriptional factor 
required for the formation of myeloid (Xie et al., 2004). While when B progenitor cells are 
deficient Pax5, a key factor regulating B cells commitment, they displayed multipotential 
differentiation capacity (Nutt and Kee, 2007). All these findings demonstrate the instructive role 
of transcriptional factor in cell fate decision during hematopoiesis process. With these, the 
concept of reprogramming has come out that cell fate can be conversed with specific 
transcriptional factors.  
 
In 2006, Yamanaka’s group showed that iPSC can be generated from MEF by enforcing 
expression several pluripotency transcription factors (Takahashi and Yamanaka, 2006). Since 
then, iPSC have been obtained from a wide range of tissue/organ cells, including hematopoietic 
cells (Hanna et al., 2010). HSC represent one of excellent cell sources for studying cell fate 
determination or being used for reprogramming. Compared to other tissues, HSC can be isolated 
prospectively and analyzed by well-defined assays. Indeed, perhaps because their epigenetic state 
is more amenable to induce transcriptional factors, HSC and HPC were found more efficiently to 
be reprogrammed than their lineage committed cells (Eminli et al., 2009).  
 
1.5 Objectives and Main Findings of this Thesis 
 
Functional hematopoietic cells have been derived from ESC. However, compared to other cell 
lineages, hematopoietic cell differentiation from ESC still remains elusive and inefficient. Here, 
we evaluated the activity of Bmi1, a key regulator for adult stem cells on ESC hematopoietic cells 
generation. In this part, we showed that: (I) Bmi1 has a differential expression pattern between 
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pluripotent ESC and adult stem/somatic cells; (II) enforced Bmi1 expression has no obvious 
effects on ESC self-renewal; (III) Bmi1 does not affect on hemangioblast development upon ESC 
differentiation; (IV) Bmi1 promotes primitive hematopoiesis; (V) Bmi1 confers robust 
proliferation capacity of ESC-derived HPC. Based on these data, we concluded that Bmi1 might 
be specifically functional for adult stem cells. Finally we suggested that Bmi1 might be a 
candidate gene for facilitating adult stem/progenitor cells derivation from pluripotent cells. 
 
HSC/HPC represent an advantage cell source for reprogramming. Our lab has long been 
establishing ex vivo culture systems for expanding HSC. From mouse bone marrow, we can 
expand large number of Flt3+ HSC with a cocktail of hematopoietic cytokines. In the second part 
of this thesis, I reprogrammed Flt3+ cells into pluripotent states by different approaches, 
including fusion with ESC and pluripotent factors induction. By studying behavior of Flt3/ESC 
hybrids, we found that reprogrammed Flt3/ESC hybrids maintained epigenetic memories of 
somatic Flt3+ HSC.  To answer the question of similarity between reprogrammed cells and ESC, 
and somatic memory of reprogrammed cells related to the approach of reprogramming, we 
compared the gene expression profiles of Flt3 ESC hybrids, Flt3 iPSC and ESC by DNA 
microarray. Based on these results, we found that (I) Flt3+ HSC could be reprogrammed into 
pluripotent state through ESC fusion and factor induction (II) Compared to ESC, Flt3 ESC 
hybrids and Flt3 iPSC maintained some unique transcriptional signatures.  
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2.  Materials 
 
2.1 Chemicals and Solutions 
 
All chemicals used in this study were in analytical grade and ordered from Sigma (St Louis, 
USA) or Merk (Schwalbach, Germany). Radiochemical:  [3H] thymidine (29 Ci/mmol) was 
purchased from Amersham Biosciences. General solutions and buffers were prepared with 
double deionized water, which was obtained though water purification system (Millipore). 
 
2.2 Instruments  
 
Instruments Manufactures 
 
Polymerase chain reaction 
(PCR) 
Thermocycler (Eppendorf, Hamburg, Germany) 
Real-time RT-PCR Applied Biosystems 7300 Real Time PCR System 
(Applied Biosystems, Foster City, CA, USA) 
DNA sequencing Value Read Service in Tubes 
www.eurofinsdna.com 
Nucleic acid and protein 
quantification: 
SpectraMAX spectrometer (Molecular 
Devices, Sunny- vale, CA). 
Gel documentation system Gel-Doc XR system (Bio-Rad, Hercules, CA, 
USA) 
Flow cytometry 
 
FACScalibur (Becton Dickinson, Heidelberg, 
Germany) 
FACScanto (Becton Dickinson, Heidelberg, 
Germany) 
DNA sequence analysis and 
primer design software 
MacVector (MacVector, Inc.,  Cambridge, UK ) 
Microarray  Affymetrix Microarray Suit 5.0.1 (Affymetrix 
Santa Clara, CA, USA) 
GeneSpring 6.2 (Agilent Technologies, Santa 
Clara, CA, USA)  
CASY Cell Counting and 
Analysis System 
Schärfe Systems (Schärfe Systems, Reutlingen, 
Germany) 
Microscopes Axiovert 200 microscope (Carl Zeiss, Jena, Germany) 
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5% CO2 Incubator Heraeus (Hanau, Germany) 
Centrifugation Heraeus (Hanau, Germany) 
 
2.3 Computers and Bio-softwares 
 
Computers Software 
MAC Mini 
SAMSUNG PC 
Office: Word, Excel, Power Point 
EndNote, Adobe Photoshop, Freehand., Image J 
FACS analysis: Cell Quest Pro, FlowJo 
DNA sequence analysis: Mac Vector 
 
2.4 Commercial Kits  
 
          The following kits were used in molecular and biochemistry assay: 
 
 
 
 
 
 
 
 
 
 
 
2.5 Primers for PCR 
 
All primers were purchased from Sigma Company (www. sigma.com/oligo) 
 
Primers for semi-quantities PCR   References 
Gene Sequences information   
GAPDH 
 
GGGGTGAGGCCGGTGCTGAGTAT  
CATTGGGGGTAGGAACACGGAAGG  
Oct4 AGGCCCGGAAGAGAAAGCGAACTA  
TGGGGGCAGAGGAAAGGATACAGC  
Nanog 
 
AGGGTCTGCTACTGAGATGCTCTG  
CAACCACTGGTTTTTCTGCCACCG  
Sox2 GTGGAAACTTTTGTCCGAGAC  
Kits Manufacures 
Plasmid preparation kit Qiagen mini/maxi plasmid kit 
RNA isolation kit Qiagen mini/midi RNA isolation kit 
High-Capacity cDNA Reverse 
Transcription Kits 
Applied Biosystems 
Power SYBR Green PCR Master Mix Applied Biosystems 
Alkaline phosphates kit Stemgent 
Gel/PCR extraction kit Macherey & Nagel 
DNA extraction from gel Macherey&Nagel 
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TGGAGTGGGAGGAAGAGGTAAC  
PU.1 TGGAAGGGTTTTCCCTCACC (Carotta et al., 2004) 
TGCTGTCCTTCATGTCGCCG  
G-CSFR ACAGGAGTGTGAACTTCGCT  
TTGCTTCTTCTGACACCACG  
GM-CSFRa CGGAGGTCACAAGGTCAAGG  
AACCTCCTGCACGTCACTCC  
Flt3 TCTTGAGACCGTTACAAACC (Carotta et al., 2004) 
ATGTCTGTTCCGAACAACTC  
Gata1 TAAGGTGGCTGAATCCTCTGCATC (Carotta et al., 2004) 
ACGTTCTTGGACACCTTGAAGACGG  
Gata2 ACACACCACCCGATACCCACCTAT (de Pooter et al, 2006) 
CCTACGCCATGGCAGTCACCATGCT  
Scl ATTGCACACACGGGATTCTG  
GAATTCAGGGTCTTCCTTAG  
c-Kit AGGAGATAAATGGAAACAATTATGT (Peters et al, 2003) 
 CTTCCTTGATCATCTTGTAGAACTT  
Primers for q-PCR 
Gene Forward and reverse sequences information  
Bmi1 AATTAGTCCCAGGGCTTTTCAA (Boyer et al., 2006) 
TCTTCTCCTCATCTGCAACTTCTC  
Ezh2 CGAGAGTGTGACCCTGACCTC (Boyer et al., 2006) 
CACATCAGACGGTGCCAGC  
Suz12 ACTATTGCTGTTAAGGAGACGCTGA (Boyer et al., 2006) 
GCAGGTCGTCTCTGGCTTCT  
Flk1 TTGTGAATGTCCCACCCCA  
CCATAGGCGAGATCAAGGCTT  
Scl GCTCGCCTCACTAGGCAGT (Pearson et al., 2008) 
CTTCACCCGGTTGTTGTTG  
Brachury(T) CCCCAGCCCCATTGCTCATC  
TGAATTGTCCGCATAGGTTGG  
p16Ink4a CGAACTCTTTCGGTCGTACCC (Nishino et al., 2008) 
CGAATCTGCACCGTAGTTGAGC  
p19Arf GTTCTTGGTCACTGTGAGGATTCAG (Nishino et al., 2008) 
CCATCATCATCACCTGGTCCAG  
Gata1 ATGGAATCCAGACGAGGAAC (Pearson et al., 2008) 
CTCCCCACAATTCCCACTAC  
Gata2 CACAAGATGAATGGACAGAACC (Pearson et al., 2008) 
ACGGTGCCCGCTCTTCT  
Hoxb4 CCTGGATGCGCAAAGTTCA  
CGTCAGGTAGCGATTGTAGTGA  
CD31 TACTGCAGGCATCGGCAAA (Li et al., 2007) 
 GCATTTCGCACACCTGGAT  
CD144 AGGACAGCAACTTCACCCTCA (Li et al., 2007) 
 AACTGCCCATACTTGACCGTG  
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Zic1 TCTGCTTCTGGGAGGAGTGT  
 CGGATGTGGTTGACCAGTTT  
Hoxa3 CAATGGGTTCGCTTACAATGC  
 AGGCAGGTCGATGGTACTCAAC  
Hoxa9 CCGAACACCCCGACTTCA  
 TTCCACGAGGCACCAAACA  
Hoxa11 AGATTTCTCCAGCCTCCCTTCTT  
 TGGAGGAGTAGGAGTATGTCATTGG  
Hoxd10 CTGCCTGGCTGAGGTTTCC (Boyer et al, 2006) 
 AGCGTTTGGTGCTTGGTGTAA  
Myh6 CATGGCTACACTCTTCTCTACCTATGC  
 TACCACTGTCACCGGTATCAGC  
Myl2 GAGAGGGTGGCAAGTCACTG  
 CAGTCACCGTCTTGCCATTCT  
β-actin TTTGCAGCTCCTTCGTTGC  
 CATCCATGGCGAACTGGTG  
c-Kit ACAGGACCTCGGCTAACAAAGG (Pearson et al, 2008) 
 AAGCACTGGCATCAGAGTTGG  
Primers for genomic analysis Flt3 iPSC 
pMX GACGGCATCGCAGCTTGGATACAC (Addgene) 
Oct4 TTCATGTCCTGGGACTCCTC  
Sox2 CTCCGGGAAGCGTGTACTTA  
Klf4 GGAGGTGGCGCAGATTCTCG  
c-Myc ACTGAGGGGTCAATGCACTC  
 
2.6   Enzyme and Enzyme Inhibitors 
 
Enzymes used for DNA restriction digestion were mainly from Fermentas and New England 
Lab.  The enzymes and proteinase inhibitors were listed as below: 
 
Enzymes Manufacture 
DNase I Fermentas 
Conventional DNA restriction enzymes Fermentas 
Taq polymerase Fermentas 
Klenow fragment DNA polymerase Fermentas 
RNase A Fermentas 
RNase inhibitor Fermentas 
Shrimp alkaline phosphatase Roche & Fermentas 
T4 DNA ligase Fermentas 
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2.7 Additives, Cytokines and Growth Factors for Cell Culture 
 
Name Source 
SCF Recombinant mouse SCF or 1% supernatant of SCF producing CHO KLS C6 cells 
Hyper-IL6 
Recombinant IL6/IL-6 receptor fusion protein was 
produced in yeast and was kindly provided by S. Rose-
John, University of Kiel , Germany 
IGF1, long-range, 
human 
Sigma-Aldrich 
GM-CSF 
Mouse GM-CSF was produced in E. coli which was 
transformed with pETH2A-His-mGM-CSF (S.M. 
Kurz, PhD thesis) 
Human LIF 
Recombinant human leukemia inhibitory factor 
(ESGROR LIF, Chemicon, Temecula, CA, USA). 
Human LIF was produced in BL21 E. coli strain, 
which was transformed with pGEX2T-LIF58. LIF 
protein was expressed, purified and GST tag was 
removed by thrombin. 
Flt3 ligand Purchased from PeproTech 
Mouse IL3 Purchased from Peprotech 
Dexmethasone Sigma-Aldrich 
β-mercaptoethanol Sigma-Aldrich 
 
2.8 Eukaryotic Cells 
 
Cells Definition  Characteristics 
MEF  Moue embryonic fibroblasts 
Isolated from day 14 
embryos. Adherent in culture 
Flt3+ cells Fetal liver kinase 3 positive cells 
Isolated from mouse BM. 
Suspension in culture 
HEK 293T 
Human embryonic kidney 
cells 
Expressing the large T 
antigen of the SV40 virus. 
Adherent in culture. 
NIH3T3 cells Mouse embryonic fibroblast cell line 
Adherent in culture 
OP9 cells 
A mouse stomal cell line 
established from new born 
B6C3F1 op/op mouse that 
lack functional M-CSF 
(Kodama et al, 1994). 
Adherent in culture 
iPSC Induced pluripotent stem cells 
Showed pluripotent 
characteristics. ESC-like 
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morphology and adherent 
during culture. 
ESC 
Embryonic stem cells Isolated from the inner cell 
mass of blastosysts and can 
be maintained in self-renewal 
during culture. 
 
2.9 Plastic Dishes for Cell Culture 
 
If there is no specific notification, all the plastic dishes and flasks were purchased from Nunc 
(www.nuncbrand.com) 
 
2.10 Reagents for Cell Culture 
 
Reagents Manufacture 
DMEM GIBCO® Invitrogen Cell Culture 
RPMI-1640 GIBCO® Invitrogen Cell Culture 
PBS GIBCO® Invitrogen Cell Culture 
Ficoll GIBCO® Invitrogen Cell Culture 
Penicillin-streptomycin GIBCO® Invitrogen Cell Culture 
L-Glutamin GIBCO® Invitrogen Cell Culture 
Non-essential amino acid GIBCO® Invitrogen Cell Culture 
Serum free medium GIBCO® Invitrogen Cell Culture 
β-mercaptoethanol GIBCO® Invitrogen Cell Culture 
HEPS GIBCO® Invitrogen Cell Culture 
Trypsin-EDTA GIBCO® Invitrogen Cell Culture 
StemPro34 plus nutrient 
supplement GIBCO® Invitrogen Cell Culture 
α-MEM PAN Biotech, Aidenbach Bavaria, Germany 
MethoCult® media STEMCELL Technologies, Vancouver, Canada 
FCS for OP9 PAN Biotech, Aidenbach, Germany  
FCS for ESC/iPSC Lanza, Cologne, Germany 
FCS for Flt3 cells Invitrogen Life Technologies 
FCS for cell lines Invitrogen Life Technologies 
 
2.11 Medium Recipes for Culturing Cell  
 
Cells Recipes of the medium 
ESC/iPSC DMEM, High glucose 25 mM HEPES, 
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15% (heat-inactivated) FCS for ESC 
0.1 mM β-mercaptoethanol  
100 U/ml Pen-Strep 
2 mM L-glutamine 
0.1 mM Non-essential amino acids  
OP9 cells 
α-MEM  
20% FCS for OP9 
1% Glutamine  
100 U Pen/Strep 
0.1 mM β-mercaptoethanol  
293T /NIH3T3 cells 
DMEM, high glucose 
1% Glutamine  
10% FCS  
1 mM sodium pyruvate 
100 U/ml penicillin/streptomycin 
Flt3+ cells 
RPMI 1640  
10%  FCS  
2 mM Glutamine 
100 U/ml penicillin/streptomycin 
50 M β-mercaptoethanol 
 
2.12 Buffers 
 
The following buffers were used. 
 
Buffer Recipes 
Phosphate-buffered 
saline (PBS):  
Purchased from PAA 
Ficoll-Hypaque buffer 1.077 g/cm3 from PAA Laboratories for density 
gradient centrifugation  
Red blood cells (RBC) 
lysis buffer 
150 mM NH4Cl, 100 mM NaHCO3, 10 mM EDTA 
in ddH2O, pH adjusted to 7.4 
Saponin buffer 0.02% saponin, 5 mM EDTA, 0.5% BSA, 0.1% 
sodium citrate in PBS 
EDTA 0.5 M or 0.05 M EDTA, Gibco-BRL 
4% Paraformaldehyde 
(PFA), pH 7.3 
4 % Paraformaldehyde in PBS, pH 7.3 
Flow cytomentry buffer  PBS, 1% bovine serum albumin (BSA, Fraction V, 
Sigma)  
10 x TBE 0.89 M Tris/HCl, 0.89 M boric acid, 20 mM EDTA 
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2.13 Antibodies 
 
Antibody Clone number Source Application 
CD45 30-F11 BD Phamingen FACS 
c-Kit AcK2 BD Phamingen FACS 
CD24 M1/69 eBioscience FACS 
Sca-1 D7 eBioscience FACS 
CD34 MEC14.7 Invitrogen FACS 
CD133 13A4 eBioscience FACS 
CD115 AFS89 eBioscience FACS 
CD11b M1/70 BD Phamingen FACS 
Ter119 Ter119 BD Phamingen FACS 
Gr-1 RB6-8C5 BD Phamingen FACS 
CD135 A2F10 eBioscience FACS 
CD14 mC5-3 BD Phamingen FACS 
Flk1 AVAS12α1 BD Phamingen FACS 
Bmi1 F6 Upstate signaling Immunochemistry 
Actin AC-74 Sigma Western blot 
 
2.14 Bacteria Strain 
DH5α strains were used to amply plasmids (recA1 endA1 gyrA96 thi-I hsdR17 supE44 
relA1 deoR lacIqZΔM15 Δ(lacZYA-argF U169). Rosetta-gami™ B host strains which are 
Bl21 derivatives (F- ompT hsdS (rB-mB-) gal dcm, Novagen) were used as host to express 
recombinant human LIF.  
 
2.15  Vector and Plasmid Constructs 
 
Backbone Constructs Source 
pMX 
GFP (mouse) Add Gene 
Oct4 (mouse) Add Gene 
Sox2 (mouse) Add Gene 
Klf4 (mouse) Add Gene 
c-Myc (mouse) Add Gene 
pFUGIE Bmi1 (mouse) FUGIE vector is a gift from Dr. Filip Farnebo 
(Karolinska Institute, Stockholm, Sweden) 
pMSCV Bmi1 (mouse) MSCV vector is a gift from Dr. Melissa L. 
Holmes (Walter and Eliza Hall institute, Victoria, 
Australia) 
pJET1.2  Fermentas 
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2.16 Animals 
 
The animal breeding facility of University Hospital Aachen provided all the mice which were 
used in this study. Mice were maintained under specific pathogen-free conditions in the 
central animal facility of University Hospital Aachen.  Mice were used for experiments 
between 7-14 weeks of age. All animal experiments were approved by local authorities with 
German animal protection law. The following mice strains were used: 
Mouse Origin and genetic background 
BL/6 BL/6, WT mice, maintained at central animal facility of University 
Hospital Aachen, Germany. 
OG2  Obtained from Max-Plank-Institute for molecular Biomedicine, 
Muenster, Germany (Do and Scholer, 2004). 
NOD/SCID Obtained from University of Würzburg, Würzburg, Germany 
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3.  Methods 
 
3.1  Molecular Biology Methods 
 
3.1.1 Preparing DNA and RNA 
 
Isolating cells genomic DNA, bacteria plasmid and cells RNA was all performed with 
commercial kits (2.4). Quality and concentrations of DNA and RNA were examined with a 
spectrophotometer and calculated based on the absorbance at the wavelength of 260 nm. Purity of 
DNA or RNA samples was determined by the ratio of 260/280 (nm). For DNA, the ratio was 
approximately 1.8 to 2.0, and RNA was from 1.8 to 2.1. 
 
3.1.2 Polymerase Chain Reaction (PCR) 
 
PCR reaction 
 
PCR is an efficient technique to amplify a particular DNA fragment in vitro. Primers are designed 
containing sequences complementary to the target region. The PCR reaction was performed on 
thermal cycling machine in the presence of DNA polymerase, optimal buffer solution for the 
reaction. A typical PCR reaction contains:  
 
cDNA template 50 ng in 2 µl 
10 x Buffer 2 µl 
10 x MgCl2 2 µl 
Primers 5 µm in 0.5 µl water of each 
dNTP 0.5 µl  
Taq polymerase 1 U 
(dd) water  Up to 20 µl 
  
 
The reaction was performed on thermal cycler apparatus. Firstly, the reaction was given a 
preheating step on 95°C for 5 min and the template DNA was denatured. According the annealing 
temperature of specific primers, amplifying cycle (denaturation at 95°C for 30 sec, annealing 
temperature for 1 min and elongation at 72°C for 1 to 2 min) was followed. The number of 
reaction cycles was determined according the requirements of the experiments.  
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Reverse Transcription 
 
For evaluating the level of specific gene expression or copy number of specific mRNA, synthesis 
cDNA by reverse transcription is required firstly. Reverse transcription was carried out by high 
capacity cDNA reverse transcription kit from ABI (www. Appliedbiosystems.com); briefly, 1 µg 
of total RNA was used as template, including the reaction mixture from the kit.  Thermal cycle 
was: 10 min at 25°C, 37°C 2 h and 75°C for 5 min. 
 
PCR Cloning DNA Fragment 
 
To clone DNA fragment, the PCR reaction was performed with pfu polymerase (Fermentas). A 
typical reaction mixture consists were: 
 
cDNA template 50 ng in 2 µl 
10 x Buffer 2 µl 
10 x MgCl2 2 µl 
Primers 5 µm in 0.5 µl water of each 
dNTP 0.5 µl  
pfu polymerase 2 U 
(dd) water  Up to 20 µl 
 
Separation DNA Fragment by Agrose Gel Electrophoresis 
 
To read out PCR product, the amplified DNA reaction was mixed with DNA loading buffer 
(Fermentas) and loaded on 1.0-2.0% agarose gel with ethidium bromide in 1 x TAE buffer. After 
separation by the gel with electrophoresis, DNA was visualized with a UV light from Gel-Doc 
system and photographed directly. To clone DNA fragment, gel was visualized under UV 
wavelength with short periods, desired bands were positioned and excised with a clean scalpel. 
The DNA was purified by gel extraction kit, following the manufacturer’s instruction.  
 
Quantitative Real-Time PCR (q-PCR) 
 
Compared to classical PCR, q-PCR can immediately detect amplified product on any cycles. 
Thus, q-PCR is more sensitive and easier to calculate the beginner copy number of target cDNA, 
which correspond the transcription level of target gene. We performed all q-PCR reaction on ABI 
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7300 PCR system. All reagents and plastic plates for q-PCR were ordered from ABI Company. 
Typical volume of reaction mixture was 30 µl and a typical consists was shown as below: 
 
Syber green Master mix 15 µl 
Primers 1 µl of each (10 µm stock) 
Template 50 µg 
Water  up to 30 µl 
  
The q- PCR reaction was carried out by the program as below: 
 
 Temperature Time Number of cycles 
Enzyme activation 95°C 15 min 1 
Denaturation 95°C 15 sec 40 
Annealing and extension 60°C 60 sec 
 
Calculating q-PCR Results: 
 
For calculating expression level of specific gene, ∆Ct method was used. 
Relative expression level of target gene was calculated as following: ∆Ct = Ct (sample) – Ct 
(calibrator, Actin); ∆∆Ct = ∆Ct (treatment, time point) - ∆Ct (baseline); 
Ratio of expression was calculated by 2-∆∆Ct (Livak and Schmittgen, 2001) 
 
3.1.3 Restriction Endonuclease Digestion and Ligation 
 
Digestion DNA with the restriction endonuclease was performed according the enzymes 
instruction. Briefly, proper amount of plasmid or PCR product DNA was mixed with enzyme, 
optimal 1x reaction buffer and the volume was adjusted to 20 µl. Digestion reaction was 
incubated at enzymes optimized temperature and the digested product was detected by agrose gel. 
 
For ligation reaction, DNA fragment or lineated plasmid was mixed (molar ratio around 5:1). By 
adding T4 ligase, liagase buffer and adjusting the volume by H2O, reaction mixture was 
incubated at 4°C overnight or at room temperature for 2 h. 
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3.2  Bacteria Work 
 
Competent Cells 
 
Competent E.coli cells were prepared by the CaCl2 method and stocked by freezing in -80°C. For 
DNA cloning and amplifying plasmid, stain DH5α was used. For protein production, BL21 strain 
was used.  
 
Transforming Bacteria 
 
Around 100 µl the competent cells were thawed on ice. Mix with plasmid DNA or ligation 
mixture (around 50 ng) and incubate on ice for 30 min. The cells were heat shocked at 42°C for 
90 sec exactly. Then the cells were continued being incubated on ice for 2 min. After that, the 
cells were supplied with 800 µl LB medium and incubated at 37°C for 1 h on the shaker. Then, 
proper amount of the cells were aliquot and plated on pre-warmed LB-agar plates with antibiotics. 
The plates were incubated at 37°C overnight.  Single colony was picked and amplified by culture 
for the requirement of experiments. 
 
Recombinant Cytokine and Growth Factors from Bacteria 
 
For preparing recombinant growth factors from bacterial, experiments were done by following 
established protocols. Mouse GM-CSF containing plasmid pETH2Ahis-mGM-CSF was 
transformed and expressed in BL-21 E. coli strain bacteria. The purification was done with 
established protocol by S.M. Kurz (S.M. Kurz, Ph.D thesis, MDC, Berlin, 2000). Activity of GM-
CSF was examined with FDCP cell line, which is cell line depending on GM-CSF. The GST 
tagged human LIF construct was a gift from Anna M. Wobus, Gatersleben, Germany. The 
construct was transformed into BL-21 (DE3). Protein was expressed and purified with 
glutathione-agarose beads. The GST tag was removed by thrombin. Activity of recombinant LIF 
was tested with ESC colony forming assay.  
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3.3 Cell Culture and Cell Biology Methods 
 
3.3.1 Cells and Cell Culture 
 
293T and NIH3T3 Cells 
 
293T cells and NIH3T3 cells were grown in DMEM medium supplemented with 10% FCS, 2mM 
L-glutamine and 1% penicillin/streptomycin. Cells grew in 5% CO2 incubator. For 293T cells, 
were always maintained less than 80% confluent before splitting. To split the cells, cells were 
wash one time with PBS and incubate with 0.05% trypsin-EDTA for 5 min. The trypsin was 
inactivated by adding cells medium. After cells counting, proper amounts of cells were plated in 
cell culture dish. 
 
ESC Culture 
 
In this study, several mouse ESC lines were used, including HM1, R1, CCE and E14. All these 
lines were adapted in culture to complete ESC medium. HM1 and R1 cell lines were feeder 
dependent, while CCE and E14 ESCs were maintained on gelatin coated dishes.  The following 
protocols were followed for culturing ESC. Briefly, take ESC vial from liquid nitrogen tank. 
Thaw vial in 37°C water bath. After thawing, transfer cells to a 15 ml tube containing 4 ml ESC 
medium. Pellet the cells (850 rpm, 5 min).  Then resuspend cells in 2 ml ESC medium. Plate cells 
on a 3.5 cm or 10 cm dishes with approximately 80% confluent inactivated MEF or gelatin pre-
coated dishes. Seeding proper number of ESC is important. Add recombinant human LIF. 
Refresh medium the next day and prepare a fresh plate with inactivated MEF the following day. 
Maintain ESC by repeating this procedure and allow them to become not more than 80% 
confluent.  
 
For splitting ESC, medium was removed and cells were washed gently with 1x PBS. Aspirate 
PBS and incubate cells with 2 ml 1x trypsin (10 cm dish) for 5 min. Then inactivate trypsin by 
adding 4 ml ESC medium. Pipette up and down several times to disaggregate cells. Pellet cells by 
centrifugation and resuspend cells with medium. The cell number was determined by CASY (Cell 
Counter and Analysis System). Plate cells on inactivated MEF feeder with ESC medium.  
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To prepare frozen stocks of ESC, ESC were dissociated by trypsin and re-suspended with ice-
cold ESC medium, supplied with 10% DMSO. Cells were put in aliquots into cryovials. Transfer 
the vials on ice to a –80°C freezer. Leave the vials at least overnight at –80°and transfer them to 
liquid nitrogen for long-term storage on the next day.  
 
OP9 Cell Culture 
 
Thaw a vital of OP9 cells as described for handling ESC but with OP9 cell medium. Cells are 
recovered by centrifugation and plated in a 10 cm dish with OP9 medium (around 1 x 106 cells). 
Change the medium the next day. Avoid high cell densities (not more than 80% confluency) 
before splitting. To passage OP9 cells, remove the medium, wash 1 x with PBS. Remove PBS 
and incubate with 2 ml 0.05% trypsin-EDTA for 5 min. To stop the reaction, 6 ml medium was 
added and pipetted up and down several times.  Pellet the cells (850 rpm, 5 min); resuspend them 
in 1 ml medium. Determine the cells number by CASY. For using as stromal cells, 3 x105 cells 
was seeded in a 10 cm dish (5 x 104 cells/well of 6 wells plate) on the other day before starting 
co-culture. Gently shake the plates to distribute the cells evenly. 
 
ESC/OP9 Co-culture 
 
Protocol of deriving hematopoietic cells from ESC by OP9 co-culture system was adapted from 
an established protocol (de Pooter et al., 2006). Briefly, two days before starting ESC/OP9 cell 
co-culture, OP9 cells were prepared (5 x 104/well of 6-well plate or 3 x 105 cells/10 cm dish). On 
day 0, the starting co-culture day, refresh OP9 stromal cell medium and cells should be less than 
80% confluent. Prepare single ESC suspension as described before. Adjust ESC at a 
concentration of 1 x 106cells/ml with OP9 medium. Add 10 µl ESC suspension medium per well 
of 6-well plate or 50 µl per 10 cm dish. On day 3 aspirate medium without disturbing the cells 
and replace with fresh OP9 medium. On day 5 aspirate medium and wash one time with PBS. 
Add 0.25% trypsin and incubate plates for 5 min at 37°C. Pipette the cells up and down to 
disaggregate cells into a single homogenous suspension. Add OP9 medium and plate cells into a 
new dish for 30 min to remove OP9 stromal cells. Then collect the non-adherent cells and pass 
cells through a 40 µm cell strainer. Count cells and plate them on OP9 cells, around 1 x 106 cells 
for a 10 cm dish. Cells medium is supplemented with Flt3L, SCF, IGF-1, hyperIL-6 and GM-
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CSF. On day 8, small clusters of blast-like cells can be seen, indicating effective differentiation. 
Gently harvest the cell cluster and rinse them by PBS to recover all the round suspending cells. 
Pass cells though a 40 µm cell strainer and pellet cells. Transfer cells to fresh OP9 stromal cell 
coated dishes, mostly a well of 6-well or 12-well plate. The cells are then being cultured and 
expended with OP9 medium (15% FSC) and hematopoietic cytokines as above. Refresh medium 
according the growth conditions of cells. By this protocol, we successfully generated ESC 
derived CD45+CD11b+ hematopoietic cells (see 4.1.2). 
 
Preparing MEF Cells 
 
MEF, being mitotically inactivated by treatment with mitomycin C or γ-ray irradiation provide 
suitable niche for maintaining pluripotent stem cell self-renewal and has been widely used for 
culturing mouse and human ESC. In this study, primary MEF were prepared from day 14 
pregnant wt 129SV stain or OG2 transgenic mice. Protocol for isolating MEF was briefly 
described as below: Day 14-16 of pregnant mouse was received from Animal Facilities (Klinikum 
RWTH, Aachen); Mice were sacrificed, the uterus was located and the uterus was opened to 
extract the fetal bag, which includes the embryos and placenta. Transfer them to a plastic dish, 
pick out the embryos and put them into a 50 ml Falcon tube with 1 x PBS. The following steps 
were performed under sterile conditions (cell culture hood). Wash the embryos one time with 1 x 
PBS and transfer the embryos to a 15 cm tissue culture dish. Remove head, liver and the inner 
organs from each embryo by scalpel and forceps. Transfer the left tissue to a new dish. Wash the 
tissue twice with PBS. Rinse the tissue once with 1 x trysin/EDTA solution. Mince the tissue with 
scissors or scalpel. Incubate the tissue with 1 x trypsin at 37°C for 10-20 min. Vortex or pipette up 
and down for 1-2 min. Finally prepare the homogenous cells suspension. Add 20 ml cell culture 
medium and pass through 40 µl cell strainer. Pellet cells at 850 rpm for 4 min and plate cells to 
cell with 2 x 106 cells per 10 cm culture dish with medium. Refresh medium every 2-3 days and 
split the cells when they are confluent. Freeze the cells either as vital cells or γ-ray inactivation.  
 
Ex vivo Flt3+HSC Culture 
 
Mouse BM Flt3+ cells culture was adapted as described before  
(Hieronymus et al., 2005; Felker et al., 2010). The protocol for preparing Flt3+ HSC is briefly 
described here:  6-10 week old mice were sacrificed by cervical dislocation; mouse was opened 
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and femur and tibia were located and isolated (clean the muscles surrounding the bones in a 
sterile environment). With a 23G needle and syringe, flush the bone by rinsing with medium for 
Flt3+ cell culture and transfer in a 15 ml Falcon tube. Let debris and tissue fragments settle for 2 
min and collect cells suspension without taking debris. Transfer cells into another falcon tube and 
recover cells by centrifugation around (1400 rpm, 4 min). Count cells by CASY and adjust cell 
concentration to 2 x 106 cells/ml in medium (RPMI 1640 supplemented with 10% FCS, 2 mM L-
glutamine, 100 U/ml penicillin/streptomycin and 50 µM β-mercaptoethanol). The following 
growth factors were used for maintaining self-renewal and proliferation of Flt3+ cells (see also 
2.7): 
 
SCF 30 U/ml 1% supernatant of stably transfected CHO KLS 
C6 cells 
Hyper-IL-6 5 ng/ml Kind gift from S. Rose-John (Kiel, Germany) 
Flt3 ligand 25 ng/ml PeproTech 
IGF-1 long range, human 40 ng/ml Sigma 
 
On day 3 of culture, cells were subjected to density gradient centrifugation using Ficoll-Hypague 
(1,077 g/ml) to remove dead cells and debris. Briefly, cells were suspended in 20 ml medium, and 
added to a 50 ml falcon tube, containing 14 ml Ficoll-Hypague. Centrifuge cells at 2000 rpm for 
15 min (slow deceleration). After ficoll, cells were washed one time in medium and adjusted to 
1.5-2.0 x 106 cells/ml and supplied with growth factors as described above; refresh medium every 
second day and adjust cells concentration to 1.5 x 106 cells/ml. On day 6 or 7, FACS analysis 
shows that about 80% of cells express HSC marker Flt3. We term these ex vivo-expanded cells as 
Flt3+ HSC. The Flt3+ cells can be further differentiated into a variety of dendritic cell subtypes 
with Flt3 ligand (Felker et al., 2010).  
 
ESC Differentiation by EB Formation 
 
ESC were subjected to differentiation by embryoid body (EB) assay. Briefly ESC were 
trypsinized into single cell suspensions. EB were generated in hanging drops at 100 cells per 10 
µl drops in an inverted bacterial Petri dish for 2 days with ESC differentiation medium. EB were 
then collected and cultured in bacterial Petri dishes for additional 4 days. For some experiments, 
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ESC were directly subjected to EB formation in mass culture as described before (Ensenat-Waser 
et al., 2006). 
 
Colony Forming Cell Assay 
 
Day 6 EB were dissociated into single cells with 0.05% trypsin/EDTA as described above. Cells 
was collected and re-suspended in DMEM, 10% FCS at 1 x 106 cells/ml and 100 µl of cell 
suspension was added to 3 ml MethoCult GF M3434 methylcellulose, containing insulin, 
transferrin, SCF, IL-3, IL-6, and erythropoietin (StemCell Technologies, Vancouver, British 
Columbia, Canada). Methylcellulose cultures were plated in two 35 mm dishes and incubated at 
37°C with 5% CO2. The number of erythroid colonies was scored on day 4-5; myeloid colonies 
were evaluated at day 10. 1 x 104 ESC-derived hematopoietic progenitor cells (ESC-HPC) were 
subjected to CFU assay in MethoCult GF M3434 methylcellulose as described above. Individual 
colonies were picked, washed and cyto-centrifuged on slides. Cells were stained with neutral 
benzidine and histological dyes (Briegel et al., 1993) and photographed. 
 
Hematopoietic Cells Generation from EB-Derived Cells 
 
Hematopoietic cell differentiation from ESC was adapted from the protocol by Carotta et al. 
(Carotta et al., 2004). Briefly, ESC were differentiated by EB formation as described above. On 
day 6 EB were dissociated into single cells with 0.05% trypsin/EDTA solution (Invitrogen) and 
cells were passed through a 40 µm cell strainer. Cells were then plated on gelatin-coated dishes at 
2 x 106 cells/ml in serum-free medium (StemPro34 plus nutrient supplement; Invitrogen) 
supplemented with 25 ng/ml Flt3 ligand (Flt3L; PeproTech, London, UK), 30 U/ml murine SCF, 
5 ng/ml IL-6/soluble IL-6R fusion protein (hyper-IL-6) (Fischer et al., 1997), 40 ng/ml long-
range IGF-1 (Sigma-Aldrich), 2 ng/ml murine IL-3 (PeproTech) and 1 µM dexamethasone 
(Sigma-Aldrich). After 2-3 days non-adherent cells were harvested, passed through a 40 µm cell 
strainer and further cultured in the same culture medium plus growth factors as above. The cell 
concentration was maintained at 2 x 106 cells/ml and the medium was refreshed every 1-2 days. 
Cumulative cell numbers were determined with a CASY-1 Cell Counter and Analyzer System 
(Schärfe Systems, Reutlingen, Germany). 
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3.3.2  Cell Bology Methods 
 
Determining Cells Number 
 
Cells proliferation and cells number were determined by counting cells number. Cell numbers 
were determined with a CACY-1 Cell Counter and Analyzer System (Schärfe Systems, 
Reutlingen, Germany). 25 µl aliquots of cell suspension were diluted with 5 ml CASY solution. 
Cells number were counted and determined by the CASY-1 Cell Counter and Analyzer System.  
 
Immunofluorescence 
 
For immunofluorescence staining ESC were grown on gelatin-coated chamber slides, fixed with 
1% formaldehyde and permeabilized with PBS buffer containing 0.5% BSA, 0.1% Triton X-100. 
Cells on cover-slips were washed 2 times with 0.5% BSA in PBS buffer and then incubated with 
anti-Bmi1 antibody (Clone F6, Millipore). Secondary antibody was anti-mouse Alexafluor647 
(Invitrogen) and DAPI was used to stain nuclei. Cover-slips were mounted on the glass slide with 
mounting medium and imagines were acquired under bright and fluorescent fields with an 
Axiovert 200 microscope (Carl Zeiss, Jena, Germany). 
 
FACS Analysis 
 
FACS is a powerful technique for analyzing cell phenotype, mostly by measuring cell surface 
antigens expression. In this study, FACS was performed with FACSCalibur and FACSCanto 
devices (BD Biosciences). Data were collected and analyzed with CellQuest and FlowJo software. 
For staining cells, proper amounts of cells were collected, ranging from 1 x 105 to 1 x 106 cells 
per sample. Cells were washed one time with FACS buffer and incubated with specific antibodies 
at 4°C for 30 min. Cells were washed 3 times with FACS buffer and resuspended with FACS 
buffer (around 400 µl). In some cases, secondary antibodies were added after washing with 
primary antibodies. Incubation and washing were as performed with primary antibody. The 
working concentration of most antibodies was 1: 100 diluted. 
 
FACS sorting was performed with FACSVantageTM (BD Bioscience) by Cell Sorting Facilities, 
Fraunhof Institution for Molecular Biology and Ecology (IME), RWTH Aachen, Germany; or 
with FACSAria (BD Bioscience) at RWTH Aachen University Hospital (kindly operated by 
METHODS 
46 
 
Saskia Mitzka). 
 
Cells Proliferation and Apoptosis Assay 
 
To study the impact of Bmi1 expression on apoptosis during ESC differentiation, day 6 EB were 
dissociated with 0.05% trypsin/EDTA and passed through 40 µm cell strainer. Single cell 
solutions were incubated with 7-amino-actinomycin D (7AAD) and allophycocyanin (APC)-
conjugated Annexin V (BD Bioscience) according to the manufacturer’s instruction. Cells were 
then subjected to flow cytometry. To determine the growth factor responses of Bmi1-ESC-
derived HPC, a total of 5 x 104 cells were incubated in 200 µl serum-free medium supplemented 
with different combinations of growth factors in 96-well flat-bottom plate at 37°C for 48 h. 
Samples were then pulsed with 0.75 µCi/well [3H] thymidine (29 Ci/mmol; Amersham 
Biosciences) for 4 h and harvested onto glass fiber filters. Radioactivity was measured by liquid 
scintillation counting in a Microbeta counter (Wallac). 
 
Western Blotting  
 
Cells were lysed in 2% SDS with 5 mM EDTA lysis buffer. 20 µg protein per well were 
subjected to PAGE (12% SDS-polyacrylamide gels) and transferred onto nitrocellulose 
membranes by Western blotting. Membranes were blocked overnight with 2% non-fat milk in 
PBS at 4°C and reacted with anit-Bmi1 antibody (Clone F6, 1:1000 dilution; Millipore, Billerica, 
MA) at room temperature for 2 h. Actin (Clone AC-74, Sigma) served as a control. Peroxidase-
conjugated anti-mouse secondary antibody (NA931, Amersham Biosciences) was incubated for 1 
h at RT and detected by chemiluminescence (ECL, Amersham Biosciences). Imagines were 
acquired by Image Reader Las-1000 (Fujifilm). 
 
Cell Cycle Analysis 
 
For cellular DNA content and cell cycle analysis, cells were washed one time with PBS and 
incubated with 7-AAD or Hoechst 33342 in saponin buffer (0.02% saponin, 5 mM EDTA, 0.5% 
BSA, 0.1% sodium citrate in PBS) for 30 min at 4°C. Then cells were washed with washing 
buffer (5 mM EDTA, 0.5% BSA, 0.1% sodium citrate in PBS) and subjected to FACS analyzing 
within 1 hour. Data were processed with FlowJo software. 
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3.4 Preparing Virus and Transduction Cells 
 
3.4.1 Preparing Retrovirus 
 
The protocol of preparing retrovirus was adopted from Nalan lab 
(www.standford.edu/group/nolan). Prepare 293T cells for transfection. 18-24 hours prior to 
transfection, plate 3.5-4 x 106 293T cells per 10 cm dish with culture medium for cell lines (2.7). 
Gently shake the dish forward and backward to distribute cells well in the dish. Before 
transfection, cells should be around 2/3 confluents. One hour before transfection, refresh medium 
of the growing cells. During this time, prepare DNA in calcium chloride and HBS buffer. The 
transfection was carried out using calcium phosphate/DNA co-precipitation.  
 
 
Add DNA solution drop by drop to HBS buffer with continuously bubbling. Plate the HBS/DNA 
solution drop-wise onto cells and distribute well. After incubating 12 hours, refresh the medium. 
1st round virus was harvest at 36 hours post-transfection. The supernatant of cells is collected and 
pass by 0.45 µm filters.  Virus supernatant can be used directly to infect target cells.  
 
3.4.2 Concentrating Virus 
 
Virus supernatant were collected and passed through 0.4 µm filters to remove debris and 293T 
cells. Virus supernatant was incubated with 0.08 µg/ml CSC (chondroitin sulphate C) and PB 
(polybrene) (Landazuri and Le Doux, 2006) for 20 min at 37 °C. Virus was precipitated collected 
by centrifugation at 4000 g for 15 min. Precipitated virus was well re-suspended and plated on 
cells.  
 
3.4.3 Lentivirus Infection ESC  
 
FUGIE vector based lentivirus was used for Bmi1 gene expression in moue ESC. The human Ubc 
promoter in this vector has been successfully used for exogenous gene expression in ESC and 
generation of transgenetic mice (Li et al., 2007). Prepare virus producing 293T cells as described 
Target construct (10 µg)  
 
500 µl 
Envelope pVPack-Eco (8  µg) 
Gag, pol pVPack GP (8  µg) 
62.5 µl 2 M CaCl2 
Water up to 500 µ 
2 x HBS 500 µl 
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above. 70% confluent 293T cells were transfected with 10 µg FUGIE or FUGIE-Bmi1 plasmid 
DNA, 7.5 µg pCMVΔR8.74 packaging plasmid and 2.5 µg envelope vector pVSV-G mixture. 
Virus supernatant was harvested and used to infect ESC in the presence of 8 µg polybrene. After 
two passages, GFP+ ESC was examined by flow cytometry and FACS sorted GFP+ ESC were 
further expanded. 
3.5 Reprogramming Flt3+ HSC 
 
3.5.1 Reprogramming Flt3+ HSC by ESC Fusion  
 
Somatic cells can be reprogrammed into pluripotent state by fusion with ESC. PEG 4000 
(polyethylene glycol, Fermentas) was used to mediate cell fusion. We reprogram Flt3+ HSC into 
pluripotent cells through fusion with ESC (E14 line). Flt3+ HSC were isolated from OG2 mice 
and expanded as described before (Felker et al., 2010). Prepare day 6 proliferating Flt3+ HSC and 
ESC (cells number is around 5 x 106 and 1 x 106). Cells were re-suspended with PBS. Mix both 
cell types and spin cells down around (300 g, 10 min). Remove the PBS with Pasteur pipette 
(complete removal of PBS is essential to avoid dilution of PEG). Break the pellet by gently 
tapping the bottom of the tube. Add 1 ml 50% PEG (PEG is pre-warmed to 37°C). PEG is added 
dip by dip over 1 min, continuously stirring cells with the pipette tip. Continue stirring cells for 2 
min. Add 1 ml pre-warmed medium to the mixture, continuously stirring as before over 1 min. 
Add 3 ml medium over of 3 min with stirring the cells. Add slowly 10 ml medium. Incubate for 5 
min at 37°C. Spin the cells down. Remove the supernatant and re-suspend the pellet with 
medium. Plate the cells on inactivated MEF with antibiotic selection. Culture the cells with 
selection medium (400 ng/ml, G418). After 8 days of culture, GFP+/G418R colonies are picked 
under microscopy. Expanded colonies were frozen and analyzed.  
 
3.5.2 Generation Flt3 iPSC 
 
Flt3 iPS cells were obtained from Flt3+ HSC by retrovirus transduction of mouse Oct4, Sox2, 
Klf4 and c-Myc cDNA in pMX vector, essentially as discribed by Takahashi and Yamanaka 
(Takahashi and Yamanaka, 2006). Flt3+ HSC were prepared from OG2 mouse, which contain 
GFP under Oct4 promoter as a reporter. The pluripotency gene Oct4 will be activated when cells 
acquire the pluripotent state and thus reprogrammed cells will become GFP+ (Kim et al., 2008). 
Briefly, pMX based retroviruses, containing reprogramming factors: Oct4, Sox2, Klf4 and c-Myc 
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were prepared as described before. The pMX-GFP virus was used as control to assess virus titer. 
Virus containing reprogramming factors were pooled and concentrated with CSC and PB as 
described above. Concentrated virus was used to infect day 6 Flt3+ HSC. 48 h after infection, 
Flt3+ HSC was submitted to Ficoll to remove debris. GFP control virus infected cells were 
analyzed by FACS to determine the efficiency of infection. After purification, four factor infected 
cells were seeded on inactivated MEF feeder at a concentration of 1 x 106 cells/well of 6-well 
plate. Cells were cultured with complete ESC medium. Medium was refreshed every day. Before 
reaching over-concentrated, suspending cells were harvested and re-plated on fresh inactivated 
MEF feeder. Over one week after infection, GFP+ cells were routinely obtained. At around day 
15-20, individual GFP+ clones were picked under microscope. According to cell morphology and 
GFP expression, iPSC clones were established and further analyzed. 
 
3.6  DNA Microarray and Data Analysis 
 
DNA microarray analysis was performed as described before (Hacker et al., 2003; Hieronymus et 
al., 2005). Briefly, total RNA was extracted using RNeasy mini Kit (Qiagen) with DNAase 
digestion (Fermentas). RNA quality and concentration were examined by Agilent 2100 
Bioanalyzer system. Probe preparation was with 1 µm RNA using the Affymetrix One-Cycle 
Target Labeling Kit, according to the manufacturer’s instructions. Labeled RNA was fragmented 
by heating to 95°C for 35 min in 200 mM TRIS (PH 8.1), 500 mM KOAc, 150 mM MgOAc 
buffer. Affymetrix arrays were prehybridized with 200 µl MES hybridization buffer for 10 
minutes at 45˚C with rotation (60 U/min) in an Affymetrix Hybridization Oven 640. After 
removing the prehybridization solution, 10 µm of labeled cRNA in 200 µl MES hybridization 
buffer were applied to the array leaving a small air bubble. Arrays were incubated overnight at 
45˚C with rotation (60U/min) in the hybridization chamber. Arrays were scanned using 
Affymetrix GeneChip Scanner 3000. DNA microarray analysis was performed as described 
before (Hacker et al., 2003; Hieronymus et al., 2005). Data were normalized using MAS5 
algorithm (scaled to 300) and further analyzed using GeneSpring (Agilent Technologies, Palo 
Alto, CA, USA) and BioConductur (Ihaka and Gentleman, 1996). Microarray data were 
submitted to GEO database (http://www.ncbi.Nlm.nih.gov/geo/; series accession number 
GSE20958). 
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3.7 Animal Work and Teratoma Formation Assay 
 
Mice used in this study were bred in the central animal facilities of RWTH Aachen University 
Hospital. Handling animals for all experiments is according to the roles of the institution. For 
teratoma formation assay, approximately 2 x 106 ESC/iPSC were injected into the rear thigh of a 
NOD-SCID mouse. After approximately one month mice were sacrificed and teratoma excised, 
fixed in 4% paraformaldehyde, embedded in paraffin and sectioned. 
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4. Results 
 
4.1  ESC Culture and Differentiation  
 
Under appropriate conditions during culture, ESC process self-renewal without limitation (Smith, 
2001). Mouse R1 ESC line depends on MEF feeder cells for maintaining their undifferentiated 
state. With serum and recombinant LIF cytokine, R1 cell colonies displayed tightly packed 
cluster with bright edge, which are known as the typical morphology of mouse ESC colony 
(Figure 4.1A, left panel). ESC can undergo spontaneously differentiation into multi-lineages of 
tissue cells after removing the conditions for self-renewal.  In low attaching dishes, such as Petri 
dish, differentiating R1 ESC aggregate and form 3-dimensional EB structure (Figure 4.1A, right 
panel). The EB formation process is assumed to highly recapitulate the early stages of embryo 
development. EB structures contain ectoderm, endoderm and mesoderm germ layers cells. 
Studying ESC self-renewal/differentiation has provided an invaluable model system to 
understand the mechanisms of cell fate decision and organism’s development. Also, 
differentiation of ESC towards specific lineage cells represents a promising source of cell-based 
therapy in future (Keller, 2005).  
 
 
4.1.1 Hematopoietic Gene Expression During ESC Differentiation 
 
To derive hematopoietic cells from ESC, two differentiation systems have been widely used. One 
is spontaneous differentiation of ESC by EB formation. EB are assumed to contain all 3-germ 
layer derived cells. EB derived mesoderm cells are cultured in the presence of hematopoietic 
cytokines. Hematopoietic lineage cells can be expanded under culture selection. Another one is 
co-culturing ESC with stromal cells. Stromal cells derived from bone marrow or fetal liver 
hematopoietic organs can provide an environment for ESC differentiation specifically into 
mesodermal hemangioblasts and further hematopoietic cell lineages. To investigate 
hematopoietic cell generation in differentiating ESC, we first performed time course experiments 
of ESC differentiation by EB formation and examined expression patterns of key hematopoietic 
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cell related genes. ESC were dissociated into single cell suspension and subjected to 
differentiation in Petri dishes by removing LIF cytokine. EB samples were collected from day 0 
to day 10. Total RNA was isolated from EB-derived cells. Expression of pluripotency genes, 
mesodermal and hematopoietic genes was assessed by q-PCR. The calculated q-PCR results were 
depicted in heat-map format, as showed in Figure 4.1B. Oct4, a master regulator of pluripotent 
stem cells, was highly enriched in pluripotent ESC and decreased gradually in expression with 
differentiation. Brachury (Bry), a transcriptional factor expressed in early mesoderm cells, was 
not present in self-renewal ESC, started the expression on day 2 and decreased transiently. Fetal 
liver kinase 1 (Flk1), also known as KDR, and VEGF-2 receptor, started expression on day 3 of 
differentiation and peaked on day 5. Flk1+ cells are enriched with mesodermal hemangioblast 
(Keller, 2005).  
 
Scl is critical for establishing hematopoiesis and proper endothelial development. By taking ESC 
differentiation as a model system, it was found that Scl is indispensable for the establishment of 
this haemogenic endothelium population, which can directly generate hematopoietic cells 
(Lancrin et al., 2009). The PCR results show that Scl expression started on day 4 and Scl was 
highly expressed on day 6 of differentiation, coinciding with mesoderm formation and the 
emergence of primitive hematopoietic cells. Gata1, a zinc finger transcriptional factor, has been 
known to be indispensable for the development of proerythroblasts. Its expression followed the 
appearance of Flk1+ hemangioblasts. Gata2 expression followed mesoderm formation, as it is not 
only essential for hematopoietic cell formation, but also involved in mesoderm development 
(Lugus et al., 2007).  
 
Keller and colleagures, by analyzing mouse ESC differentiation provided direct evidence that 
Flk1+ Scl+ hemangioblast cells are direct precursors of primitive hematopoietic cells. Recent 
studies demonstrated that haemangioblast generates haematopoietic stem cells through the 
formation of a haemogenic endothelium intermediate (Eilken et al., 2009; Landry et al., 2009). 
However, whether mesoderm cells can directly commit into hematopoietic cells still remains 
elusive. Runx1 is important for primitive hematopoiesis and promotes hematopoietic cell 
transition from haemogenic endothelium cell. Runx1 expression started on day 4 differentiation 
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and subsequently increased; while, Pu.1, a target gene of Runx1 and regulating myeloid lineage 
cells, was expressed subsequently to the expression of Runx1 (Hoogenkamp et al., 2009).  
 
From these results, we conclude that under the conditions described here, mouse ESC are 
maintained in an undifferentiated state and the growing cells display typical ESC colony 
morphology. When subjected to differentiation by plating dissociated cells in Petri dishes, three-
dimensional EB structure are formed. PCR results revealed that key hematopoietic cell genes are 
sequentially induced in ESC/EB differentiation system. 
 
 
 
 
Figure 4.1: Hematopoietic gene expression in differentiating ESC. 
A: Phase contrast imagine of growing ESC on MEF feeders (left); EB (day 3) growing in suspension culture 
(right). Scale bar represents 100 µm.  
B: Heatmap represents pluripotent, mesodermal and hematopoietic gene expression during ESC differentiation 
by EB formation. EB samples were collected on separated days and total RNA was isolated. The expression 
pluripotency gene (Oct4), mesoderm genes (Bry, Flk1 and Scl) and hematopoietic genes (Scl, Gata1, Gata2, 
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Runx1 and Pu.1) was determined by q-PCR. PCR results were subjected to analysis by R software and show the 
relative expression level of indicated gene in heat-map format.   
 
Also, gene expression pattern indicates the sequential hematopoietic cell commitment from 
mesoderm precursors, which are derived from differentiating ESC. These results also indicate the 
faithful recapitulation of ESC/EB system to the in vivo embryonic development. Thus, studying 
ESC hematopoiesis will be helpful to understand how hematopoietic cells form during 
development.  
 
4.1.2 Generation CD45+ Hematopoietic Cells by ESC/OP9 System 
 
Previously, we have developed culture systems for ex vivo expanding Flt3+ HSC from mouse BM 
(Hieronymus et al., 2005; Felker et al., 2010). By the described culture systems, Flt3+ HSC can 
be maintained as homogenously self-renewing cell populations and showing multipotent 
differential potential both in vitro and in vivo. Pluripotent stem cells are generally accepted as an 
unlimited cell source for producing adult stem/progenitor cells and represent a novel cell source 
for regenerative medicine. Therefore, we investigated whether Flt3+ can be derived from ESC.  
 
 
 
Figure 4.2:  Schematic representation of ESC/OP9 co-culture system. 
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Step 1: Single cell suspension of ESC was seeded on OP9 cells. On day 5 of differentiation, cells were 
dissociated into single cells. Flk1+ cells were enriched by MACS.  
Step 2: Flk1+ cells were further cultured on fresh OP9 cells in the presence of cytokines and growth factors 
(SCF, Flt3L, hyper-IL6, IGF-1, GM-CSF and Dex). On day 8, clusters of blast-like cells were collected.   
Step 3: Blast-like cells were seeded on OP9 cells in 15% FCS OP9 medium. The cells were maintained at 
proper cell concentration. According the cell density, over-confluent cells were reseeded on fresh OP9 cells. 
 
 
 
 
 
Figure 4.3: Mesodermal cell differentiation from ESC by OP9 co-culture system.  
R1 ESC were dissociated into single cells and seeded on OP9 stromal cells. The culture was processed as 
shown in Figure 4.2. Phase contrast imagines were taken on day 3, 4 and 5. Scale bar represented 25 µm.  
 
OP9 cells, a stromal cell line, was established from newborn BL6 op/op mice (Kodama et al. 
1994) that lacks functional M-CSF, a cytokine for macrophage development. Co-culturing ESC 
with OP9 cells has been widely used to model hematopoiesis in vitro (Nakano, 1995).  
 
Based on ESC/OP9 stromal cell co-culture system, we established a three-step culture system to 
derive hematopoietic cells from ESC. The three-step experimental protocol is shown as Figure 
4.2. The protocol includes (I) ESC co-culture with OP9 cells and inducing mesoderm germ layer 
differentiation (II) Inducing hematopoietic cells generation from MACS sorted Flk1+ cells (III) 
Expansion ESC derived hematopoietic cells with hematopoietic cytokines.  
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Figure 4.4: Mesodermal Flk1+ cells generation in the ESC/OP9 co-culture system.  
 
A: R1 ESC were subjected to differentiation by co-culture with OP9 stromal cells. At day 0, 3, 4, 5 and 6 cells were 
collected and analyzed for Flk1 expression by FACS. 
B: Histogram shows the kinetic of Flk1 expression during differentiation of ESC.  
C: Enriching Flk1+ cells by MACS strategy.  Day 5 ESC/OP9 co-cultured cells were dissociated into single cells. 
Cells were incubated with PE conjugated anti-FLk1 antibody. Then cells were incubated with anti-PE microbeads 
and subjected to immomegnetic beads selection (MACS, Miltenyi). The cells beads mixture was passed magnetic 
field.  Flk1+ cells could be enriched more than 80% purity with these strategies. 
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Firstly, we studied Flk1+ cell generation by OP9 co-culture system. Flk1, a marker for primitive 
mesoderm cells, is expressed transiently during mouse ESC differentiation. Flk1+ cell is enriched 
with hemangioblast cells, also known as blast colony forming unit (BL-CFU) cells. Flk1+ cells 
can be isolated and further cultured to give rise to hematopoietic and endothelial cells under 
specific conditions (Choi et al., 1998; Chung et al., 2002). Here, we took mouse R1 ESC (passage 
28) and studied Flk1+ cell generation during differentiation by OP9 system.  
 
Two days before starting co-culture, 5 x 104 OP9 cells are plated per well of 6-well plate. By 
starting co-culture, 1 x 104 ESC are seeded on OP9 cell with OP9 cells medium. During culture, 
ESC morphology became flat formed mesoderm-like cells and displayed with condensed cell 
nucleus. On day 5, more than 50% of the colonies displayed these mesoderm characteristics 
(Figure 4.3). We dissociated the cells from day 3 to day 6 and depleted OP9 cells by culturing 
cells 30 min on empty culture dishes. The non-adherent cells were harvested, stained with anti-
Flk1 antibody and subjected FACS analysis. Flk1+ cells were firstly detectable on day 3 of 
differentiation, peaked at day 5 and then rapidly decreased (Figure 4.4A and B).   
 
As primitive hematopoietic cell derivation is restricted to Flk1+ cells, we enriched Flk1+ cells by 
MACS separation. On day 5, differentiated cells were stained with anti-Flk1 antibody (PE 
conjugated). The cells were further incubated with anti-PE microbeads and followed by MACS 
separation. By this approach, we could achieve about 80-90% purity of Flk1+ cells (Figure 4.4C). 
The Flk1+ cells were seeded on fresh OP9 feeder cells with OP9 culture medium and 
hematopoietic cytokines (Figure 4.2). On day 8, small clusters containing 4-10 round, loosely 
adherent and blast-like cells appeared. The blast-like cells were harvested and re-plated on OP9 
stromal cells. With these conditions, the cells could be expanded for about one month (Figure 
4.6A). 
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Figure 4.5: Emergence and expansion of hematopoietic cells by ES/OP9 system.  
 
The sorted day 5 Flk1+ cells were seeded on fresh OP9 stromal cells. Imagines were taken on day 12, day 15 and day 
25 separately (Scale bar represents 50 µm). 
 
 
 
Figure 4.6: Characterization ESC-HPC from OP9 co-culture system. 
 
A: Growth curve of ESC-HPC cells on OP9. 6 x 105 Flk1+ cells, enriched by MACS from day 5 ESC co-culture with 
OP9 were seeded on fresh OP9 cells. Cells numbers were determined by CASY Cell Counter and Analyst System.  
B: FACS analysis day 20 ESC-HPC showed that most of cells were CD45.2+ and CD11b+. 
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C: Hematopoietic cell gene expression in ESC-HPC. Day 20 and day 25 ESC-HPC from OP9 co-culture system were 
harvested and RNA was isolated. BM cells and ex vivo Flt3+ HSC served as positive controls, OP9 and water being 
used as negative controls. PCR products were separated by 2% agarose gel and imagines were acquired by Gel-Doc 
system. 
 
How similar are ESC-derived HPC and BM mononuclear cells or in vitro expanded Flt3+ HSC? 
Next, we characterized the three-step derived ESC-HPC by examining the expression of 
hematopoietic cell related genes. Cells were harvested on day 20 and day 25 and gene expression 
was examined by RT-PCR. These ESC-HPC from our three-step protocol expressed myeloid 
genes, such as Pu.1 and csf receptors, but different to BM Flt3 HSC. They did not express Flt3. 
These results are consistent with reported ESC-derived hematopoietic cells in that 
morphologically they different from bone marrow derived cells, such as lack Flt3 receptor 
expression (Lu et al., 2004). Hematopoietic cells derived from ESC are more reflecting the 
behavior of hematopoietic populations of embryonic yolk sac and fetal liver than adult bone 
marrow cells. Even though, kinds of lineage functional hematopoietic cells have been derived 
through these protocols, hematopoietic progenitor/stem cells displaying in vivo repopulation 
capacities remained difficult to obtain. Collectively, by the three-step co-culture system described 
here, hematopoietic cells were successfully derived from ESC. These ESC-derived hematopoietic 
cells are mainly myeloid lineage cells in phenotypes.  
 
Hematopoietic cell differentiation from ESC has been firmly established and different lineages of 
hematopoietic cells have been derived from ESC (Lensch and Daley, 2006; Olsen et al., 2006). 
However the differentiation efficiency remains of quite low. By ESC differentiation, only subsets 
of mesodermal cells commit into hematopoietic lineages and the ESC-HPC showed limited 
proliferation capacities (Era et al., 2008). The production of HSC/HPC that can reconstitute 
different hematopoietic cell lineages in vivo has remained a challenge. This represents a hurdle to 
achieve high cell numbers, which are required for transplantation of hematopoietic cells in the 
clinical. To achieve direct differentiation and increase the efficiency, genetic modifying the ESC 
differentiation process has been explored (Table 1.2). 
 
  
4.2 Bmi1 Promotes Hematopoietic Cell Generation from ESC 
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4.2.1 Bmi1 Promotes Adult Flt3+ HSC Self-renewal 
 
 
Bmi1, a member of PcG protein, is critical for maintaining the pool of postnatal adult stem cells, 
including HSC, NSC and endothelial progenitors (Lessard and Sauvageau, 2003; Park et al., 
2003; Molofsky et al., 2005; Liu et al., 2006). For introducing Bmi1 expression in Flt3+ HSC and 
ESC, we cloned Bmi1 gene from neural stem cells (Ruau et al., 2008) and sub-cloned into MSCV 
and FUGIE vectors.  FUGIE based lentivirus was prepared and used to infect NIH3T3 cell line. 
After infection, most NIH3T3 cells became GFP+. We did immune fluorescence staining to 
detect expression of Bmi1 protein. Cell nucleus was detected with DAPI staining. Under 
microscopy we observed that Bmi1 protein was expressed and located in cell nucleus (Figure 
4.6B).  
 
 
 
Figure 4.7: Cloning and introducing Bmi1 expression in eukaryotic cell.  
 
A:  Bmi1 cDNA is cloned into FUGIE vectors. 
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B: Bmi1 protein located in cell nucleus. NIH3T3 cells were infected with FUGIE-Bmi1 based lentivirus. The 
cells were fixed and stained with anti-Bmi1 antibody. The nucleus was stained with DAPI (blue). Scale bar 
represents 50 µm.  
 
To further examine the biological impacts of Bmi1 on adult stem cells, we took ex vivo expanded 
Flt3+ cells as a model and studied the effects of enforced Bmi1 expression. Flt3+ HSC were 
prepared from BL6 mice (Hieronymus et al., 2005).   
 
 
 
 
Figure 4.8: Lentivirus introducing Bmi1 expression in mouse Flt3+ HSC 
 
A: Phenotype analysis expanded Flt3+ HSC from mouse bone marrow. Bone marrow cells from BL6 mouse was 
isolated and cultured according the established protocol(Felker et al., 2010) . FACS analyzed the phenotypes of day 7 
cultured cells (grey area, isotype control). 
B: Over expression Bmi1 in Flt3+ cells by lentivirus. Day 7 bone marrow Flt3+ HSC were infected with empty 
FUGIE vector (vector) and FUGIe-Bmi1 (Bmi1) based lentivirus. FACS detected GFP expression, 48 h after 
transduction, relative to uninfected cells (grey area). 
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Day 7 bone marrow Flt3+ HSC were transduced with lentivirus. Transduction efficiencies were 
determined by FACS measuring GFP expression and the infection efficiencies were found to be 
50%-70% (Figure 4.8B). After infection, cells were maintained in proliferating condition as 
described above. Cells numbers were determined in regular time intervals upon expansion of 
cells. By calculating the accumulative of cell numbers, Bmi1 transduced cells showed a more than 
3-fold higher proliferation capacity versus control (Figure 4.9A). We further performed CFU 
assay with transduced cells. Over-expression of Bmi1 resulted in a 2-fold increase of in CFU 
cells. We should point out that cells used for CFU assay were without sorting, but from Bmi1 
transduced Flt3+ HPC, most colonies were GFP+ (Figure 4.9C).  
 
One characteristics of self-renewing HSC is that a fraction of HSC that can grow under stromal 
feeder cells and form cobblestone area (Wagner et al., 2005). To test self-renewal and interaction 
of Bmi1 transdcued Flt3+ HSC with stromal feeder cells, we performed co-culture experiments. 
Day 18 Flt3+ cell, transduced with empty vector and Bmi1 construct were co-cultured with OP9 
stromal cells, including the hematopoietic growth factors described above.  After 4 days of 
culture with OP9 cells, Bmi1 transduced Flt3+ HSC showed the capacity of forming cobblestone 
areas. The cells appeared round morphology and grew underneath the stromal cells. While empty 
vector transduced control cells trended to differentiation or apoptosis with the enlarged cell sizes 
(Figure 4.9D).  
 
By q-PCR analysis, we found that Flt3+ HSC expressed very low level of endogenous Bmi1, 
while cells infected with Bmi1 lentivirus construct showed an approximately 8-fold increase of 
Bmi1 expression.  Interestingly, the HSC self-renewal related gene Gata2 was found to be up-
regulated by Bmi1. The erythroid lineages marker Gata1 was also up-regulated. Expression of the 
myeloid cells transcriptional factor Pu.1 was not affected or even somewhat decreased. In a very 
recent study, Bmi1 was found to be critical for multipotency of HSC and multipotent progenitors 
(MPPs), as Bmi1 is required to reinforce bivalent domains on key lineage instructive genes 
(Oguro et al., 2010). 
.  
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Figure 4.9: Bmi1 enhances self-renewal and proliferation of ex vivo Flt3+ HSC. 
 
 A: Growth kinetics of Flt3+ HSC. Day 7 Flt3+ HSC were transduced with Bmi1vector (Bmi1); empty vector 
was used as control (Vector). Cells were maintained in the same culture condition and cumulative cells 
numbers were determined.  Bmi1 transduced cells (red) showed growth advantages over control cells (blue). 
B: Colony forming assay of Flt3+ HSC. 2.5 x 103 of each Bmi1 transduced Flt3+ HSC were cultured with semi-
solid methylcellulose medium in 3.5 cm dishes. Cells were cultured for 5 days. Colonies type and numbers 
were scored by microscope. WT, untreated cell; Vector, empty vector transduced cells; Bmi1, Bmi1 vector 
transduced cells. 
C: Represents imagine of G-CFU (G), BFU-E and GM-CFU (GM) colonies. Phase contrast, top; GFP 
florescence, below. 
D: Bmi1 promotes self-renewal of Flt3+ HSC. Flt3+ HSC were transduced Bmi1 vector (Bmi1) or empty 
vector (EV) and maintained in self-renewal conditions. On day 18, cells were started co-culture with OP9 
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stromal cells. After 5 days, phase-contrast imagines were taken under light microscope. The dark cells show 
cobblestone forming cells, which grew beneath feeder cells.  
E: Bmi1 induced Gata2 expression. Day 7 Flt3+ HSC were transduced with Bmi1 and empty vector as control.  
On day 15, RNA was prepared and gene expression levels were determined by q-PCR.   
 
Collectively, we took ex vivo expanded Flt3+ HSC as a model and studied the effects of Bmi1 on 
adult HSC. From these results, we can conclude that the self-renewal of Flt3+ HSC is increased 
with ectopic Bmi1 expression. These results are consistent with literature that Bmi1 promotes 
mouse HSC and human cord blood CD34+ cells self-renewal (Iwama et al., 2004; Rizo et al., 
2008). 
 
4.2.2 Differential Bmi1 Expression Between ESC and Adult Stem Cells 
 
Bmi1 is an essential epigenetic modifier in a variety of adult stem cells, including HSC and NSC. 
Increasing Bmi1 expression can promote HSC and NSC self renewal by orchestrating stem cell 
symmetric division; while down-regulation Bmi1 expression results in impaired self-renewal and 
proliferation capacities of adult stem cells (Iwama et al., 2004; Bruggeman et al., 2005; Rizo et 
al., 2008). With our ex vivo Flt3+ HSC culture system, enforced Bmi1 expression leads to 
increased expansion and self-renewal (Figure 4.9). More importantly, several types of human 
malignancies are characterized with increased Bmi1 expression (Schuringa and Vellenga, 2010).  
However, the expression and role of Bmi1 in pluripotent stem cells remains unclear. And to our 
knowledge, so far there are still no detail studies of Bmi1 in ESC.  
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Figure 4.10: Bmi1 is not expressed in undifferentiated ESC. 
A: Gene expression of Bmi1, Ezh2 and Suz12 in undifferentiated ESC (R1, E14 and CCE lines), mouse 
embryonic fibroblasts (MEF), neural stem cells (NSC) and bone marrow (BM) cells was analyzed by q-PCR. 
Expression levels were normalized to β-actin and relative RNA levels are shown (Bmi1, Ezh2 and Suz12 
expression in MEF was set as a reference to 1.0; Oct4 expression in CCE ESC was arbitrarily set 10). Average 
values from 2 independent experiments are shown. 
B: RT- PCR shows that Bmi1 is not expressed in ESC lines.  As described above, the expressions of Polycomb 
protein genes (Suz12, Ezh2 and Bmi1) and pluripotency gene (Oct4) were detected by RT- PCR. GAPDH gene 
was used as loading control. PCR products were separated by 2% agarose gel electrophoresis and imagines 
were taken by Gel-Doc system. 
C: Kinetics of Bmi1 expression during ESC differentiation in EB assay was measured by q-PCR and 
normalized to β-actin. 
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First, we measured expression of Bmi1 and other PRC components in the pluripotent ESC lines, 
MEF, NSC (Ruau et al., 2008), and BM (after depletion red cells). By RT- PCR analysis, we 
observed that Bmi1 had no or very low expression in pluripotent ESC lines, compared to MEF 
(Figure 4.10A). By q-PCR analysis, Bmi1 transcription was higher in NSC and BM than ESC 
(Figure 4.10B). Oct4, a key regulator of pluripotent stem cells, only expressed in ESC lines and 
was not expressed in adult stem cells and lineages committed cells. In accordance with previous 
report, Ezh2 and Suz12 were highly expressed in ESC lines, in line with their transcriptional 
repression activities in ESC (Boyer et al., 2006).  
 
Importantly, Bmi1 expression was rapidly induced during ESC differentiation in EB assays 
(Figure 4.10C).The absence of Bmi1 in ESC and its up-regulation during their differentiation was 
surprising and we thus sought to investigate the impact of enforced Bmi1 expression on ESC 
growth and differentiation. 
 
4.2.3 Lentivirus mediated Bmi1 expression in ESC 
 
The epigenetic status of pluripotent stem cells is resistant to several types of virus vectors, which 
can introduce exogenous gene expression in somatic cells. In ESC, promoters regulating 
exogenous gene expression can be silenced progressively by epigenetic modification; for 
example, MSCV based retrovirus might be silenced by DNA methylation in ESC (Minoguchi and 
Iba, 2008).  
 
FUGIE lentivirus-backbone vector, containing human Ubiquintin C promoter and an internal 
ribosomal entry site to regulate the downstream GFP expression, is able to introduce exogenous 
gene expression in ESC (Li et al., 2007). To introduce Bmi1 expression in ESC, we used FUGIE 
vector lentivirus to infect ESC (Figure 4.7A). Mouse Bmi1 cDNA was cloned into FUGIE vector. 
Empty FUGIE vector and FUGIE-Bmi1 vector based lentivirus were prepared and used to 
infection CCE ESC line.  
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Figure 4.11: Introducing Bmi1 expression in ESC by lentivirus 
 
A: CCE ESC were transduced with Bmi1 vector or empty vector control (vector). GFP+ cells were purified by 
FACS and are shown (black line). Non-transduced ESC, grey line.  
B: Immunostaining of Bmi1 in Bmi1-transduced ESC by Bmi1-specific antibody (red). Cell nuclei were stained 
with DAPI (blue). Size bar, 200 µm. 
C: Western blot analysis of Bmi1 expression in Bmi1-transduced ESC under growth conditions (plus LIF) and 
after differentiation in EB assays (day 14). β-actin is shown as loading control.  
 
 
The infected ESC were maintained in undifferentiated state and cultured on MEF for 2 passages.  
FACS examined the IRES-regulated GFP expression and the transduction efficiency was 
demonstrated around 50% (data not shown). To get purifying cell populations, the GFP+ cells 
were sorted by flow cytometry. After sorting, 95% GFP+ cells were obtained and the cells were 
remained as GFP+ during culture (Figure 4.11A). Bmi1 construct infected ESC were designated 
as Bmi1-ESC. The uninfected WT ESC, EV transduced ESC were taken as control cells. During 
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culture, we found the transduced cells can maintain the homogenously GFP expression. Hence, 
FUGIE based lentivirus system can stable genetic modification ESC. To test Bmi1 expression in 
protein level, Bmi1-ESC and EV transduced ESC were cultured on cover slides and stained with 
anti-Bmi1 antibody. Followed by fluorescence conjugated second antibody staining, Bmi-ESC 
showed a stable Bmi1 expression. Consisting RT-PCR data, there was no Bmi1 protein 
expression in control cells either (Figure 4.11B). To further examine Bmi1 proteins expressed in 
self-renewal ESC and differentiation process, protein lyses from ESC and day 14 EB 
differentiated cells were subjected to WB. There was no Bmi1 protein expression in control ESC 
EB derived cells; even the endogenous mRNA was increased with differentiation (Figure 4.13). 
As expected, the Bmi1-ESC, as well as their EB derived cells showed Bmi1 protein expression 
respectively (Figure 4.11C). Therefore, by lentivirus, we stably introduced Bmi1 expression in 
ESC and during the course of ESC differentiation.  
 
4.2.4 Bmi1 Transduced ESC can Process Normal Self-renewal  
 
Bmi1-ESC had an ESC morphology similar to parental ESC and stained positive for alkaline 
phosphatase (Figure 4.12). ESC are characterized with a pluripotency gene expression profile 
(Kim et al., 2008; Young, 2011) and thus we subjected Bmi1-ESC to genome-wide gene 
expression profiling with DNA microarray. Scatter plot analysis and hierarchical clustering show 
that Bmi1-ESC and parental ESC were very similar and also clustered with a panel of other ESC 
lines (Figure 4.12).  
 
In adult stem cells Bmi1 over-expression causes enhanced self-renewal capacity by promoting 
cell division (Iwama et al., 2004; Oguro et al., 2006; Rizo et al., 2008). Thus, we examined the 
influence of exogenous Bmi1 on ESC self-renewal. Expression of the pluripotency-associated 
genes Oct4, Nanog and Sox2 in Bmi1-ESC was the same as in empty vector ESC and uninfected 
ESC control (Figure 4.13A). In adult stem cells Bmi1 represses transcription of the Ink4a/Arf 
locus, which encodes the CDK inhibitors p16Ink4a and p19Arf (Jacobs et al., 1999; Molofsky et 
al., 2005), and thereby promotes cell proliferation. In ESC expression of the Ink4a/Arf locus is 
repressed by bivalent chromatin and Ink4a/Arf mRNA levels are very low (Figure 4.13B) (Ohm 
et al., 2007). Ink4a/Arf expression was further down-regulated in Bmi1-ESC, showing that the 
repressive activity on this locus is reinforced by exogenous Bmi1. 
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Figure 4.12: Alkaline phosphatase staining and gene expression profiling of Bmi1-ESC. 
A: Bmi1-ESC and ESC control were fixed and stained for alkaline phosphatase activity.  
B: Scatter plot analysis of global gene expression between Bmi1-ESC, untreated ESC (control) and empty vector 
ESC (vector) as indicated.  
C: Hierarchical cluster analysis of Bmi1-ESC, control ESC, empty vector ESC, a panel of ESC lines and NSCs (Kim 
et al., 2008). 
 
Repression of Ink4a/Arf by Bmi1 in adult cells directly translates in an altered cell cycle profile 
(Jacobs et al., 1999; Molofsky et al., 2005) and we thus proceeded to investigate the impact of 
Bmi1 on ESC proliferation by cell cycle analysis. Bim1-ESC have a similar frequency of cells in 
S phase as controls (Figure 4.13C; 31-34%), which is in line with the same proliferation rate and 
growth potential of Bmi1-ESC as controls (Figure 4.13D). Taken together, these results indicate 
that exogenous Bmi1 expression is compatible with ESC self-renewal and maintenance of the 
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pluripotent state. 
 
 
 
Figure 4.13: Bmi1 transduced ESC can be maintained in undifferentiated state during in vitro culture. 
 
A:  RT-PCR analysis of pluripotency genes (Oct4, Sox2 and Nanog) in Bmi1-transduced ESC under growth 
conditions. GAPDH is shown as loading control.  
B: Expression of the Bmi1 target genes p16Ink4a and p19Arf in ESC as in (E) was determined by q-PCR 
analysis. Relative expression normalized to β-actin is shown.  
C: For cell cycle analysis Bmi1-transduced ESC were stained with Hoechst 33342 and subjected to analysis by 
flow cytometry. Gating for cells in S phase is indicated (bar). Control, untreated ESC; Vector, empty vector 
treated ESC. 
D: Fold changes of cells number between passanges. 
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4.2.5 Unaffected Hemangioblasts Development of Bmi1 Transduced ESC 
 
To assess the impact of Bmi1 on differentiation, Bmi1-ESC were subjected to differentiation by 
EB formation. Bmi1-ESC gave rise to EB with similar morphology, size and frequency as 
controls (Figure 4.14A and Figure 4.15A). The frequency of apoptotic cells was the same for 
Bmi-ESC and controls, as determined by 7-AAD and annexin V staining (Figure 4.14B). 
 
 
 
 
Figure 4.14: EB size and apoptosis during EB assay. 
 
A: Bmi1-ESC (Bmi1) and ESC control were subjected to EB assays and size of ~100 EB (day 5) was 
determined by Imagine-Pro software and plotted.  
B: Apoptosis assay for EB-derived cells. EB (day 6) were disaggregated, cells were stained with APC annexin 
V and 7-AAD and analyzed by flow cytometry. Uninfected ESC, control; empty vector control, vector. 
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Figure 4.15: Effects of Bmi1 on mesoderm formation.  
 
A: ESC were subjected to differentiation by EB formation. Phase contrast imagines show EB morphology at days 3 
and 6. 
B: Kinetics of Flk1+ cell generation during EB formation (day 3-6). Single cell suspensions of EB were stained with 
anti-Flk1 antibody and analyzed by flow cytometry. The results shown are the means of 3 independent experiments. 
C: Kinetics of gene expression during EB formation assessed by q-PCR (days 0-10). Expression was normalized to 
β-actin and relative RNA levels of mesodermal genes (Brachyury, Flk1 and Scl), hematopoietic genes (Gata1, Gata2, 
Hoxb4 and Runx1) and the pluripotency gene Oct4 are shown. Normalized expression levels at day 0 were set to 1.0 
and normalized Oct4 expression at day 10 was arbitrarily set to 1.0. One representative experiment is shown. 
 
Lineage tracing and reporter studies demonstrated that during ESC differentiation the 
hemangioblast is emerging around day 3 of EB culture and is detected by expression of the 
receptor kinase Flk1 (VEGF receptor-2) (Keller, 2005). Hemangioblast development is followed 
by patterning of specific subsets of mesodermal cells, including hematopoietic, vascular and 
cardiac somatic cells (Chung et al., 2002; Ema et al., 2003). To determine the influence of Bmi1 
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expression on mesoderm formation, Bmi1-ESC were subjected to differentiation in EB assay and 
Flk1 expression was examined by flow cytometry. Flk1+ cells first emerged on day 3 of 
differentiation in both control and the Bmi1-ESC (Figure 4.15B). The frequency of Flk1+ cells 
peaked at day 5 (around 40% of Flk1+ cells) and from day 6 onwards started to decrease. Thus, 
the temporal pattern of Flk1+ cell generation is similar between Bmi1-ESC and ESC controls. 
 
To study the impact of Bmi1 on early stages of development, RNA was extracted at various 
periods of time of EB culture and expression of pluripotency genes, mesodermal and 
hematopoietic markers were measured by q-PCR. Oct4 expression decreased gradually in both 
Bmi1-ESC and controls. Importantly, we found a prominent up-regulation of Gata2, which 
persisted over the entire period of analysis (day 10) and was not observed in controls (Figure 
4.15C and Figure 4.17). Gata2, a zinc finger transcription factor, is essential for primitive 
hematopoietic cell generation from mesoderm (Tsai et al., 1994; Cantor and Orkin, 2001). Gata1, 
another member of the same family, was also up-regulated. Yet this up-regulation was transient 
and the same for Bmi1-ESC and controls (Figure 4.15C and Figure 4.17). 
 
The activation of Brachyury (T), an early mesoderm marker, showed a similar profile in Bmi1-
ESC as control (Figure 4.16). Scl, a member of the basic helix-loop-helix transcriptional factor 
family, is involved in mesoderm patterning and primitive hematopoietic cell generation. Scl and 
Flk1 are involved in a combinatorial manner in regulating hemangioblasts fate (Ema et al., 2003). 
These two genes were activated sequentially both in Bmi1-ESC and controls (Figure 4.15C and 
Figure 4.17). Runx1 is expressed in yolk sac mesodermal cells prior to the establishment of the 
blood islands and also in the corresponding EB-derived hemangioblasts (Lacaud et al., 2004). 
The homeobox gene Hoxb4 is implicated in growth of both embryonic and adult HSC, and is 
important for engraftment potential of ESC-derived hematopoietic cells (Kyba et al., 2002). 
Runx1 and Hoxb4 displayed a similar pattern of expression for Bmi1-ESC and control ESC 
(Figure 4.15C). 
 
CD41 represents one of the early markers during hematopoiesis in EB assays and in the mouse 
embryo (Mikkola et al., 2003). Therefore, to determined frequencies and kinetics of CD41+ c-
Kit+ hematopoietic precursor cells in differentiating Bmi1-ESC, EBs from day 2-10 were 
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dissociated and analyzed by flow cytometry. There was a prominent increase in CD41+ c-Kit+ 
cells between day 4 and 6 (Figure 4.16A). CD41+ c-Kit+ cells were then obtained by cell sorting 
and analyzed for expression of hematopoietic genes. We observed strong up-regulation of Gata2 
in CD41+ c-Kit+ cells at days 8 and 10 (Figure 4.16B). 
 
 
 
Figure 4.16: Gata2 is up-regulated in expression by Bmi1 in CD41+ c-Kit+ cells 
A: Kinetics of CD41+ c-Kit+ cell generation during EB formation (days 2-10) in Bmi1-ESC. Single cell suspension 
were stained with CD41 and c-Kit specific antibodies and analyzed by flow cytometry. The results shown are the 
means of 3 independent experiments.  
B:  Expression of hematopoietic genes in CD41+ c-Kit+ cells at days 6, 8 and 10 of EB formation. CD41+ c-Kit+ + 
cells were obtained by cell sorting and analyzed by q-PCR. Expression values were normalized to β-actin and 
expression in empty vector transduced cells was set to 1.0. 
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Figure 4.17: RT-PCR determining mesoderm, hematopoietic genes expression during Bmi1-ESC 
differentiation by EB formation assay.  
 
ESC were subjected to differentiation by EB formation. RNA samples were prepared in regular time intervals as 
indicated and gene expression examined by RT-PCR. GAPDH is shown as control. Uninfected ESC, control; empty 
vector control, vector. 
 
Taken together, our results demonstrate that forced expression of Bmi1 allows ordered mesoderm 
and hemangioblast development of ESC. Remarkably, Gata2, a gene expressed in primitive 
hematopoietic cells, was efficiently increased by Bmi1. 
 
4.2.6 Transcriptional repressive activity of Bmi1 during differentiating ESC 
 
To obtain further insights into gene regulation by Bmi1 during differentiation in EB assay, we 
performed genome-wide gene expression studies with DNA microarray. RNA from Bmi1-ESC 
at day 10 of differentiation was extracted and subjected to Affymetrix GeneChip arrays and data 
were analyzed by hierarchical clustering. Empty vector transduced ESC were used as control. 
We identified 304 genes that were differentially expressed between both groups: 221 genes were 
found to be up-regulated and 83 genes were down-regulated by Bmi1. Many differentially 
regulated genes were found to be involved in specific biological functions and Figure 4.18A 
shows a panel of transcription factors and development-associated genes. 
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Several members of Hox gene family of transcriptional factors, which play a critical role in 
development, are known to be dynamically regulated by Bmi1 or other PcG proteins (Simon et 
al., 1992; van der Lugt et al., 1996). We find four Hox genes, Hoxa3, Hoxa9, Hoxd10 and 
Hoxa11 being repressed by Bmi1 (Figure 4.18A). The zinc-finger domain transcription factor 
Zic1, which is required for neuronal differentiation, was also repressed by Bmi1. This is 
consistent with the observation that Zic1 represents a known target of PcG proteins (Bracken et 
al., 2006). Several members of hemoglobin genes (Hbb-y, Hba-a1 and Hbax), markers for 
erythroid cell differentiation, were also down-regulated in differentiating Bmi1-ESC. Yet 
repression of the Ink4a/Arf locus, which is a direct target of Bmi1 in adult stem /somatic cells 
could not be detected by microarrays, probably due to very low expression levels (see also below 
Figure 4.21A). Several genes were up-regulated in Bmi1-ESC during differentiation (Figure 
4.18A), including transcription factors, cell structure proteins, membrane receptors and 
extracellular matrix proteins. As expected, Gata2 was also found to be up-regulated in Bmi-ESC, 
which is in line with the PCR data described above (Figure 4.16 and Figure 4.17). Elevated 
expression of these up-regulated genes is most likely due to secondary and indirect effects of the 
repressive Bmi1 activity. 
 
PCR analysis of the Hox genes Hoxa3, Hoxa9, Hoxd10 and Hoxa11 and of the Zic1 and Gata2 
transcription factors confirmed the DNA microarray data (Fig. 4B). The myosin genes Myh6 and 
Myl2 showed elevated expression in Bmi1-ESC, which is also consistently with microarray data 
(Figure 4.18). The hematopoietic genes c-Kit, Hoxb4 and Gata1 and the endothelial cell markers 
CD31 and CD144 (VE-Cadherin) remained unaffected by Bmi1, both by microarray analysis and 
q-PCR. Thus, forced Bmi1 expression during EB differentiation entails repression of known 
Bmi1/PcG protein target genes but causes also elevated expression of yet another group of genes, 
most probably through indirect mechanisms. 
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Figure 4.18: Gene expression profiling of differentiated Bmi1-ESC. 
A: Hierarchical cluster analysis shows changes in gene expression induced by Bmi1 in differentiated ESC. Bmi1-
ESC and vector control ESC at day 10 of EB differentiations were subjected to microarray analysis (Affimetrix 
GeneChip arrays). Differentially expressed genes (> 2fold) were analyzed by hierarchical clustering and are depicted 
in heatmap format. Duplicates are shown and each gene is represented by a single row of colored boxes: Green, 
expression levels below median; red, expression levels above median.  
B: q-PCR validation of microarray data. Five Bmi1 repressed genes (4 homebox genes: Hoxa3, Hoxa9, Hoxa11, 
Hoxd10 and the zinc family member 1, Zic1) and 3 up-regulated genes (Gata2, Myh6 and Myl2) were selected for q-
PCR. Average values of duplicates are shown. Relative expression levels were normalized to β-actin and gene 
expression changes were calculated by ΔΔCT as before. Values are shown as Log2 induction values. Microarray 
data were submitted in GEO database (series accession number: GSE20958). 
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4.2.7 Bmi1 Promotes HPC Development from ESC 
 
 
Given the prominent up-regulation of Gata2 in Bmi1-ESC, we chose to study the impact of Bmi1 
on the generation hematopoietic cells from ESC. 
 
 
 
 
 
Figure 4.19: Bmi1 promotes the development of BL-CFU from EB-derived cells 
 
A: Hematopoietic colony forming assay of EB-derived cells at day 6 of differentiation. Bmi1-ESC, empty vector 
ESC and untreated ESC control (CCE) were differentiated by EB formation for 6 days and 1 x 105 cells were seeded 
into semi-solid methylcellulose culture with cytokines (SCF, IL-3, IL-6, and erythropoietin). After 5 and 10 days of 
culture, numbers of CFU-E, CFU-GM and CFU-GEM were scored by microscopy and are shown.  
B: Phase-contrast imagines were taken from representative CFU-E, CFU-GM and CFU-GEM colonies (upper panel); 
neutral benzidine stained isolated colonies (lower panel). A representative result of 5 independent experiments is 
shown. 
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Primitive hematopoietic colony forming units (CFU), particularly erythroid and erythroid-
myeloid CFU cells, are first detectable in differentiating ESC at day 5 and 6. Therefore, single 
cell suspensions of day 6 EB were plated in semi-solid methylcellulose cultures supplemented 
with hematopoietic cytokines and the number and morphology of colonies was evaluated, 
including CFU-E (erythroid colony-forming units), CFU-GM (granulocyte and macrophage 
colony-forming units) and CFU-GEM (erythrocyte, granulocyte and macrophage colony-forming 
units). Strikingly, Bmi1 enhanced the number of hematopoietic CFUs up to 3-fold over controls 
(Figure 4.19A). The morphology and frequency of different types of colonies for Bmi1-ESC and 
controls were quite similar (Figure 4.19B). Therefore, Bmi1 promoted development of 
hematopoietic cells from ESC, but there appears to be no specific impact of Bmi1 on the 
development of specific hematopoietic lineages. 
 
4.2.8 Bmi1-HPC show Robust Proliferation Capacity  
 
To further assess the effects of Bmi1 on definitive hematopoiesis in differentiating ESC, we 
studied hematopoietic progenitor cells differentiation by ESC/EB system. This culture system has 
been used been widely used to generate HSC/HPCs from ESC and the experimental outline was 
shown as Figure 4.20A. Firstly, ESC were subjected to differentiation by EB formation. On day 
6, EBs were disaggregated into single cells and seeded in serum free medium with hematopoietic 
cytokines. After 2 days of culture, the non-adherent cells, including most of the blast forming 
cells were harvested and further kept in culture with serum free medium and cytokines. The 
accumulative of cells number was calculated to address the proliferation potential of the cultures. 
Strikingly, Bmi1 markedly enhanced the proliferation capacity of suspending cells and so Bmi1-
HPC (Bmi1-ESC derived hematpoietic progenitor cells) could be expanded up to nearly 100-fold 
within 3 weeks of culture (Figure 4.20B).  
We maintained the cells in culture for nearly 2 month without losing their high proliferation 
potential and could generate a vast number of cells. In contrast, for the control ESC-HPC, the 
suspending cells were failed to thrive and were rapidly lost after a few days of culture. The low 
expansion capacity of control ESC-HPC made it was difficult to get enough cells for analysis 
(Figure 4.20B). Further analysis of Bmi1-HPC by cytospin staining revealed that they retained a 
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primitive morphology, which resembled blast-like cells, as revealed by cytospin staining (Figure 
4.20C), while the control cells gave a lot dead cells and debris in the staining. 
 
 
 Figure 4.20: Bmi1 leads to the robust proliferative capacity of ESC-derived hematopoietic cells. 
 
A: Schematic representation of the culture system used for hematopoietic cell differentiation from ESC. ESC were 
subjected to differentiation by EB formation. Day 6 EB were disaggregated and EB-derived cells were plated on 
gelatin-coated dishes with hematopoietic cell cytokines in serum free medium. At day 8-9 of culture non-adherent 
cells were harvested and expanded.  
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B: Growth kinetics of ESC-derived hematopoietic cells. Cumulative cell numbers of 2 independent experiments is 
shown.  
C: Colony forming unit assay from day 12 ESC-HPC.  
D: Morphology of Bmi1-HPC on day 26 of differentiation. Cytospin preparations were stained with May-
Gruenwald/Giemsa. 
 
To further determine the role of Bmi1 in definitive ESC hematopoiesis, we did colony-forming 
assay from day 12 differentiated cells. 1 x 104 ESC-HPC were plated in methylcellulose culture 
medium; after 5-10 days of culture, colonies number was scored. Bmi1-HPC showed an 
approximately 10-fold increase in the capacity of colony forming units comparied to the control 
cells. The colony types mainly included CFU-E, CFU-GM and CFU-GEM. This indicated Bmi1-
HPC were highly enriched with CFUs. Thus, Bmi1 confers the proliferative capacity to ESC 
derived HPCs and promotes definitive hematopoietic cells generation. As Bmi1 promoting the 
self-renewal of adult HSC is known at least partially though repressing the expression of 
p16Ink4a and p19Arf, we compared the transcripts of Inka4a/Arf locus in ESC, day 6 EB and day 
12 ESC-HPC. The results showed that with the differentiation, the expression of p16Ink4a and 
p19Arf were induced in control ESC-HPC, while in Bmi1-HPC their expression was effectively 
repressed (Figure 4.21A). Thus, similar to the effects of Bmi1 on adult stem cells, Bmi1 might 
confer the proliferation capacity of ESC-HPC perhaps at least partially through repressing the 
Ink4a/Arf locus. 
 
 
 
Figure 4.21: Ink4a/Arf locus is repressed in Bmi1-HPC 
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A: Expression of p16Ink4a and p19Arf in undifferentiated ESC, day 6 EB and day 15 ESC-HPC. p16Ink4a/p19Arf 
expression was examined by q-PCR and normalized to β-actin. 
B: Schematic model showing the expression for Ink4a/Arf locus during embryonic hematopoiesis in wild type and 
Bmi1-ESC. The red indicates a repression of its expression and the green indicates the activated expression. 
 
The self-renewal of HSC is closely related with their adhesion properties (Wagner et al., 2005), 
as it influences their interaction with stromal cells in vivo and regulates symmetric division. To 
test the interaction of Bmi1-HPC interaction with stromal cells, we harvested the suspending cells 
from day 8 differentiated cells, plated them on OP9 stromal feeder cell and continued culturing 
them in the presence of growth factors. Most of ESC-HPC from control ESC were died during 
this culture; while ESC-HPC with constitutively expression of Bmi1 could form the typical 
cobblestone area which grew beneath the stromal (Figure 4.22). Taken together, these data 
demonstrated that enforced Bmi1 expression enhanced hematopoietic cell differentiation, survival 
and was responsible of the continued and extensive proliferation property of Bmi1-ESC derived 
HPC. 
 
 
 
Figure 4.22: Cobblestone forming assay of Bmi1-HPC  
 
Cobblestone area forming assay of Bmi1-HPC. Day 9 Bmi1-HPC were collected and seeded on OP9 stromal cells 
with OP9 medium and hematopoietic cytokines. Bmi1-HPC show formation of cobblestone areas (arrow). Phase 
contrast imagine, left panel; GFP expression, right panel. 
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4.2.9 Bmi1-HPC are Heterogeneous in Phenotype 
 
To characterize the phenotype of Bmi1-HPC, cells were stained for a panel of hematopoietic cell 
surface antigens and analyzed by flow cytometry (Figure 4.23). More than 90% of cells expressed 
c-Kit, probably because Bmi1-HPC were always cultured in the presence of c-Kit ligand SCF. 
There was also expression of other stem cell markers, such as Sca1, CD34 and CD133, however 
these cells represented only 10-30% of the cell population. A rather high fraction of cells 
expressed myeloid lineage markers, including CD11b, CD14 and Gr1 (30-45%), and the 
erythroid lineage marker Ter119 (60%). 
 
 
Figure 4.23: Bmi1-HPC are heterogeneous population of cells. 
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A: Bmi1-HPC (day 20) were analyzed by flow cytometry using a panel of hematopoietic surface markers as 
indicated. 
B: Day 20 expanded Bmi1-HPC were analyzed by FACS for. Data represented the mean value of 2 independent 
experiments. 
 
We also examined the surface phenotype of cells at day 15, 30 and 40 and there were no obvious 
changes over extended culture periods. Thus, Bmi1-HPC are heterogeneous in phenotype, which 
is similar to Hoxb4 ESC-HPC (McKinney-Freeman et al., 2009). 
 
To further characterize Bmi1-HPC, we compared the hematopoietic gene expression profile of 
Bmi1-HPC with fetal liver cells and adult bone marrow cells by RT-PCR (Figure 4.24). Bmi1-
HPC showed high expression of the hematopoietic transcription factors Gata1, Gata2 and Pu.1, 
and abundantly expressed the cytokine receptors c-Kit and G-CSF receptor, but not Flt3. 
 
 
 
 
Figure 4.24: Hematopoietic genes expression by Bmi1- HPC 
 
RNA was prepared from ESC, day 20 and day 40 Bmi1-HPC, embryonic (day14) fetal liver (FL) cells and adult bone 
marrow (BM) cells. Expression of selected genes was determined by semi-quantitative RT-PCR. GAPDH was used 
as control 
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4.2.10  The Survival of Bmi1-HPC Depends on Hematopoietic Cytokines  
 
Deregulation of Bmi1 is a common feature in several types of leukemias and high Bmi1 
expression is frequently found in primary leukemia cells (Lessard and Sauvageau, 2003). This 
raises the question whether enforced Bmi1 expression is sufficient to promote Bmi1-HPC self-
renewal or to transform the cells. Therefore we tested the cytokine and growth factor response of 
Bmi1-HPC in 3H-thymadine incorporation assays (Figure 4.25). We found that Bmi1-HPC were 
critically dependent on growth factors for survival and proliferation. SCF and IL-3 conferred 
some proliferative potential, yet multiple factor combinations were required for maximal 
proliferative rates (Figure 4.25). Since survival of the majority of leukemia cells is aberrantly 
independent on cytokines signals (Van Etten, 2007), this finding suggests that forced Bmi1 
expression causes more potent proliferation rates and but is not sufficient to transform cells. 
 
 
 
Figure 4.25: Hematopoietic cytokines responsiveness of Bmi1-HPC 
 
Different combinations of growth factors were applied to Bmi1-HPC culture as indicated. A total of 5 x 104 cells 
were incubated in 200 µl serum-free medium in 96-well flat-bottom plate at 37°C for 48 h. Samples were then pulsed 
for 4 h with 0.75 µCi/well [3H] thymidine. The cells were harvested onto glass fiber filters. Radioactivity was 
measured by liquid scintillation counting in a Microbeta counter.   
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4.3 Reprogramming Flt3+ HSC  
 
Pluripotent cells have great potential in tissue and cell replacement-based therapy. If we are able 
to use a combination of pluripotency factors to switch skin or blood cells into pluripotent states, it 
will be a great step towards cell and tissue-based therapy. It has been known that ESC contain 
factors of reprogramming differentiated somatic cell into pluripotent state (Do and Scholer, 
2004). In the last couple of years, deep understanding has been made for the underlying 
molecular mechanisms of pluripotency. Pluripotency is dominant due to the transcriptional 
circuitry formed by the key pluripotency regulators (Boiani and Scholer, 2005a). In 2006, 
pluripotent cells were for the first time generated from mouse fibroblasts by retroviral 
transduction of several pluripotency-related transcription factors (Oct4, Sox2, Klf4 and c-Myc). 
These reprogrammed cells from somatic cells were termed as induced pluripotent stem cells 
(iPSC) (Takahashi and Yamanaka, 2006). Since then, iPSC technology has received extensive 
research and interest. Currently, iPSC can be routinely generated from a wide range of tissue 
specific cells in both human and mice, such as fibroblasts, neural stem cell and hematopoietic 
cells (Hanna et al., 2007; Amabile and Meissner, 2009; Kim et al., 2009). Both scientists and the 
public expected that iPSC technology will provide a valuable platform to model human disease 
and hold a great potential in regenerative medicine.  
 
However, several issues need to be taken into consideration with studying and applying iPSC. 
One important concern is deciding on proper starting cell populations for reprogramming. For a 
variety of reasons, HSC/HPC represent a preferred cell source for generating iPSC (Kaneko et al., 
2010). For example, compared to other lineages cells, the cascade of HSC development has been 
well characterized. Most of HSC locate in the bones and it means that HSC are protected by bone 
and surrounding tissues. Additionally, HSC contain relatively stable genomic information. In 
clinical setting, hematopoietic cells can be easily isolated without severe burdens to donors, and 
blood banks have been widely established. Another point is that HSC/HPC can be readily 
expanded as they response to many growth factors and cytokines. Nevertheless, HSC are a rare 
cell population and represent 0.01% of cell population in bone marrow. The low number of HSC 
potentially hampers and complicates for the generating of iPSC from HSC. Our lab has long been 
establishing ex vivo culture systems for expanding HSC. Therefore, we attempted to generate 
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iPSC from ex vivo expanded Flt3+ HSC. Here, we provide evidence of reprogramming Flt3+ 
HSC into pluripotent state by transduction with pluripotency-related factors and fusion with ESC.  
 
4.3.1 Ex vivo Expanding Flt3+ HSC from OG2 Mouse 
 
Primary Flt3+ HSC were prepared as reported before (Felker et al., 2010). Briefly, bone marrow 
cells were isolated from OG2 mouse. Bone marrow derived-cells were subjected to culture with a 
cocktail of hematopoietic growth factors (SCF, IGF1, hyper-IL6 and Flt3 ligand). On day 3, the 
cultured cells were given a ficoll to remove debris and dead cells. After that, the cells were 
maintained at a concentration of 2 x 106  cells/ml and cultured in RPMI medium with growth 
factors as described above. On day 6, this culture resulted in highly proliferating and homogenous 
Flt3+ HSC (Figure 4.26A). Cell phenotypes were analyzed by FACS. As shown in Figure 4.26B, 
all cells were GFP negative indicating that the transgenetic Oct4-GFP reporter was silenced in 
Flt3+ HSC. All cells were homogenously expressing CD45, a specific marker for hematopoietic 
cells (Figure 4.26B). They were also homogenously expressing Flt3 and CD11b. Flt3, a type of 
tyrosine kinas, has no expression on long-term HSC, but is transiently expresses on short term 
HSC and multipotent hematopoietic progenitor cells (Felker et al., 2010). We refer to these ex 
vivo expanded bone marrow hematopoietic cells as Flt3+ HSC. By transplantation in vivo and in 
vitro differentiation system, Flt3+ HSC showed the potential of giving rise to all lineages of 
hematopoietic cells (Felker et al., 2010). 
 
4.3.2 Generation iPSC from Flt3+ Cells  
 
Oct4, Sox2, Klf4 and c-Myc genes have been successfully used for reprogramming MEF 
(Takahashi and Yamanaka, 2006). Here we used the same combination of pluripotency factors to 
reprogram Flt3+ cells. Oct4, a master regulator of pluripotency, is specifically expressed in 
pluripotent stem cells (Boiani and Scholer, 2005a). If Flt3+ HSC are successfully reprogrammed, 
cells will become GFP+. The pMX-GFP was taken as a control to evaluate the efficiency of 
infection. Virus was generated from transfected virus-packaging cell line 293T cell as described 
above. Virus supernatants were pooled and concentrated with 80 µg/ml PB and 80 µg/ml CSC. 
Virus pellet was re-suspended by 200 µl medium and used for infection of Flt3+ HSC (1 x 106 
/ml, 3 ml/ well of 6 well plate).  After 48 h, the infected cells were subjected to ficoll to remove 
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debris. pMX-GFP virus infected cells was used to measure GFP expression by FACS. As shown 
in Fig 4.26C, 50-70% GPF+ cells were routinely obtained. OSKM (Oct4, Sox2, Klf4 and Sox2) 
mixed virus-infected cells were seeded on inactivated MEF feeder. Cells were cultured with ESC 
medium and LIF.   
 
After introducing pluripotency factors (Oct4, Sox2, Klf4 and c-Myc) by virus, we checked the 
kinetics of GFP+ cell emergence by fluorescence microscopy. With MEF feeder and LIF, infected 
Flt3+ HSC showed very good survival. The cells were frequently forming large cell clusters. 
Perhaps due to the reprogramming factors, including the Klf4 and c-Myc, which are known as 
transforming factors in several types of malignancies, four factor infected Flt3+ HSC displayed 
robust proliferation capacity. Once non-adherent cells became too dense, we gently harvested 
non-adherent cells and replated them on fresh MEF feeder cells.  
 
GFP+ cells were observed about day 7 post infection. There were no GFP+ cells in virus 
untreated dishes. Figure 4.27 shows the kinetics of changes in cells morphology and the 
emergence of eGFP cells during the process of reprogramming. About three weeks after 
infection, we observed compact colonies with diffuse cell edges, resembling mouse ESC in 
morphology. On day 20, we scored the GFP+ colonies by microscopy. In the first experiment, we 
obtained approximately 12 GFP+ and typical ESC-like colonies from 1 x 106 Flt3+ HSC. In the 
second experiment, around 600 GFP+ colonies were obtained from 3 x 106 Flt3+ HSC. By 
considering the starting number of Flt3+ HSC, the efficiency of Flt3 iPSC generation was 
calculated (Table 4.1). Thus, similar to other types of somatic cells, the efficiency of inducing 
pluripotency from Flt3+ HSC was quite low (less than 0.02%) (Hanna et al., 2010). Eminli et al. 
reported that HSC/HPC give rise to iPSC up to 300 times more efficiently than terminally 
differentiated B and T cells (Eminli et al., 2009). We did not compare the reprogramming 
efficiency between Flt3 HSC and their differentiated progeny, like dendritic cells. The low 
efficiency of reprogramming Flt3+ HSC described here might be due to the different cell culture 
and iPSC inducing systems.  
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Figure 4.26: Preparing Flt3+ HSC and over-expression pluripotency factors in Flt3+ HSC by retrovirus.   
A: Schematic representation of isolating and expanding BM Flt3+ HSC from OG2 mice. On day 6, Flt3+ HSC 
were infected with retrovirus containing pluripotency factors OKSM (Oct4, Sox2, Klf4 and c-Myc). eGFP 
construct was taken as control to monitor efficiency of virus infection.  
B: Phenotype analysis Flt3+ HSC. Bone marrow cells were isolated from OG2 mice. Cells were cultured with 
Flt3L, SCF, IGF-1 and hyper-IL6. On day 6 cells phenotype was analyzed by FACS. Cells were stained with a 
panel of antibodies and measured by FACS (black line, isotype control; black area, signal of staining). 
C: FACS analyzed the efficiency of retrovirus infection of Flt3+ HSC. Day 6 Flt3+ HSC were infected with 
pMX-GFP based retrovirus. After 48 h cells were subjected to FACS analysis. Around 70% of Flt3+ HSC were 
routinely infected. 
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Figure 4.27: Kinetic of Oct4-eGFP expression during the process of Flt3 iPSC generation. 
Oct4, Sox2, Klf4 and c-Myc were over-expressed in Flt3+ HSC through retrovirus infection. The infected cells were 
seeded on MEF and cultured in ESC medium with LIF. Imagines were taken on indicated days and show the kinetic 
eGFP expression during reprogramming. The scale bar represents 50 µm. 
 
Table 4.1: Efficiency of Reprogramming Flt3+ HSC 
 
Experiments Number of starting 
Flt+ cell (106) 
Number of eGFP+ 
colonies 
Efficiency of iPSC 
generation (%) 
I 1 12 0.0012 
II 3 600 0.02 
 
 
To establish Flt3 iPSC clones, GFP+ clones, with typical ESC-like morphology from day 14-20 
of infection (Figure 4.28A) were mechanically picked under microscopy. The picked clones were 
disaggregated into single cells with trypsin and replated on inactivated MEF. Clones with 
homogenously eGFP+ expression and typical ESC-like morphology were expanded (Figure 
4.28B and C). The expanded clones displayed similar growth kinetics as ESC and were expanded 
and crypreserved in liquid nitrogen.  
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Figure 4.28: Morphology and GFP expression of Flt3 iPSC.   
 
A: At day 20 after infection Flt3+ HSC show ESC-like eGFP+ colonies. 
B. Establishing Flt3 iPSC clones. eGFP+ colonies were picked under microscopy and re-plated on inactivated MEF 
with ESC culture conditions. iPSC colonies could be expanded and show ESC-like morphology.  
C: Established Flt3 iPS clone. Flt3 iPSC colonies could be crypreserved, thawed and cultured like ESC. The scale bar 
indicates 100 µm. 
 
4.3.3 Characterizing Flt3 iPSC 
 
To examine the integration of reprogramming factors into the genomic DNA of iPSC, DNA was 
isolated from iPSC clones. Specific primers for exogenous genes were used and genomic PCR 
was performed. The four factors cDNA, which were introduced by virus, could be detected in all 
Flt3 iPSC clones. Thus, the Flt3 iPSC clones retained the external four factor DNA sequences. 
The copy number of virus-introduced pluripotency factors in different iPSC clones might be 
different, according to the signal intensity of the different PCR products (Figure 4.29).   
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Figure 4.29: Integration of pluripotency factors into Flt3 iPSC genomic DNA.  
 
DNA was isolated from different Flt3 iPSC clones and ESC. PCR primers binding to pMX vector and to cDNA of 
reprogramming factors were used (see 2.5). PCR products were loaded and separated by 2% agarose gel 
eletrophoresis. Genomic sequence of IL2 was taken as positive controls. C, negative control (no DNA). 
 
We further analyzed pluripotent and somatic gene expression by RT-PCR. The results showed 
Flt3 iPSC expressed pluripotent stem cell marker genes. The endogenous Oct4, Sox2 and Nanog 
were activated and expressed at similar levels as in ESC (Figure 4.30B). The expression of Nanog 
could also be detected at the protein level (Figure 4.33A). Flt3+ HSC related gene Flt3, c-Kit, 
Gata2 and Pu.1, which were only expressed in Flt3+ HSC were silenced in iPSC clones. Thus, 
RT-PCR results demonstrate that simultaneously with the reprogramming process, iPSC clones 
had acquired the pluripotency gene expression program and genes expressed in Flt3+ HSC were 
silenced. In addition, Flt3 iPSC were characterized with high level of alkaline phosphatase (AP) 
expression, as demonstrated by AP staining (Figure 4.30A). After removing self-renewal 
condition and submitting suspension culture, Flt3 iPSC formed three dimensional EB structures. 
With ongoing differentiation, Oct4-eGFP expression decreased (Figure 4.30C). All together, Flt3 
iPSC displayed characteristics of ESC, such as, expressing pluripotency factors (Oct4, Nanog and 
Sox2), exhibiting AP activity and the ability of forming EB structures.  
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Figure 4.30: Characterization Flt3 iPSC.  
 
A: Flt3 iPSC are AP+. R1 ESC and Flt3 iPSC were grown on MEF feeder. Cells were fixed and stained with 
substrate to AP. 
B: Gene expression of Flt3 iPSC. RNA was isolated from ESC, iPSC clones and Flt3+ HSC. RT-PCR was 
performed to examine expression of HSC gene Flt3, Gata2, c-Kit and Pu.1, and pluripotency gene Nanog, Sox2 
and Oct4. GAPDH served as loading control.  
C: Differentiation of Flt3 iPSC. Flt3 iPSC form EB. EB was generated by differentiating Flt3 iPSC in 
suspension culture. The upper panel indicates kinetics of Oct4-eGFP expression during differentiation. The 
lower panel shows merged imagines of Oct4-eGFP expression and autofluorecence to indicated EBs (in 
collaboration with Paul Wanek, BSc, Institute for Biomedical Engineering, Department of Cell Biology, RWTh 
Aachen University, Aachen Germany). 
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One of classical assays for testing pluripotency is teratoma formation (Yamanaka, 2008). After 
injecting into immune-deficient mice, pluripotent cells form teratoma, cell derivatives of all three 
germ layers. To examine pluripotency characteristics of Flt3 iPSC, we performed teratoma 
formation experiments. 2 x 106 iPSC were suspended in 100 µl PBS and injected into NOD-SCID 
mice. HM1 ESC were taken as control. 4 weeks after injection, teratomas were observed in all 
injected mice. The size of teratomas for iPSC and ESC injected mice was comparable. Mice were 
sacrificed and teratomas were isolated, fixed with 4% paraformaldehyde, sectioned and stained 
with HE. The results indicated that teratomas from iPSC contained derivatives of all three germ 
layers, including epithelium (ectoderm), muscle (mesoderm) and cuboidal epithelium (endoderm) 
(Figure 4.31). Collectively, all the data indicated the successful of reprogramming Flt3+ HSC into 
pluripotent state. Flt3 iPSC clones displayed pluripotent potential in differentiation.  
 
 
 
 
 
 
Figure 4.31: Teratoma formation of Flt3+ iPSC. 
 
2 x 106 cells of Flt3 iPSC clones were injected into NOD-SCID mouse subcutaneously. 3 mice were injected for each 
Flt3 iPSC clone. HM1 ESC line was taken as a control. 4 weeks after injection, mice were sacrificed and teratoma 
excised. The samples were fixed, sectioned and stained. Representative imagines of mesoderm, ectoderm and 
endoderm were shown (in collaboration with Rebekka Schneider, MD, Institute of Pathology, RWTH Aachen 
University, Aachen, Germany).  
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Based on these experimental results, we concluded that ex vivo expanded Flt3+ HSC can be 
successfully reprogrammed into pluripotent state by over-expressing the pluripotency factors.  
Flt3 iPSC clones displayed the pluripotency characteristics, such as in vitro growth, AP+, 
endogenous pluripotency transcriptional network being activated and hematopoietic genes being 
silenced and teratoma formation after injecting into NOD-SCID mice.  
 
 
4.3.4 Reprogramming Flt3+ HSC Thought ESC Fusion 
 
Somatic cell nucleus can be reprogrammed into pluripotent state by fusion with ESC. Fusion with 
ESC has been demonstrated as an efficient and fast approach for reprogramming somatic cells. 
For example, activating Oct4, the master regulator of pluripotency occurred within the first cell 
cycle after fusion (Han et al., 2008). The fast kinetics of cell fusion mediated reprogramming 
implies that alternative or additional reprogramming factors might be existed. Studying fusion 
mediated reprogramming might be helpful to find factors involved in reprogramming and finally 
to improve reprogramming efficiency. Also, it is an invaluable system for elucidating the 
molecular mechanisms behind reprogramming. 
 
Here, we used bone marrow Flt3+ HSC as somatic donor cells and fused them with ESC. Ex vivo 
expanded Flt3+ HSC have been demonstrated representing a homogenous and multipotent stem 
cell population (Felker et al., 2010). Furthermore, Flt3+ HSC are non-adherent cells and this 
characteristic makes it easy to distinguish fused and unfused events during culture. We isolated 
bone marrow cells from OG2 mice and expanded Flt3+ HSC as described above. I chose the E14 
ESC line for reprogramming by cell fusion. E14 is a feeder independent ESC line and can be 
maintained on gelatin coated dishes with ESC complete medium and LIF. The experimental 
outline is shown as Figure 4.32. Flt3+ HSC from OG2 mice were GFP negative and neoR. E14 
ESC are eGFP negative and neoS. If fusion happens between these two cell types, the cell nucleus 
becomes tetroploid (4n). Expression of eGFP under Oct4 promoter in Flt3+ HSC will be activated 
once the Flt3+ cell nucleus is reprogrammed. With neomycin selection, only fused and 
reprogrammed cells could grow and display GFP+.  
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Figure 4.32: Experiment scheme of ESC fusion mediated reprogramming of Flt3+ HSC. 
Flt3+ HSC were obtained from OG2 mice and expanded in vitro.  Flt3+ HSC are GFP- neo R. Flt3+ HSC were fused 
with E14 ESC. If Flt3+ HSC are reprogrammed after fusion, the Oct4-eGFP is activated the hybrids are GFP+ and 
G418 resistant.  
 
 
After PEG mediated fusion of Flt3+ HSC and E14 ESC, cells were seeded on gelatin-coated 
dishes with ESC medium in presence of LIF and G418 selection. After 48 h GFP+ cells were 
observed by microscopy. This indicated activation of Oct4-eGFP and the reprogramming Flt3+ 
HSC. On day 8 G418 resistant and GFP+, ESC-like colonies were observed by microscopy. Such 
colonies were picked and expanded them under G418 selection (Figure 4.33B). The established 
Flt3 ESC hybrids clones displayed a morphology similar to ESC. Additionally, such Flt3 ESC 
hybrid clones showed growth kinetics similar to ESC and were expanded and cryopreserved.  
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Figure 4.33: Reprogramming Flt3+ HSC through ESC fusion.  
 
 A: GFP activation after fusion of OG2 Flt3+ HSC and E14 ESC. Cells were cultured on gelatin-coated dishes 
with G418. 48 h post fusion, GFP+ cells could be detected under microscopy (indicated by red arrow). GFP+ 
clones were seen after one-week of selection with G418. 
B: Establishing Flt3 ESC hybrids clones. GFP+ clones were picked at day 8-post fusion. The picked clones 
were cultured on gelatin-coated dishes with ESC culture conditions.  
C: Flow cytometry analysis of DNA content of Flt3 ESC hybrids. E14 ESC and Flt3 ESC hybrids were fixed 
and stained with Hoechst 33342. Cells were subjected to FACS analysis. E14 ESC show 2n and 4n DNA 
content; Flt3 ESC hybrids are 4n and 8n.  
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Figure 4.34: Flt3+ HSC are reprogrammed by fusion with E14 ESC. 
 
A: Flt3 ESC hybrid and Flt3 iPSC are GFP+ and express pluripotency factor Nanog. Cells were cultured in 
chamber slides and subject immunofluence staining. Nanog expression is in red and cell nucleus was stained by 
DAPI (blue).  
B: Schematic representation of Oct4 activation during reprogramming. The green color indicates eGFP 
expression, which is induced from the Oct4 promoter. 
 
 
Collectively, Flt3+ HSC can be reprogrammed into pluripotent state through fusion with ESC. 
Oct4-eGFP activation occurred after about 48 hours post fusion, which is consistent with 
previous reports and indicate that the reprogramming might be finished at cells first cycle (Han et 
al., 2008).  
 
All together, with OG2 reporter mice, we demonstrated that ex vivo expanded Flt3+ HSC could 
be reprogrammed into the pluripotent state through pluripotency factor induction and fusion with 
ESC. The reprogrammed cells expressed the pluripotency factor Nanog (Figure 4.34). According 
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to the kinetics GFP expression, the kinetics of these two reprogramming systems were quite 
different. For example, fusion mediated reprogramming occured within 24 h; while pluripotency 
factor induced reprogramming took more than one week, as GFP+ cells appeared around day 
8~10 after infection (Figure 4.34B). 
 
 
4.3.5 Transcriptional Signatures of Reprogrammed Flt3+ HSC 
 
Since the first report on iPSC generation by Yamanaka in 2006, iPSC technology has become the 
most popular approach of reprogramming somatic cells. Pluripotency of iPSC was demonstrated 
by stringent pluripotency tests, such as contributing to tissue in the developing fetus and 
generating offspring after injection into pre-implantation embryos (Zhao et al., 2009). However, 
one of the opening questions concerning iPSC is how similar iPSC and ESC are. Considering 
their different origin, differences between these two types of pluripotent cells should exist. 
Transcriptional profiling studies indicate that iPSC represent a unique sub-type of pluripotent 
stem cells (Marchetto et al., 2009). A small population of differently expressed genes exits 
between iPSC and ESC. However, it is still unclear that this small percentage of differently 
expressed genes between iPSC and ESC is caused by the different approaches of acquiring 
pluripotency. To answer this question, comparing reprogrammed cells by different approaches is 
a logical choice. We reprogrammed bone marrow Flt3+ HSC by fusion and obtained 4n tetroploid 
hybrid clones. We also generated iPSC from Flt3+ HSC by retrovirus introducing 4 pluripotency 
factors. Since we used the same somatic cells Flt3+ HSC, this allows us to compare the 
differences between reprogrammed Flt3+ HSC through different approaches. 
 
To compare global transcriptional signatures of reprogrammed Flt3+ HSC with the starting cells 
Flt3+ HSC and ESC, gene expression profiles were generated using mouse genome Affymetric 
GeneChip arrays. RNA was isolated from Flt3+ HSC, ESC, 4 clones of ESC Flt3 hybrids and 5 
clones of Flt3 iPSC. Probes were hybrided with DNA microarray. The arrays were scanned and 
data was subjected to cluster analysis (in collaboration with Christine Becker and Qiong Lin, 
MSc, Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen 
University, Aachen Germany). Flt3+ HSC and reprogrammed pluripotent cells (Flt3 ESC hybrids 
and Flt3 iPSC) formed two distinct clusters (Figure 4.35A).  Thus, we can conclude that Flt3+ 
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HSC had been reprogrammed and Flt3+ HSC have acquired the pluripotency characteristics 
though different approaches of reprogramming. Another interesting observation was that ESC 
and Flt3 ESC hybrid clones are clustered in a sub-family (Figure 4.35A). This might demonstrate 
that fusion mediated reprogramming is more complete than pluripotency factors induction. It 
might also be due to Flt3 ESC hybrids containing parental ESC genomic information. Despite 
close similarity between Flt3 ESC clones and ESC, they clustered clearly into two sub-groups. 
This indicates that Flt3 ESC hybrids have their own specific transcriptional signatures, compared 
to ESC. We have more extensively analyzed the Flt3 ESC hybrids. Interestingly, Flt3 ESC 
hybrids displayed memories of adult Flt3+ cells both in epigenetic of chromatin and ex vivo 
differentiation behaviors (unpublished data). Currently, further studies are currently undergoing 
in our lab.  
 
Interestingly, closely related with these findings, two very recent reports showed that early-
passage iPSC retained a transient epigenetic memory of their original somatic cells. The 
epigenetic memory is maintained through the reprogramming selection and in turn influences 
iPSC differentiation potential (Kim et al., 2010; Polo et al., 2010). Thus, to clarify somatic 
memory of reprogrammed cells, it is interesting to compare the expression profile of 
reprogrammed cells through different approaches. Detail studies of reprogrammed Flt3 HSC will 
provide valuable information on understanding the epigenetic reorganization during 
reprogramming and finally these studies will be helpful to better understand cell pluripotency. 
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Figure 4.35: Transcriptional analysis of reprogrammed Flt3+ HSC 
 
A: Hierarchical clustering of global gene expression profiles of Flt3+ HSC, ESC, Flt3 ESC hybrids and Flt3 iPSC 
with the red branches of Flt3 HSC and the green to blue branches representing the pluripotent cells from different 
origins. 
B: Scatter plots of global gene expression profiles comparisons. Flt3 iPSC against ESC; Flt3 ESC hybrids against 
ESC. The green dots indicated the pluripotency factor Oct4, Sox2 and Nanog.
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5 Discussion 
 
ESC differentiation has become as an established tool for studying tissue homeostasis, including 
hematopoietic cell development. During the last couple of years, by taking ESC differentiation as 
a model system, significant advances have been made in understanding early stages of 
hematopoiesis. Conversely, the deep understanding of embryonic hematopoiesis will further lead 
to deriving transplantable hematopoietic cells from ESC, which can be used in clinical therapy. 
The first part of this thesis focused on establishing culture systems of ESC differentiation, mainly 
into hematopoietic lineage cells. I found that the PcG protein, Bmi1, an essential regulator for 
adult HSC, lacks expression in ESC. With the lentivirus system, Bmi1 expression was 
successfully introduced in ESC. By ESC in vitro differentiation, we demonstrated that Bmi1 is a 
candidate gene for promoting hematopoietic cell differentiation and proliferation. With defined 
role of Bmi1 in adult stem cells, we proposed that Bmi1 acts as an intrinsic regulator specific for 
adult stem cells. 
 
Reprogramming, especially converting somatic cells into pluripotent state has become a hot topic 
of contemporary biology. Since 2006, with the remarkable finding of generating iPSC from 
somatic cells (Takahashi and Yamanaka, 2006), reprogramming has come into iPSC age. In the 
second part of this thesis, I generated iPSC from ex vivo expanded Flt3+ HSC. Flt3+ HSC could 
also be reprogrammed through ESC fusion and generated Flt3 ESC hybrids. Gene expression 
profile studies of Flt3 iPSC and ESC hybrids were compared by DNA microarray. Interestingly, 
Flt3 pluripotent cells reprogrammed by different approaches were clustered uniquely together.  
 
In this part, I highlight on discussing data from this thesis with recent findings from the literature. 
In particular, I focused on hematopoietic cell differentiation from ESC and somatic cell 
reprogramming. 
 
5.1 ESC Hematopoiesis 
 
Studying ESC differentiation has a variety of benefits for elucidating cell fate decision during 
early stage of development, namely (I) the early stage of germ layer-derived cells can be obtained 
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without living embryos (II) cells of different stages can be purified and evaluated during 
differentiation (III) developmental-associated gene can be studied by genetic modification of 
ESC.  
 
Hematopoiesis is one of the best studied ESC differentiation programs (Olsen et al., 2006).  
During the last years, studying ESC hematopoiesis has shed new light on the old and intriguing 
question: the formation of blood cells. Mesoderm formation is a pivotal process during 
development and mesodermal cells are known as common precursors of major tissues and organs, 
including hematopoietic, cardiovascular and endothelial cells. However whether the first 
hematopoietic cells arise from mesodermal cells, mesenchymal progenitors or bipotent 
endothelial precursors has remained as a controversy (Eilken et al., 2009). Keller and colleagues 
have pioneered ESC differentiation as a model to study hematopoietic cell generation during 
development (Keller, 2005). Under optimized differentiation conditions, around 50% of the cells 
express hematopoietic/vascular receptor tyrosine kinase Flk1 (VEGF receptor 2) on day 5 of 
differentiation. With VEGF, the Flk1+ cells can further give rise to blast-like colonies consisting 
of hematopoietic and vascular progenitors in methylcellulose cultures (Keller, 2005). These 
results led to the conclusion that Flk1+ hemangioblasts might be the direct precursors of 
hematopoietic cells. Time-laps microscope studies on ESC differentiation showed that there is an 
intermediate stage cell population, named haemogenic endothelial cells which can directly give 
raise to blood cells (Eilken et al., 2009). Importantly, the transiently existed haemogenic 
endothelial cells express endothelial markers. These results directly monitored generation of HSC 
from ESC  (Eilken et al., 2009). 
 
By following the kinetics of ESC differentiation, we can find consecutive hematopoietic gene 
expression, following mesoderm formation (Figure 4.1B). By OP9 co-culture system, 
CD45+CD11b+ myeloid cells can be routinely obtained from ESC-derived Flk1+ cells. However, 
the efficiency of generating hematopoietic cells from ESC is very low (Figure 4.5). To improve 
hematopoietic cell differentiation and study function of hematopoietic gene in early stage of 
development, overexpression and loss-of-function of HSC related genes in ESC has been widely 
used (Table 1.2). Most of HSC associated regulators displayed activities on ESC hematopoiesis. 
On the other hand studying ESC differentiation system has provided new clues for understanding 
DISCUSSION 
104 
 
early stages of hematopoietic cell development. Conversely, the deep understanding of 
hematopoietic cell development will make it possible to reaching the aim of generating 
engineered HSC/HPC from ESC, which finally will be used in clinical.  
 
5.2 PcG Proteins in Stem Cells 
 
One of fundamental questions in stem cell biology is to understand the molecular mechanisms by 
which stem cells maintain their undifferentiated states. ESC are derived from inner cells mass of 
early embryo. It is suggested that pluripotency transcriptional network, mainly formed by Oct4, 
Nanog and Sox2 plays a dominant role in maintaining ESC identity (Boiani and Scholer, 2005b). 
In adult stem cells, for example HSC self-renewal highly depends on the microenvironment, also 
known as stem cell niche. A couple of transcriptional regulators, such as Hoxb4, Stat5, Gata2 and 
Bmi1 are known for being essential for maintaining the pool of adult HSC (Akala and Clarke, 
2006). Several studies have tried to clarify whether there are common stemness regulators for 
different types of stem cells (Ramalho-Santos et al., 2002; Galan-Caridad et al., 2007; 
Hieronymus et al., 2008). Until now it is still hard to define “stemness” among different stem cell 
types, even though, for example Zfx was found being required for both ESC and HSC (Galan-
Caridad et al., 2007). 
 
PcG proteins have attracted significant attention in stem cell research. Most of them are 
demonstrated of being directly involved in stem cell self-renewal, differentiation and cancer stem 
cell formation (Sparmann and van Lohuizen, 2006; Sauvageau and Sauvageau, 2010). PcG 
proteins form a transcription repressing complex and are crucial for maintaining identities of both 
ESC and various adult stem cells, such as HSC, NSC and endothelial precursor cells. ESC have 
been frequently taken as a model from investigating roles of PcG components and several PcG 
proteins are highly expressed in ESC. For example, O’Carroll et al. showed the failure of 
establishing ESC from Ezh2-/- embryo, indicating the essential role of Ezh2 in establishing 
pluripotency (O'Carroll et al., 2001). Mice lacking Suz12 were not viable and died during early 
post-implantation stages (Pasini et al., 2004). In a very recent study the Fisher group showed that 
ESC require PRC2 to reprogram somatic cells towards pluripotency through cell fusion (Pereira 
et al., 2010). All these studies demonstrate that PcG proteins might be involved in establishing 
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pluripotency. Eed-/- and Suz12-/- ESC can self-renew in culture, even though PcG repressed 
genes were de-repressed (Lee et al., 2006). This indicates that once cell pluripotency is 
established, PcG proteins become dispensable for maintaining pluripotency. PcG proteins are also 
demonstrated being essential for ESC differentiation. For example, Suz12-/- ESC were impaired 
in proper neuronal differentiation and fail to suppress pluripotency gene expression upon 
differentiation. Ezh2-/- ESC failed in mesoderm germ layer formation (Pasini et al., 2007; Shen et 
al., 2008). A recent study showed that simultaneous loss of PRC1 and PRC2 in ESC abrogated 
differentiation (Leeb et al., 2010). Compared to pluripotent stem cells, assessing PcG proteins in 
tissue organogenesis has been hampered because of the embryonic lethality of PRC component 
knockouts (Ezhkova et al., 2009). Recent investigations demonstrate that PRC2 component, e.g. 
Ezh2, Suz12 also orchestrate gene expression programs of several types of adult stem cells 
(Majewski et al., 2008; Cui et al., 2009; Ezhkova et al., 2009). 
 
5.3  Bmi1, an Epigenetic Modifier Might be Specific for Adult Stem Cells 
 
Bmi1, a member of PRC1, is indispensable for maintaining the pool of adult stem cells. 
However, Bmi1 deficiency has no obvious effects on embryogenesis (Lessard and Sauvageau, 
2003; Park et al., 2003; Molofsky et al., 2005). Importantly, several malignancies were also 
characterized with deregulated Bmi1 expression (Lessard and Sauvageau, 2003; Liu et al., 2006). 
In our study, we found Bmi1 is not or only expressed at very low levels in pluripotent ESC. By 
using lentivirus, we constitutively enforced Bmi1 expression in ESC and investigated its effects 
on hematopoietic cell arising in differentiating ESC. Ectopic Bmi1 expression showed no 
influence on ESC self-renewal and mesodermal hemangioblast development upon 
differentiation. However, hematopoietic cell derivation from hemangioblast precursors was 
significantly increased. Correspondingly, with Bmi1 expression, ESC derived hematopoietic 
stem/progenitor cells displayed robust proliferation capacity in liquid culture. Our results 
indicated the distinctive biological effects of Bmi1 along the process of ESC differentiation. This 
demonstrated that Bmi1 might be an intrinsic regulator specifically for adult stem cells. Bmi1 can 
be a candidate to improve adult stem/progenitor cell derivation from pluripotent stem cell.  
 
The impact of Bmi1 on adult stem cells is mainly through repressing Ink4a/Arf locus, which is 
also referred to as Cdkn2a and encodes p16Ink4a and p19Arf, two CDK inhibitors. In ESC and 
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fetal tissues, Ink4a/Arf expression is silenced; while its expression is progressively up-regulated 
during development (Collado et al., 2007). In ESC, Ink4a/Arf expression is very low and 
bivalent chromatin domains existe in its transcriptional regulatory region (Ohm et al., 2007). By 
RT-PCR and Western blot, we demostrated that Bmi1 was not expressed at very low levels in 
ESC. Thus repressing of the Ink4a/Arf locus through H3K27Me3 might be due to alternative 
PcG proteins. We also found that exogenous Bmi1 expression reinforced the repressive activity 
on this locus in ESC, as revealed by q-PCR analysis (Figure 4.13B).  
 
Mesodermal hemangioblast cell commitment to hematopoietic cells is spatially associated with 
embryonic hematopoietic precursors in yolk sac (Kabrun et al., 1997; Lugus et al., 2009). How 
the dynamic repression activities of PcG protein during development occurs an interesting 
question. Indeed, a large number of genes, which are known to be regulated by PcG proteins, are 
altered in expression during ESC differentiation (Boyer et al., 2006). This process also 
accompanied with the dynamic changes of PcG protein regulatory function (Ren et al., 2008). As 
the ESC/EB differentiation system recapitulates early stages of development, it will provide a 
valuable tool for elucidating the repressive activities of PcG components during development. 
 
Cell cycle analysis indicated that decreased Ink4a/Arf expression did not affect ESC proliferation 
(Figure 4.13C and D). Thus, the specific chromatin status of ESC allows over-expression of 
p16Ink4a/p19Arf and other inhibitors (Burdon et al., 2002). During ESC differentiation by EB 
formation, the expression of Ink4a/Arf locus remained low. Perhaps due to the low transcripts of 
p16Ink4a an p19Arf in EB, we did not detect the alteration of their expression by microarray 
analysis. However, in EB-derived HPC, Ink4a/Arf was found to increase in expression in control 
cells (Figure 4.21A). While in Bmi1-HPC, its expression was continuesly repressed and cells 
displayed robust proliferative capacity.  
 
 
5.4   Repressive Activity of Bmi1 in Differentiating ESC 
 
 
Bmi1 acts as transcriptional repressor (Sauvageau and Sauvageau, 2010) and thus its activity 
directly translates into changes in gene expression. Gene expression profiling by microarray 
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represents a powerful tool to survey transcriptional pattern on a genome-wide scale and thus 
Bmi1 expressing cells were subjected to microarray analysis. We identified are large number of 
genes that were repressed by Bmi1, which was expected. For instance, several Hox genes were 
down-regulated, but Gata2 was up-regulated. This finding is interesting, since we and others have 
shown before that Gata2 plays a key role in hematopoietic cell proliferation and maintaining the 
pool of adult HSC (Briegel et al., 1993; Tsai et al., 1994; Akala and Clarke, 2006). Additionally, 
doxycycline-induced Gata2 expression in differentiating EB promoted hematopoietic mesoderm 
formation and suppressed endoderm and ectodermal lineages (Lugus et al., 2007). 
 
Up-regulated Gata2 expression in Bmi1 ESC-derived EB is unlikely to be due to an increased 
frequency of hematopoietic cells, since other hematopoietic genes, like Scl, c-Kit, Runx1 and 
Hoxb4 showed no large difference in expression compared to controls. Additionally, Bmi1 over-
expression in adult bone marrow Flt3+ HSC (Felker et al., 2010), also caused an up-regulation of 
Gata2. Gata2 and Bmi1 are both essential for adult HSC and thus it is tempting to speculate that 
both are important components of a circuitry in maintaining the HSC pool and keeping 
progenitors immature. In addition, HPC generated from Bmi1-ESC, despite the fact of being 
highly proliferative, were fully responsive and dependent on cytokine for survival in culture. This 
suggests that the extended lifespan observed for Bmi1-HPC is not related to malignant 
transformation. 
 
 
 
5.5   Bmi1, a Candidate Gene for Enhancing HSC/HPC Derivation from ESC 
 
 
The derivation of tissue specific stem/progenitor cells and terminally differentiated cells from 
ESC for stem cell-based replacement therapies represents a major challenge in regenerative 
medicine. In vitro generation of hematopoietic cells from ESC has been demonstrated by several 
studies but remained rather inefficient compared to other cell lineages (Olsen et al., 2006). 
Additionally, several previous studies demonstrated that intrinsic regulators for adult HSC, like 
Hoxb4, Stat5 and Runx1, can promote hematopoietic cell development from ESC (Kyba et al., 
2002; Schuringa et al., 2004; Pilat et al., 2005; Sakai et al., 2009). In particular, Hoxb4 supports 
the generation of long-term repopulating HSC from mouse ESC (Kyba et al., 2002; Pilat et al., 
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2005). However, data on a similar activity of Hoxb4 on hematopoiesis of human ESC are still 
inconsistent (Wang et al., 2005a; Unger et al., 2008). Thus, the identification of genes that 
enhance the hematopoietic cell development from ESC, as reported here for Bmi1, represents an 
important step towards the aim of obtaining high cell numbers for treatment of hematopoietic 
diseases. In initial transplantation, we did not find long-term repopulation activity of Bmi1-HPC, 
but also no tumor formation. 
 
5.6   Bmi1 and Adult Stem/Progenitor Cell Derivation from ESC 
 
Initially, Bmi1 was identified as a cooperating factor of c-Myc in the induction of B-cell 
lymphomas (van Lohuizen et al., 1991). In recent years, a variety of malignancies were found to 
show with increased Bmi1 expression (Lessard and Sauvageau, 2003; Chowdhury et al., 2007). 
We observed Bmi1 transduced ESC-derived hematopoietic cells displayed an advantage of 
proliferation capacity. However, their survival and proliferation were still fully dependant on 
specific cytokines. Thus, Bmi1 might be only capable of enhancing cell proliferation and 
malignancy perhaps still needs a second mutation. With patient specific iPSC, the ESC/EB 
system will provide a platform for elucidating the association of how aberrant Bmi1 expression 
relates to the occurrence of malignancy. 
 
As mentioned above, in adult tissue, Bmi1 is not only essential for HSC self-renewal but also 
plays an important role in a variety of other adult stem cells, such as NSC and hepatic stem cells 
(Molofsky et al., 2003; Chiba et al., 2010). Regarding to NSC, deficiency of Bmi1 leads to 
progressive postnatal growth retardation and neurological defects (Molofsky et al., 2003). 
Conversely, similar to HSC system, the self-renewal of NSC is enhanced by over-expression 
Bmi1. The effects of Bmi1 in adult stem cells can be partially explained through repressing 
Inka4a/Arf locus (Bruggeman et al., 2005; Fasano et al., 2009). Protocols of deriving hepatic cells 
and neural cells from ESC have been firmly established from both human ESC and iPSC. They 
represent an promising cell source treatment of a variety of diseases (Erceg et al., 2009). Yet, 
how Bmi1 affects derivation of other adult stem cell derivation from pluripotent cells has not been 
explored before. At this point, it is worthy to evaluate Bmi1 role in other adult/somatic cell 
derivation with the ESC/iPSC differentiation system.  
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The final aim of differentiating pluripotent stem cells is to generate somatic/progenitor cells, 
which can be used in clinical tissue replacement therapy. As described before, pluripotency 
makes them hard to differentiate into specific lineages. It is still a challenge to generate 
homogenous somatic cell population from ESC (Murry and Keller, 2008). For facilitating 
differentiation, most studies used to introduce exogenous gene expression (Table 1.1). It is 
important to point out the drawbacks of genetic modification ESC by virus. The random insertion 
of virus might bring mutation to the host cell genome. Here, we used lentivirus to introduce Bmi1 
expression in ESC. In the future, it is need to develop novel techniques, such as virus-free 
systems for progenitor or somatic cell generation. Indeed, pioneering work with Hoxb4, 
recombinant TAT-HoxB4 protein to expand human HSC demonstrate the feasibility of this 
approach (Krosl et al., 2003). Thus, bypassing virus-based systems to expand stem cells is an 
essential step for using stem cells for clinical purpose.  
 
5.7   Cell Reprogramming and Cell Plasticity 
 
 
Reprogramming refers to that under certain experimental conditions committed cell lineages are 
reverted into an undifferentiated state or converted to other cell lineages (Graf and Enver, 2009). 
Cell reprogramming indicates the plasticity of the cell nucleus. Mammalian cell plasticity has 
been an intriguing question for many years. Earliest proof of reprogramming showed that 
lineages committed cells can be changed from one to another by enforcing expression of specific 
transcriptional factors. MyoD, known as a myogenic regulatory factor can induce myotube 
formation from fibroblast cell line (Davis et al., 1987). In hematopoietic system, cell fates 
determination and lineages commitment dependents on lineage instructive transcriptional 
factors. C/EBPa is a transcription factor required for forming granulocyte-macrophage 
precursors. It can convert committed B and T cell progenitors into macrophages (Xie et al., 
2004).  
 
iPSC technology further proved mammal cell plasticity. A cocktail of pluripotency factors can 
reprogram a wide range of somatic cells into pluripotent state (Hanna et al., 2010). Importantly, 
iPSC are indistinguishable with ESC in many respects, including cell morphology, proliferation 
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and gene expression profile (Takahashi and Yamanaka, 2006). Generating iPSC provides an 
invaluable platform to analysis molecular mechanisms and epigenetic alterations during 
programming and reprogramming. Two Recent studies showed that, contrasting normal 
developmental process of EMT (epithelial to mesenchymal transition), MET (mesenchymal to 
epithelial transition) is an essential step for reprogramming mouse fibroblasts (Li et al., 2010; 
Samavarchi-Tehrani et al., 2010). Studying the intersections between programming and 
reprogramming will contribute to a better understanding of mammal cell plasticity and 
developmental biology. 
 
 
5.8   HSC/HPC Represent an Advantage Cell Source for Reprogramming 
  
 
Choosing the appropriate starting cell populations for cellular reprogramming is an important step 
for iPSC generation. So far lineages-committed cells from multi-tissue have been demonstrated 
that they can be reprogrammed into pluripotent state. We have long been establishing protocols of 
in vitro expanding HSC both from human and mouse. CD34+ human HSC can be isolated from 
cord blood and expanded in vitro (Ju and Zenke, 2003). Similarly, from mouse bone marrow we 
established protocols for generating large number of Flt3+ HSC (Hieronymus et al., 2005; Felker 
et al., 2010). Flt3+ HSC can be maintained as homogenous cell population and display 
multipotent differentiation potential both in vitro and in vivo. It has been reported that iPSC can 
be generated from both mouse and human hematopoietic cells. However deriving iPSC from ex 
vivo expanded HSC have not been investigated before. In this study, Flt3+ HSC were expanded 
from OG2 mice. We took Flt3+ HSC as cell source and successfully reprogrammed them into 
pluripotent states through retrovirus introducing pluripotency factors (Oct4, Sox2, Klf4 and c-
Myc). Flt3 iPSC displayed pluripotency characteristics: (I) the endogenous pluripotency program 
was activated; (II) they can form teratoma in NOD-SCID mice.  
 
For several reasons, HSC/HPC represent an advantageous cell source for reprogramming. The 
hematopoietic systems have been well characterized, including self-renewal, hierarchical multi-
lineage differentiation and senescence. In addition, the hematopoietic system provides an 
invaluable material to decipher how cell type and status influence reprogramming process. 
Perhaps because adult stem/progenitors, such as HSC/HPC exhibit the indefinite growth potential 
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and share similar epigenetic status with pluripotent stem cells, HSC/HPC can be reprogrammed 
into pluripotent state with a higher efficiency than lineage committed cells (Eminli et al., 2009). 
Oct4 alone is sufficient to reprogram NSC into iPSC, but has not been proved in HSC (Kim et al., 
2009). Clinically, blood cells can be easily accessed without causing severely damages to donors. 
Furthermore, hematopoietic cells can be preserved and the already established blood bank can be 
used for generating iPSC. Also HSC/HPC can be expanded in large cells number with specific 
cytokines. Investigators have recently reported the successful reprogramming human CD34+ 
hematopoietic progenitors from both mobilized and non-mobilized blood donors (Giorgetti et al., 
2009; Haase et al., 2009; Loh et al., 2009). During preparing this thesis, iPSC were successfully 
derived from human peripheral blood cells by three different groups (Loh et al., 2010; Seki et al., 
2010; Staerk et al., 2010). Considering that their availability is much easier, blood cells will serve 
as an invaluable cell sources from reprogramming. 
 
For disease model, iPSC can also be generated from human chronic myeloid leukemia cell lines. 
In hematopoietic system, leukemia is mostly caused by mutations of oncogenes. iPSC, generated 
from a parental cell line, which is dependent on continuous BCR-ABL signaling, lost the 
dependency and became sensitive to BCR-ABL inhibitor imatinib. Thus, therapeutic agents, such 
as imatinib might target cells in a specific epigenetic state (Carette et al., 2010; Pereira et al., 
2010). In another study by Ye et al., iPSC were generated from peripheral blood CD34+ cells of 
patients with myeloproliferative disorders (MPD). iPSC from MPD patient displayed 
pluripotency phenotype in culture. When subjected to hematopoietic cells differentiation, CD34+ 
cells from MPD-iPSC futures of MPD (Ye et al., 2009).  
 
Studying hematopoietic cell development from disease-modeled iPSC can help to elucidate 
molecular mechanisms of disease and screening drugs for this disease. Thus, iPSC generation 
from specific hematopoietic disease combined with in vitro differentiation systems will provide 
an invaluable platform for investigating various blood diseases. 
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5.9  Transcriptional Signature of Flt3+ HSC-Derived Pluripotent Stem Cells 
 
iPSC technology represents directly reprogramming and reverts somatic cells into pluripotent 
state by resetting somatic cell epigenetic information. iPSC can be generated from a wide range 
of lineages cells. With established pluripotency standards, iPSC showed pluripotency 
characteristics, such as pluripotency gene expression profile and giving derivatives of all three 
germ layers (Stadtfeld and Hochedlinger, 2010).  
 
However, one of critical questions concerning iPSC is how similar iPSC and ESC really are. To 
prove pluripotency of iPSC, gene expression profiles and epigenetic information with ESC lines 
has been regularly used. Most studies conclude that iPSC are indistinguishable with ESC, 
including their morphology, in vitro proliferation behavior and gene expression profile. 
Considering their different origins, differences between these two types of pluripotent cells 
should exist. Finding these differences might be helpful for elucidating the reprogramming 
mechanisms and finally applying iPSC in the clinics.  Chin et al. analyzed gene expression 
profiles of iPSC with counterpart ESC systematically and found that iPSC retain a different set of 
gene expression signatures from ESC (Chin et al., 2009). They proposed the differences might be 
due to the exogenous pluripotency factors that bind to the endogenous genes promoter. This arise 
the question whether the retained gene expression signature of iPSC is true caused by the 
reprogramming technique, such as the integration of reprogramming factors to the host cells 
genomic during iPSC generation. To answer this question, we compared gene expression profiles 
of reprogrammed Flt3+ HSC through different approaches: Flt3 ESC hybrids though ESC fusion 
and Flt3 iPSC by pluripotency factor transduction. We found that even though all types of 
pluripotent cells are clustered in a big group compared to adult Flt3+ HSC, different types of 
pluripotent stem cells are clustered separately in a small group (Figure 4.33). Also, we found Flt3 
ESC hybrids cluster closer to ESC than Flt3 iPSC; but all pluripotent cells clustered in a unique 
sub-group. Because of the different processes of reprogramming, such as fusion mediated 
reprogramming takes one to two days, while iPSC generation takes around two to three weeks, 
Flt3 ESC hybrids and Flt3 iPSC display also their own transcriptional characteristics. 
Interestingly, two very recent studies showed that iPSC contain the epigenetic memory of donor 
cells within the early passage numbers during in vitro culture and with culture the epigenetic 
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memory is diminished (Kim et al., 2010; Polo et al., 2010). Before moving iPSC technology into 
application, a better understanding and assessment of their quality and homogenicity is necessary. 
Comparing the reprogrammed cells through different approaches can be helpful in understanding 
the mechanisms of reprogramming and how the ground state of pluripotency can be achieved.  
 
5.10 iPSC Technology, Future Perspectives 
 
 
Since the discovery of iPSC technology, fast progress has been made in this field. However, until 
now the underlying molecular mechanisms if iPSC generation still remain a black box. It requires 
elucidating, for example, how pluripotency factors cooperate with epigenetic modifiers to switch 
off the somatic gene expression program and at the same time activate the pluripotency program. 
It is clear that the clues of reprogramming lie in reorganizing the cell’s epigenetic information. 
Epigenetic structures of chromatin directly affect gene expression and determine cell fate. During 
the process of iPSC generation, how chromatin state, epigenetic modifiers and pluripotency 
factors cooperate to reset fully differentiated cell to a pluripotent state is an intriguing question. 
For example, PcG proteins are transcriptional repressors of development-associated genes to 
maintain cellular identity during development. How PcG proteins cooperate with reprogramming 
factors to repress differentiation associated genes and drive somatic cells into pluripotent status is 
a quite interesting question. Integrating computational and experimental tools, studying dynamic 
epigenetic alteration during iPSC generation will help uncover the underlying molecular 
mechanisms of iPSC generation, and will also lead to a better understanding cell plasticity during 
development. 
 
iPSC can be generated from somatic cells and they display comparable characteristics with ESC, 
including morphology, proliferation, gene expression profile and epigenetic information. 
Importantly, for differentiation iPSC showed the ability of contributing to chimera formation in 
vivo and iPSC can differentiate into various types of functional cells, including neurons, 
cardiomyocytes and hematopoietic cells, in vitro (Amabile and Meissner, 2009). In mice models, 
the iPSC-derived cells had proved the ability of being able to use for therapeutic purposes. For 
example, in a humanized sickle cell anemia mouse model, transplantation with hematopoietic 
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progenitors obtained in vitro antologous iPSC can rescue the defect of the donor mice (Hanna et 
al., 2007).  
 
Regarding human iPSC, the public has great expectations for their potential in regenerative 
medicine in the future. However, before applying iPSC technology in regenerative medicine and 
finally being used in the clinics, there are several issues that need to be considered. Firstly, the 
efficiency of iPSC generation needs to be increased. Many strategies have been developed for 
reprogramming somatic cells but the efficiency in reprogramming human cell is still low and 
needs to be improved (Hanna et al., 2010). Secondly, generating iPSC is mostly dependent on 
introducing external DNA. The random integration of virus into host cell genomic can result in 
potential mutations. Virus-free systems, such as adenoviruses to transiently express 
reprogramming factors, RNA- and protein-mediated reprogramming were demonstrated to be 
able to reprogram mouse somatic cells (Stadtfeld et al., 2008; Hanna et al., 2010). A method free 
of external DNA for human iPSC needs to be demonstrated. Thirdly, choosing the right starting 
cell population for reprogramming is important for iPSC generation. Currently, most iPSC 
generation experiments are based on fibroblasts. It needs to be demonstrated that similar 
efficiency of iPSC generation also works for other somatic cell lineages. For example as 
mentioned above, hematopoietic cells represent an advantage cell source for reprogramming. 
Fourthly, properties of different iPSC clones were variable. Standards for routine and high-
throughput testing iPSC quality need to be established. Lastly but not least is the specific 
differentiation of iPSC. Pluripotency is like a double-edged sword. Efficient pluripotent stem cell 
differentiation still remains as a challenge. Preliminary studies have demonstrated the different 
differentiation behaviors between iPSC and ESC. For instance, Feng and colleagues showed the 
hemangioblasts from human iPSC are prone to senescence. Similarly, the retinal-pigmented 
epithelium cells derived from hiPSC began senescing in the first passage (Feng et al., 2010).  
 
Perhaps, the immediate applications are studying disease models by generating patient-specific 
iPSC, combining in vitro differentiation systems and applying them in drug screen. We can see 
that obviously potentials of iPSC in the clinics in the future are great; nevertheless many 
uncertainties remain in many respects before this technology is going to be applied in the clinics.  
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